documents incorporated reference document part annual report stockholders fiscal year parts iiended december proxy statement annual meeting part iii stockholders held april table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules signatures ex computation ratios earnings fixed charges ex portions annual report stockholders ex subsidiaries merck co inc ex power attorney ex certified resolution board directors ex certification ex certification ex certification ex certificationtable contents part item business merck co inc merck company global researchdriven pharmaceutical company discovers develops manufactures markets broad range innovative products improve human animal health directly joint ventures company sells products primarily drug wholesalers retailers hospitals clinics government agencies managed health care providers health maintenance organizations institutions companys professional representatives communicate effectiveness safety value products health care professionals private practice group practices managed care organizations overview december merck unveiled plan reclaim leadership position pharmaceutical industry part strategy merck focusing improving research development rd productivity focusing select therapeutic areas implementing new commercial model deliver greater value customers reducing overall cost structure companywide mercks new rd model designed increase productivity improve probability success prioritizing companys rd resources nine priority disease areas alzheimers disease atherosclerosis cardiovascular disease diabetes novel vaccines obesity oncology pain sleep disorders therapeutic areas carefully chosen based set criteria including unmet medical needs scientific opportunity commercial opportunity within therapeutic areas merck commit resources achieve research breadth depth develop bestinclass targeted differentiated products valued highly patients payers physicians company also make focused investments pursue specific mechanisms following selected disease areas antibiotics antifungals antivirals hepatitis c virus human immunodeficiency virus asthma chronic obstructive pulmonary disease neurodegeneration ophthalmology osteoporosis schizophrenia stroke addition company capitalize selected opportunities outside areas continuing commercialize attractive clinical development candidates pipeline pursuing appropriate external licensing opportunities mercks latestage pipeline showing strong progress three biologics license application bla submissions us food drug administration fda one new drug application nda already filed fda two additional fda filings anticipated expected five programs phase iii first quarter three fda bla submissions include gardasil breakthrough vaccine help prevent cervical cancer second leading cause cancer deaths women worldwide zostavax vaccine reduce incidence shingles rotateq pediatric vaccine prevent rotavirus gastroenteritis leading cause diarrhea infants young children leads nearly deaths worldwide year february merck announced approval fda rotateq addition february merck announced fda accepted bla gardasil granted vaccine priority review designation fda 's review zostavax expected completed late may february merck announced nda filed fda januvia proposed trademark compound known mk novel mechanism treatment type diabetes accepted standard review merck also anticipates two additional fda filings vorinostat generic name suberoylanilide hydroxamic acid compound histone deacetylase inhibitor cancer mk intravenous prodrug aprepitant treat chemotherapyinduced nausea vomiting improve commercial selling model merck continue streamline restructure marketing sales operations worldwide improve effectiveness generate greater efficiencies united states company already reduced number sales representatives promoting product percent versus historical levels addition merck place emphasis active engagement key table contents opinion leaders accelerate development diffusion scientific information devote additional resources utilizing technology demonstrating product value physicians well payers consumers increasing influence prescription decisions united states approach already resulted considerable productivity improvements pilot programs expected lower companys spending per brand percent maximizing sales performance provide additional support upcoming vaccine launches united states merck redeploying sales representatives currently promote major inline products support launch new vaccines november company announced first phase global restructuring program designed reduce companys cost structure increase efficiency enhance competitiveness initial steps include implementation new supply strategy merck manufacturing division intended create leaner costeffective customerfocused manufacturing model next three years part program merck plans sell close five manufacturing sites two preclinical sites end eliminate approximately positions companywide december approximately positions throughout company eliminated merck incurred million costs associated global restructuring program comprised million separation costs million accelerated depreciation asset impairment costs manufacturing facilities included action ponders end united kingdom okazaki japan kirkland canada albany georgia danville pennsylvania two preclinical sites okazaki menuma japan company incur significantly larger accelerated depreciation charges associated actions asset impairment charge associated abandonment certain fixed assets longer used business result restructuring actions company also plans close basic research center terlings park united kingdom incurred additional accelerated depreciation costs million respect site additional charges approximately million billion expected recorded based estimated time completion salesclosures facilities previously discussed occur merck expects cost reduction program yield cumulative pre tax savings billion american jobs creation act ajca signed law october created temporary incentives december us multinationals repatriate accumulated income earned outside united states december connection ajca company repatriated billion result recorded income tax charge million charge partially offset million benefit associated decision implement certain tax planning strategies previously disclosed september merck announced voluntary worldwide withdrawal vioxx arthritis acute pain medication result company recorded charge pretax income million million tax adjustment net income third quarter include charges future legal defense costs vioxx withdrawal process completed costs associated withdrawal line original amounts recorded company december company established reserve million solely future vioxx legal defense costs company spent million aggregate vioxx legal defense costs worldwide fourth quarter company recorded charge million increase reserve solely future legal defense costs related vioxx million december reserve based certain assumptions best estimate amount company believes time reasonably estimate spent earnings per common share assuming dilution including impact global restructuring program per share net tax charge primarily associated ajca per share additional reserves established solely future legal defense costs vioxx litigation discussed table contents product sales sales companys products follows millions zocor fosamax cozaarhyzaar singulair proscar primaxin vasotecvaseretic cosopttrusopt cancidas maxalt propecia vioxx vaccinesbiologicals total presented net discounts returns companys products include therapeutic preventive agents generally sold prescription treatment human disorders among zocor simvastatin mercks largestselling atherosclerosis product fosamax alendronate sodium fosamax plus alendronate sodiumcholecalciferol mercks osteoporosis products treatment case fosamax prevention osteoporosis cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate companys significant hypertensionheart failure products singulair montelukast sodium leukotriene receptor antagonist respiratory product treatment chronic asthma relief symptoms allergic rhinitis proscar finasteride urology product treatment symptomatic benign prostate enlargement primaxin imipenem cilastatin sodium cancidas caspofungin acetate antibacterialanti fungal product cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution largestselling ophthalmological products maxalt rizatriptan benzoate acute migraine product propecia finasteride product treatment male pattern hair loss vaccinesbiologicals include varivax varicella virus vaccine live okamerck live virus vaccine prevention chickenpox mmr ii measles mumps rubella virus vaccine live pediatric vaccine prevention measles mumps rubella pneumovax pneumococcal vaccine polyvalent vaccine prevention pneumococcal disease recombivax hb hepatitis b vaccine recombinant vaccine prevention hepatitis b primarily includes sales human pharmaceuticals pharmaceutical animal health supply sales companys joint ventures revenue companys relationship astrazeneca lp primarily relating sales nexium esomeprazole magnesium prilosec omeprazole product approvals august company announced fda approved singulair symptoms perennial allergic rhinitis yearround allergies adults children six months age older september fda approved proquad measles mumps rubella varicella okamerck virus vaccine live proquad combination vaccine simultaneous vaccination measles mumps rubella varicella children months years age table contents february merck announced approval fda rotateq pediatric vaccine prevent rotavirus gastroenteritis rotateq oral pentavalent threedose liquid vaccine contains five human serotypes g g g g p merck also submitted applications licensure rotateq countries including australia canada countries asia latin america sanofi pasteur msd joint venture european union eu rotateq also received regulatory approval mexico november voluntary withdrawal vioxx september merck announced voluntary worldwide withdrawal vioxx arthritis acute pain medication companys decision effective immediately based new threeyear data prospective randomized placebocontrolled clinical trial approve adenomatous polyp prevention vioxx trial stopped designed evaluate efficacy vioxx mg preventing recurrence colorectal polyps patients history colorectal adenomas assess cardiovascular safety vioxx study increased relative risk confirmed cardiovascular events heart attack stroke beginning months treatment patients taking vioxx compared taking placebo results first months approve study show increased risk confirmed cardiovascular events vioxx respect similar results two placebocontrolled studies described recent us labeling vioxx company estimates million us prescriptions written vioxx may august based estimate company estimates number patients taken vioxx united states since launch approximately million number patients outside united states taken vioxx undetermined time october company received letter senator charles grassley chairman senate committee finance requesting certain documents information related vioxx company also received requests information congressional committees company intends cooperate inquiries company continue describe reasons companys voluntary withdrawal vioxx answer questions related companys development extensive testing medicine disclosures results studies february fda held joint meeting arthritis advisory committee drug safety risk management advisory committee committees discussed overall benefittorisk considerations including cardiovascular gastrointestinal safety concerns cox selective nonsteroidal antiinflammatory drugs related agents february members committees asked vote whether overall risk versus benefit profile vioxx supports marketing united states members committees voted support marketing vioxx united states company looks forward discussions fda regulatory authorities vioxx previously announced board directors company appointed special committee review companys actions prior voluntary withdrawal vioxx act board responding shareholder litigation matters related withdrawal vioxx advise board respect action taken result review review ongoing arcoxia arcoxia launched countries europe latin america asia africa october company received approvable letter fda companys nda arcoxia fda informed company letter approval nda issued additional safety efficacy data arcoxia required november european commission adopted binding decision cox inhibitor products including arcoxia marketed eu decision resulted review committee medicinal products human use chmp table contents european medicines evaluation authority emea considered aspects cardiovascular safety cox inhibitors including thrombotic cardiorenal events following voluntary withdrawal vioxx decision adopted opinion emea issued june recommended new cardiovascular contraindications warnings inclusion labeling cox inhibitors including arcoxia eu chmp concluded available data show increased risk cardiovascular adverse events cox inhibitors class relative placebo nsaids data suggested association duration use dose probability suffering cardiovascular event label modifications included emeas opinion reflected use lowest effective dose cox inhibitors shortest possible duration treatment recommended contraindication cox inhibitors patients ischemic heart disease stroke contraindication certain patients higher classes congestive heart failure included specifically respect arcoxia label changes included contraindication patients hypertension whose blood pressure control arcoxia may associated frequent severe effects blood pressure particularly higher doses cox inhibitors recommended monitoring blood pressure patients taking arcoxia additional warnings regarding hypersensitivity serious skin reactions also included labeling cox inhibitors eu regulatory agencies countries arcoxia approved made modifications product labeling arcoxia well cox inhibitors relative cardiovascular risks patient usage september venezuelan ministry health ordered market withdrawal cox inhibitors including arcoxia mexico sales arcoxia mg temporarily suspended suspension lifted acquisitions cid march company acquired aton pharma inc aton privately held biotechnology company focusing development novel treatments cancer serious diseases atons clinical pipeline histone deacetylase inhibitors represents class antitumor agents potential efficacy based novel mechanism action lead product candidate suberoylanilide hydroxamic acid known vorinostat currently phase ii clinical trials treatment cutaneous tcell lymphoma company wholly owned subsidiary msd japan co ltd completed tender offers acquire remaining common shares banyu pharmaceutical co ltd banyu already aggregate purchase price approximately billion march merck completed acquisition banyu full ownership banyu strengthens mercks position japan worlds secondlargest pharmaceutical market joint ventures cid company scheringplough corporation scheringplough entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas december cholesterolmanagement partnership agreements expanded include countries world excluding japan october zetia ezetimibe marketed ezetrol outside united states first new class cholesterollowering agents launched united states july vytorin ezetimibesimvastatin marketed inegy outside united states combination product containing active ingredients zetia zocor approved united states november merckscheringplough partnership announced commencement patient enrollment largescale clinical outcomes trial improveit improved reduction outcomes vytorin efficacy international trial trial evaluate effectiveness vytorin compared zocor alone treating approximately high risk patients coronary artery disease presenting acute coronary syndromes clinical trial sites opening throughout north america europe company entered agreement astra ab astra develop market astra products united states company astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec table contents first class medications known proton pump inhibitors slows production acid cells stomach lining company astra restructured joint venture whereby company acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership company maintains limited partner interest partnership renamed astrazeneca lp became exclusive distributor products kbi retained rights company earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing companys share undistributed partnership gaap earnings conjunction restructuring payment million astra purchased option buy companys interest kbi products excluding companys interest gastrointestinal medicines nexium prilosec company also granted astra option shares option buy companys common stock interest kbi exercise price based present value estimated future net sales nexium prilosec april astra merged zeneca group plc forming astrazeneca ab astrazeneca result merger exchange companys relinquishment rights future astra products existing pending us patents time merger astra paid million subject trueup calculation may require repayment portion amount merger also triggers partial redemption companys limited partner interest furthermore result merger astrazenecas option buy companys interest kbi products exercisable company right require astrazeneca purchase interest addition shares option exercisable two years astras purchase companys interest kbi products exercise option astra also provided year combined annual sales two products fall minimum amount provided case long either merck option astrazenecas option exercised exercise price based present value estimated future net sales nexium prilosec determined time exercise company formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture expanded europe canada significant joint venture products pepcid ac famotidine overthecounter form companys ulcer medication pepcid famotidine well pepcid complete overthecounter product combines companys ulcer medication antacids calcium carbonate magnesium hydroxide march company sold johnson johnson interest european joint venture discussed divestitures effective april company merck vaccine division connaught laboratories inc sanofi pasteur sa agreed collaborate development marketing combination pediatric vaccines promote selected vaccines united states research marketing collaboration enables companies pool resources expedite development vaccines combining several different antigens protect children variety diseases including haemophilus influenzae type b hepatitis b diphtheria tetanus pertussis poliomyelitis combination vaccine development efforts continue agreement vaccines currently promoted company merck vaccine division pasteur mrieux connaught sanofi pasteur sa formed joint venture market human vaccines europe collaborate development combination vaccines distribution existing eu european free trade association company sanofi pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc sanofi pasteur msd snc joint venture subject monitoring eu partners made certain undertakings return exemption european competition law effective december joint venture maintains presence directly table contents affiliates branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributors rest territory september sanofi pasteur msd spmsd mercks vaccine joint venture sanofi pasteur entered letter undertaking lou emea due emeas concerns regarding longterm efficacy hepatitis b component hexavac hepatitis b component hexavac manufactured merck lou requires relevant part suspension eu hexavac license suspension hexavac distribution recall hexavac product eu recall hexavac number noneu countries surveillance program possible future revaccination spmsd markets sells hexavac part eu notified merck reserving rights may seek damages merck defended indemnified held harmless merck event third party claims september emea also initiated formal review longterm efficacy hepatitis b vaccine hbvaxpro hepatitis b component hepatitis bhib combination vaccine procomvax products marketed sold spmsd european territory sold elsewhere different names merck assessment report prepared chmp mercks response considered chmp meeting february expected chmp conclude review april company rhnepoulenc sa sanofiaventis sa combined respective animal health poultry genetics businesses form merial limited merial fully integrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species merial divested entire poultry genetics business three segments domestic turkey layer segments divested respectively broiler foreign turkey segments sold competition cid markets companys pharmaceutical business conducted highly competitive often highly regulated global efforts toward health care cost containment continue exert pressure product pricing access competition involves intensive search technological innovations ability market innovations effectively longstanding emphasis research development company well prepared compete search technological innovations additional resources meet competition include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products joint ventures licenses refining sales marketing efforts address changing industry conditions enhance product portfolio company continues pursue external alliances earlystage latestage product opportunities including joint ventures targeted acquisitions however introduction new products processes competitors may result price reductions product replacements even products protected patents example number compounds available treat diseases typically increases time resulted slowing growth sales certain companys products legislation enacted states united states particularly area human pharmaceutical products allows encourages instances absence specific instructions prescribing physician mandates use generic products containing active chemical innovators product rather brandname products governmental pressures toward dispensing generic products significantly reduced sales certain companys products longer protected patents vasotec vaseretic enalapril maleate combination hydrochlorothiazide us rights sold addition zocor lost patent protection certain countries outside united states company experienced decline zocor sales countries table contents distribution cid company sells human health products primarily drug wholesalers retailers hospitals clinics government agencies managed health care providers health maintenance organizations institutions vaccines also sold directly physicians companys professional representatives communicate effectiveness safety value companys products health care professionals private practice group practices managed care organizations fourth quarter company implemented new distribution program us wholesalers moderate fluctuations sales caused wholesaler investment buying improve efficiencies distribution company pharmaceutical products new program lowered previous limits average monthly purchases company pharmaceutical products us customers following implementation program fluctuations sales caused wholesaler investment buying significantly moderated raw materials cid raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business government regulation investigation cid pharmaceutical industry subject global regulation regional country state local agencies particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states food drug administration modernization act fda modernization act passed culmination comprehensive legislative reform effort designed streamline regulatory procedures within fda improve regulation drugs medical devices food legislation principally designed ensure timely availability safe effective drugs biologics expediting premarket review process new products key provision legislation reauthorization prescription drug user fee act permits continued collection user fees prescription drug manufacturers augment fda resources earmarked review human drug applications helps provide resources necessary ensure prompt approval safe effective new drugs united states government expanded health care access enacting medicare prescription drug improvement modernization act signed law december prescription drug coverage began january new benefit supports companys goal improving access medicines expanding insurance coverage preserving marketbased incentives pharmaceutical innovation time benefit ensure prescription drug costs controlled competitive pressures encouraging appropriate use medicines addressing costcontainment pressure company made continuing effort demonstrate medicines help save costs overall patient health care many years pharmaceutical industry federal state oversight approval process new drugs drug safety advertising promotion drug purchasing reimbursement programs formularies variously review company believes continue able conduct operations including introduction new drugs market regulatory environment one type federal initiative contain federal health care spending prospective capitated payment system first implemented reduce rate growth medicare reimbursement hospitals system establishes advance flat rate reimbursement health care patients payor fiscally responsible type payment system cost containment systems widely used public private payors caused hospitals health maintenance organizations customers company cost conscious treatment decisions including decisions regarding medicines made available patients company continues work private federal employers slow increases health care costs companys efforts demonstrate medicines help save costs areas table contents encouraged use companys medicines helped offset effects increasing cost pressures also federal state governments pursued methods directly reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria provide minimum discounts defined nonfederal average manufacturer price purchases certain components federal government department veterans affairs department defense initiatives states seek rebates beyond minimum required medicaid legislation cases patients beyond eligible medicaid federal vaccines children entitlement program us centers disease control prevention cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children company awarded cdc contract supply million pediatric vaccines vaccines children program january patients previously eligible medicaid also medicare beneficiaries years older disabled leave stateadministered medicaid system covered new medicare prescription drug benefit outside united states company encounters similar regulatory legislative issues countries business primary thrust governmental inquiry action toward determining drug safety effectiveness often mechanisms controlling prices prescription drugs profits prescription drug companies eu adopted directives concerning classification labeling advertising wholesale distribution approval marketing medicinal products human use companys policies procedures already consistent substance directives consequently believed material effect companys business company subject jurisdiction various regulatory agencies therefore subject potential administrative actions actions may include seizures products civil criminal sanctions certain circumstances company may deem advisable initiate product recalls company believes able compete effectively within environment addition certain countries within eu recognizing economic importance researchbased pharmaceutical industry value innovative medicines society working industry representatives european commission proposals complete single market pharmaceuticals improve competitive climate variety means including market deregulation increasing amount focus privacy issues countries around world including united states eu united states eu governments pursued legislative regulatory initiatives regarding privacy including federal privacy regulations recently enacted state privacy laws concerning health personal information affected companys operations patents trademarks licenses cid patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance date grant legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage patent portfolios developed products introduced company normally provide market exclusivity basic patents effect following major products united states cancidas comvax haemophilus b conjugate hepatitis b recombinant vaccine cosopt cozaar crixivan emend aprepitant fosamax hyzaar invanz ertapenem sodium maxalt primaxin propecia finasteride proscar recombivax hb table contents singulair timopticxe timolol maleate ophthalmic gel forming solution trusopt zocor basic patents also effect united states zetia vytorin developed merckscheringplough partnership basic patent also effect sustivastocrin efavirenz bristolmyers squibb bms exclusive license company sells sustiva united states canada certain european countries company markets stocrin countries throughout world basic patent aggrastat tirofiban hydrochloride united states divested product company retains basic patents aggrastat outside united states fda modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant exclusivity provisions reauthorized october best pharmaceuticals children act passed january fda granted additional six months market exclusivity united states invanz august fda granted additional six months market exclusivity united states trusopt october fda granted additional six months market exclusivity united states cozaarhyzaar february fda granted additional six months market exclusivity united states singulair august information respect companys patents see patent litigation expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states market exclusivity may available federal law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset general increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties june zocor lose market exclusivity united states company expects significant decline us zocor sales time june basic patent united states covering proscar expire result company expects significant decline us proscar sales time basic patent proscar also covers propecia however propecia protected additional patents expire october fda granted additional six months market exclusivity united states fosamax february fosamax weekly january however january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid company exhausted options appeal decision based court appeals decision fosamax lose market exclusivity united states february company expects significant decline us fosamax sales time worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely table contents royalties received patent knowhow licenses rights amounted million company also paid royalties amounting million patent knowhow licenses holds discontinued operations cid august company completed spinoff medco health solutions inc medco health separate publiclytraded company spinoff effected way pro rata dividend company stockholders outstanding shares common stock medco health based letter ruling company received us internal revenue service receipt medco health shares distribution taxfree us federal income tax purposes cash received lieu fractional shares taxable divestitures cid march company completed sale johnson johnson companys equity stake european nonprescription pharmaceuticals joint venture johnson johnson company sold us rights aggrastat guilford pharmaceuticals inc including basic us product patents process patents product company sold us rights vasotec vaseretic vasotec iv injection enalaprilat biovail laboratories incorporated biovail subsidiary biovail corporation time companys canadian subsidiary merck frosst canada co merck frosst biovail entered supply agreement merck frosst agreed supply biovail minimum five years bulk tablets formulated enalapril maleate enalapril maleate combination hydrochlorothiazide distribution biovail united states vasotec vaseretic basic product patents vasotec vaseretic expired united states prior transactions research development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities expenditures companys research development programs billion billion billion estimated continue level fullyear expense company maintains ongoing commitment research broad range therapeutic areas clinical development support new products total expenditures period exceeded billion compound annual growth rate company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development mercks new rd model designed increase productivity improve probability success prioritizing companys rd resources nine priority disease areas alzheimers disease atherosclerosis cardiovascular disease diabetes novel vaccines obesity oncology pain sleep disorders therapeutic areas carefully chosen based set criteria including unmet medical needs scientific opportunity commercial opportunity within therapeutic areas merck commit resources achieve research breadth depth develop bestinclass targeted differentiated products valued highly patients payers physicians company also make focused investments pursue specific mechanisms following selected disease areas antibiotics antifungals antivirals hepatitis c virus human immunodeficiency virus asthma chronic obstructive pulmonary disease neurodegeneration ophthalmology osteoporosis schizophrenia stroke addition company capitalize selected opportunities outside areas continuing commercialize attractive clinical development candidates pipeline pursuing appropriate external licensing opportunities development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug may marketed table contents united states recorded data preclinical clinical experience included nda bla fda required approval development certain products also subject government regulations covering safety efficacy united states many foreign countries companys scientists discover new compound believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase ii studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness results phase ii trials satisfactory company commences largescale phase iii trials confirm compounds efficacy safety upon completion trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed united states fda approval process begins complete nda submitted received fda pursuant prescription drug user fee act fda review period targets ndas supplemental ndas either six months priority review ten months standard review within days receipt nda fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review review timelines defined fda act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information days extensions review period communicated company based fda statistics drug development time initiation preclinical testing nda approval range years average years june fda accepted standard review bla zostavax mercks investigational vaccine prevention herpes zoster commonly known shingles adults years age older sanofi pasteur msd submitted application licensure zostavax eu merck also submitted applications licensure zostavax australia canada countries asia latin america february fda extended review zostavax three months late may september merck presented two studies phase ii data companys dpp inhibitor januvia proposed trademark mk sitagliptin potential new approach treatment type diabetes st annual meeting european association study diabetes february merck announced nda januvia accepted standard review fda merck expects fda action nda midoctober december merck submitted bla fda gardasil quadrivalent human papillomavirus types recombinant vaccine companys vaccine protect four types human papillomavirus hpv types account estimated cervical cancer cases types account estimated genital warts cases february merck announced fda accepted bla gardasil investigational cervical cancer vaccine given priority review agency priority designation intended products address unmet medical needs prescription drug user fee act blas filed fdas goal review act blas designated priority review within six months receipt fda informed merck review goal date june since submission fda december merck also submitted applications gardasil table contents additional regulatory agencies including eu australia mexico brazil argentina taiwan singapore companys earlystage clinical pipeline includes candidates following areas arthritis atherosclerosis cancer cardiovascular disease diabetes endocrine disorders glaucoma infectious diseases insomnia neurodegenerative disease obesity osteoporosis psychiatric disease pain respiratory disease urogenital disorders vaccines company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies company completed transactions including research collaborations preclinical clinical compounds technology transactions across broad range therapeutic categories including neuroscience obesity oncology may merck bioxell entered agreement develop new treatments sepsis inflammatory disorders june vical incorporated vical exercised three options amendment existing research collaboration licensing agreement granting merck rights use vicals patented nonviral gene delivery technology cancer vaccine applications merck vertex pharmaceuticals incorporated announced june initiation additional phase clinical study vx small molecule inhibitor aurora kinases aurora kinases implicated onset progression human leukemias dainippon sumitomo pharma co ltd formerly known sumitomo pharmaceuticals co ltd sumitomo merck signed agreement june collaborate sm lurasidone atypical antipsychotic compound currently phase ii development treatment schizophrenia one chronic disabling severe mental illnesses agreement sumitomo granted merck affiliate exclusive license sm parts world except japan china korea taiwan june merck announced agreement metabasis therapeutics research develop commercialize novel small molecule therapeutics potential treat several diseases including type diabetes hyperlipidemia obesity activation enzyme liver called ampactivated protein kinase july merck geron corporation announced agreement develop cancer vaccine telomerase telomerase enzyme active cancer cells maintains telomere length ends chromosomes activity allows cancer grow metastasize long periods time september foxhollow technologies inc merck announced formation novel pharmacogenomics collaboration collaboration focus analyzing atherosclerotic plaque removed patient arteries means identifying new biomarkers atherosclerotic disease progression use development cardiovascular compounds mercks pipeline agreement includes research collaboration three years october agensys inc agensys cancer biotechnology company merck announced formed global alliance jointly develop commercialize agspsca agensys fully human monoclonal antibody prostate stem cell antigen psca agreement grants merck worldwide rights agspsca exclusive license psca proprietary target well rights therapeutic diagnostic products developed alliance also october merck bms jointly announced signed separate license agreements international partnership microbicides develop new antiretroviral compounds potential microbicides protect women hiv compounds part new class anti table contents retrovirals known entry inhibitors compounds bind directly hiv others bind ccr receptor designed prevent hiv efficiently entering host cells thus preventing infection company bms reported october fda issued approvable letter pargluva bmss investigational oral medicine treatment type diabetes fda requested additional safety information ongoing trials completed since safety data last formal regulatory submission address fully cardiovascular safety profile pargluva data requirement may cause significant delay products launch result bms company terminated collaborative agreement pargluva rights pargluva back compound pargluva returning bms december chart reflects companys current research pipeline february candidates shown phase iii include specific products candidates shown phase ii include advanced compound specific mechanism given therapeutic area back compounds regardless phase development additional indications therapeutic area additional line extensions formulations inline products shown companys programs generally designed focus development novel medicines address large unmet medical needs phase phase phase ii phase iii review alzheimers disease diabetes arthritis aids hpv related mk mk mk mk cervical cancer mk mk cancer ctcl atherosclerosis genital warts arthritis mk vorinostat mkb gardasil mk endocrine endocrine mka atherosclerosis mk mk cinv shingles mk flu vaccine hiv vaccine mk zostavax mk glaucoma hpv vaccine diabetes mk mk hypertension mka diabetes cancer insomnia mk insomnia januvia mk mk obesity gaboxadol mk obesity mk approvable agensys nastech pyy mk arthritispain mk osteoporosis osteoporosis arcoxia vx mk mk mk pain pain us approvals cancer vaccine neurogen mk osteoporosis cardiovascular parkinsons disease mk fosamax plus mk mk mk pediatric vaccine psychiatric disease pediatric vaccine proquad mk psychiatric disease respiratory disease mk us approvals mk lurasidone rotavirus aureus vaccine stroke gastroenteritis ono rotateq urinary incontinence mk mk licensed alliance acquisition pipeline multiple licenses including csl ltd merck discussions licensing partner regarding plans compound march merck terminated agreement nastech pharmaceutical company inc respect pyy product service marks appearing type form different surrounding text trademarks service marks owned licensed merck subsidiaries affiliates including zetia vytorin trademarks owned entities merckscheringplough partnership except noted cozaar hyzaar registered trademarks ei du pont de nemours company wilmington de prilosec nexium trademarks astrazeneca group us trademarks vasotec vaseretic owned table contents biovail laboratories incorporated us trademark aggrastat owned guilford pharmaceuticals inc trademark pargluva owned bms employees end company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups part costreduction initiative announced october completed end company eliminated positions company completed similar program positions eliminated december november company announced first phase global restructuring program designed reduce companys cost structure increase efficiency enhance competitiveness initial steps include implementation new supply strategy merck manufacturing division intended create leaner costeffective customerfocused manufacturing model next three years result merck incur certain costs associated exit disposal activities part global restructuring program company expects eliminate approximately positions manufacturing divisions worldwide representing global work force end half position reductions expected occur united states remainder countries merck intends sell close five manufacturing facilities worldwide reduce operations number sites company also expects close one basic research site two preclinical development sites sites identified closure expected closed end subject compliance legal obligations pretax costs restructuring million expected million billion end initial phase restructuring program substantially complete cumulative pretax costs restructuring activities announced november expected range billion billion approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities scheduled closure environmental matters company believes compliance material respects applicable environmental laws regulations company incurred capital expenditures approximately million environmental protection facilities company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million estimated million years amounts consider potential recoveries insurers parties company taken active role identifying providing costs managements opinion liabilities environmental matters probable reasonably estimable accrued although possible predict certainty outcome environmental matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess provided result material adverse effect companys financial position results operations liquidity capital resources geographic area segment information companys operations principally managed products basis one reportable segment merck pharmaceutical segment includes products marketed either directly joint ventures merck pharmaceutical products consist therapeutic preventive agents sold prescription treatment prevention human disorders table contents companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states sales sales sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions recent years company expanding operations countries located latin america middle east africa eastern europe asia pacific changes government policies economic conditions making possible company earn fair returns business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas operating segments companys business incorporated reference pages beginning caption segment reporting companys annual report stockholders available information companys internet website address wwwmerckcom company make available free charge investor information portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished securities exchange commission sec companys corporate governance guidelines charters board directors seven standing committees available companys website wwwmerckcomaboutcorporategovernance information available print stockholder requests company item risk factors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forward looking statements involve risks uncertainties companys results could materially differ anticipated forward looking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results company faces significant litigation related vioxx september company voluntarily withdrew vioxx arthritis acute pain medication market worldwide december approximately product liability lawsuits involving approximately plaintiff groups alleging personal injuries resulting use vioxx filed company state federal courts united states company also defendant purported class actions related use vioxx suits referred vioxx product liability lawsuits addition vioxx product liability lawsuits number purported class actions brought company several current former officers directors company alleging company made false misleading statements regarding vioxx violation federal securities laws suits referred vioxx securities lawsuits employee retirement income security act erisa suits referred vioxx erisa lawsuits addition number shareholders filed derivative suits one shareholder table contents filed demand asserting claims board members company officers suits referred vioxx derivative lawsuits together vioxx securities lawsuits vioxx erisa lawsuits vioxx shareholder lawsuits company also named defendant actions various countries outside united states suits referred vioxx foreign lawsuits company also sued four states respect marketing vioxx company anticipates additional lawsuits relating vioxx filed andor certain current former officers directors future sec conducting formal investigation company concerning vioxx us department justice issued subpoena requesting information relating companys research marketing selling activities respect vioxx federal health care investigation criminal statutes also ongoing investigations certain congressional committees local authorities europe group attorneys general thirtyone states district columbia conducting investigation companys sales marketing vioxx company cooperating authorities investigations investigations referred vioxx investigations company predict outcome investigations however could result potential civil andor criminal liability three vioxx product liability lawsuits us gone trial resulted jury verdicts august trial state court texas jury ernst vs merck reached verdict favor plaintiff purported award total million compensatory punitive damages texas law maximum amount could awarded plaintiff capped approximately million company intends appeal verdict completion posttrial proceedings trial court believes strong points raise appeal since company believes potential unfavorable outcome probable company established reserve respect verdict november second vioxx personal injury case go trial frederick mary jackson humeston vs merck co inc superior court new jersey law division atlantic county jury returned verdict favor company counts jury found vote company fail provide adequate warning prescribing physicians association vioxx increased risk serious cardiovascular events prior mr humestons heart attack jury also unanimously found company violate new jersey consumer fraud act marketing drug prescribing physicians february retrial case federal court new orleans brought evelyn irvin plunkett behalf late husband richard irvin jr died apparent heart attack jury returned verdict favor merck counts outcomes first three vioxx product liability trials interpreted indicate trend outcome may likely future vioxx trials company currently anticipates number vioxx product liability lawsuits tried company predict timing trials respect vioxx shareholder lawsuits company believes meritorious defenses vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits vigorously defend company believes insurance coverage respect vioxx lawsuits adequate cover defensive costs losses company spent million aggregate legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation fourth quarter company recorded charge million increase reserve solely future legal defense costs related vioxx litigation million december million december reserve based certain assumptions described legal proceedings best estimate amount table contents company believes time reasonably estimate spent company currently able estimate amount damages may required pay connection vioxx lawsuits vioxx investigations proceedings expected continue years currently early stage company little information course take view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits company established reserves potential liability relating vioxx lawsuits vioxx investigations series unfavorable outcomes vioxx lawsuits vioxx investigations resulting payment substantial damages fines resulting criminal penalties could material adverse effect companys business cash flow results operations financial position prospects certain companys major products going lose patent protection near future occurs company expects significant decline sales products company depends upon patents provide exclusive marketing rights products period time product patents several companys products recently expired expire united states countries company faces strong competition lower price generic drugs loss patent protection one companys products typically leads rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss patent protection material adverse effect companys results operations zocor companys statin modifying cholesterol currently largest revenueproducing product lost basic patent protection canada certain countries europe including united kingdom germany company experienced decline zocor sales countries result availability generic version worldwide sales zocor billion compared billion june zocor lose market exclusivity united states company expects significant decline zocor sales time august opposition division european patent office rendered decision revoke companys patent europe covers weekly administration alendronate decision appealed hearing scheduled march decisions proceedings typically rendered end hearing decision upheld company entitled market exclusivity fosamax major european markets moreover mercks basic patent covering use alendronate challenged several european countries company unsuccessful countries company could lose exclusivity rights fosamax countries company would expect significant decline european sales fosamax loss exclusivity sales fosamax outside united states already adversely affected availability generic products markets including united kingdom canada germany nonetheless global sales fosamax grew billion result strong sales united states january us court appeals federal circuit washington dc found companys patent claims weekly administration fosamax invalid company exhausted options appeal decision based court appeals decision fosamax lose market exclusivity united states february company expects significant decline fosamax sales time table contents companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products year declines sales products zocor fosamax mean companys future success dependent pipeline new products including new products develops joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties support research development efforts company must make ongoing substantial expenditures without assurance efforts funding result commercially successful product company must also commit substantial efforts funds resources recruiting retaining high quality scientists personnel pharmaceutical research development expertise based fda statistics drug development time initiation preclinical testing nda approval range years average years description research development process see research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals accordingly company may abandon product invested substantial amounts time money risks encountered research development process include following preclinical testing new compound may yield disappointing results clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved fda intended use may possible obtain patent new drug sales new product may disappointing company state certainty whether products development launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products zocor fosamax lose patent protection displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including european commission united states fda particular importance company administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases cost reduction fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval mandate product withdrawals even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant table contents delays approval process failure maintain approval jurisdiction prevent selling new products jurisdiction approval obtained ever company would able realize revenues new products jurisdiction approval company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents infringement similar claims company company aggressively defends important patents within outside united states including filing claims infringement parties see legal proceedings patent litigation particular manufacturers generic pharmaceutical products time time file abbreviated new drug applications anda fda seeking market generic forms companys products prior expiration relevant patents owned company company normally responds vigorously defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases third party patents may prevent company marketing selling product particular geographic area one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products company faces intense competition lowercost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states political pressures reduce spending prescription drugs led legislation encourages use generic products although companys policy actively protect patent rights generic challenges companys products arise time may able prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially results operations cash flow company faces intense competition new products companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer table contents effective effectively marketed sold companys products alternatively case generic competition may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business results operations cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following significant litigation related vioxx competition generic products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations enforcement thereof affecting companys business table contents efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu united states federal state governments pursued legislative regulatory initiatives regarding patient privacy including federal recently issued state privacy regulations concerning health information affected companys operations changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters located whitehouse station new jersey companys us pharmaceutical business conducted divisional headquarters located upper gwynedd west point pennsylvania companys vaccines business conducted divisional headquarters located west point principal research facilities human health products located rahway new jersey west point company also production facilities human health products nine locations united states puerto rico branch warehouses provide services throughout country outside united states subsidiaries company owns interest manufacturing plants properties australia canada japan singapore south africa countries western europe central south america asia capital expenditures billion compared billion united states amounted million billion abroad expenditures amounted million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs table contents existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions vioxx litigation product liability lawsuits previously disclosed federal state product liability lawsuits involving individual claims well putative class actions filed company respect vioxx december company served aware named defendant approximately lawsuits include approximately plaintiff groups alleging personal injuries resulting use vioxx lawsuits approximately lawsuits representing approximately plaintiff groups slated federal mdl discussed approximately lawsuits representing approximately plaintiff groups included coordinated proceeding new jersey superior court judge carol e higbee certain lawsuits include allegations regarding gastrointestinal bleeding cardiovascular events thrombotic events kidney damage company also named defendant approximately putative class actions alleging personal injuries seeking medical monitoring result putative class members use vioxx ii disgorgement certain profits common law unjust enrichment theories andor iii various remedies state consumer fraud fair business practice statutes including recovering cost vioxx purchased individuals thirdparty payors union health plans actions discussed paragraph collectively referred vioxx product liability lawsuits actions filed state courts california texas new jersey philadelphia pennsylvania respectively transferred single judge state coordinated proceedings february judicial panel multidistrict litigation jpml transferred vioxx product liability lawsuits pending federal courts nationwide one multidistrict litigation mdl coordinated pretrial proceedings mdl transferred united states district court eastern district louisiana district judge eldon e fallon judge fallon indicated intends try series cases period november following categories heart attack short term use ii heart attack long term use iii stroke iv cardiovascular injury involving prescription written april labeling vioxx revised include results vigor trial november december case brought evelyn irvin plunkett behalf late husband richard irvin jr died apparent heart attack tried houston texas plaintiff alleged mr irvin took vioxx approximately one month thus action fell within category heart attack short term use deliberating two onehalf days court found jury deadlocked declared mistrial federal court rules require unanimous verdict retrial case commenced february new orleans louisiana february jury returned verdict favor merck counts next scheduled mdl trial diaz v merck case plaintiffs claim heart attack long term use scheduled june previously scheduled may addition diaz case garza case discussed vioxx product liability lawsuits currently scheduled trial company intends provide list trials website wwwmerckcom periodically update appropriate company included website address inactive textual reference intend active link website incorporate reference information contained therein table contents merck entered tolling agreement tolling agreement mdl plaintiffs steering committee establishes procedure halt running statute limitations tolling certain categories claims allegedly arising use vioxx nonnew jersey citizens tolling agreement applies individuals filed lawsuits may may eventually file lawsuits claimants seek toll claims alleging injuries resulting thrombotic cardiovascular event results myocardial infarction ischemic stroke tolling agreement provides counsel additional time evaluate potential claims tolling agreement requires tolled claims filed federal court december approximately claimants entered tolling agreements previously disclosed august trial state court texas jury ernst vs merck reached verdict favor plaintiff purported award total million compensatory punitive damages texas law maximum amount could awarded plaintiff capped approximately million company intends appeal verdict completion posttrial proceedings trial court company believes strong points raise appeal hopeful appeals process correct verdict since company believes potential unfavorable outcome probable established reserve respect verdict november case frederick mary jackson humeston vs merck superior court new jersey law division atlantic county jury returned verdict favor merck counts case second vioxx personal injury case go trial mr humeston year old united states postal employee idaho alleged suffered heart attack september result taking vioxx sought compensatory punitive damages jury found vote merck fail provide adequate warning prescribing physicians association vioxx increased risk serious cardiovascular events prior mr humestons heart attack jury also unanimously found merck violate new jersey consumer fraud act marketing drug prescribing physicians trial garza v heart clinic evans posada merck began january th judicial district court starr county texas company believes evidence case show vioxx cause heart attack leonel garza sr mr garza died heart attack april following years cardiovascular disease prior heart attack approximately one month death company maintains mr garza given oneweek supply vioxx mg samples pain addition trial proceedings consolidated trial cona v merck mcdarby v merck began february new jersey superior court law division atlantic county judge higbee company believes evidence show vioxx cause either mr mcdarby mr cona heart attack lawsuits previously disclosed july new jersey state trial court certified nationwide class thirdparty payors unions health insurance plans paid whole part vioxx used plan members insureds named plaintiff case seeks recovery certain vioxx purchase costs plus penalties based allegations purported class members paid vioxx would known products alleged risks merck believes class improperly certified trial courts ruling procedural address merits plaintiffs allegations company intends defend vigorously new jersey state superior court appellate division accepted mercks appeal class certification order expedited basis previously reported company also named defendant separate lawsuits brought attorneys general louisiana mississippi texas attorney general alaska also recently filed lawsuit actions allege company misrepresented safety vioxx seek recovery cost vioxx purchased reimbursed state agencies ii reimbursement sums paid state agencies medical services treatment persons injured vioxx iii damages various common law theories andor iv remedies various state statutory theories including state table contents consumer fraud andor fair business practices medicaid fraud statutes including civil penalties shareholder lawsuits previously disclosed addition vioxx product liability lawsuits company along various current former officers directors company defendants number putative class actions individual lawsuits filed removed federal court shareholders federal securities laws vioxx securities lawsuits transferred jpml along related lawsuits discussed united states district court district new jersey district judge stanley r chesler inclusion nationwide mdl coordinated pretrial proceedings shareholder mdl judge chesler consolidated vioxx securities lawsuits purposes june plaintiffs vioxx securities lawsuits filed fourth consolidated amended class action complaint superseding prior complaints various cases complaint plaintiffs request certification class purchasers company stock may october complaint alleges defendants made false misleading statements regarding vioxx violation sections b securities exchange act seeks unspecified compensatory damages costs suit including attorneys fees complaint also asserts claim section securities exchange act certain defendants relating sales merck stock addition complaint includes allegations sections securities act certain defendants made incomplete misleading statements registration statement certain prospectuses filed connection merck stock investment plan dividend reinvestment plan defendants filed motion dismiss complaint pending previously disclosed august complaint filed oregon state court state oregon oregon state treasurer behalf oregon public employee retirement fund company certain current former officers directors complaint brought oregon securities law alleges plaintiff suffered damages connection purchases merck common stock artificially inflated prices due companys alleged violations law related disclosures vioxx company removed lawsuit us district court district oregon however plaintiff moved remand case state court motion granted previously disclosed number shareholder derivative actions filed federal court new jersey superior court naming company nominal defendant certain members board past present together certain executive officers defendants complaints arise substantially factual allegations made vioxx securities lawsuits derivative suits purportedly brought assert rights company assert claims board members officers breach fiduciary duty waste corporate assets unjust enrichment abuse control gross mismanagement actions discussed paragraph collectively referred vioxx derivative lawsuits jpml transferred vioxx derivative lawsuits pending federal court shareholder mdl judge chesler consolidated vioxx derivative lawsuits purposes june federal derivative plaintiffs filed verified consolidated shareholders derivative complaint superseding prior complaints various cases defendants filed motion dismiss complaint pending addition vioxx derivative lawsuits pending new jersey superior court consolidated transferred judge higbee atlantic county april state plaintiffs filed superseding verified consolidated amended shareholder derivative complaint january two shareholder derivative cases dismissed without prejudice cases dismissed court granted defendants motion stay cases courts order permits plaintiffs refile complaints consolidated federal shareholder derivative case resolved previously disclosed october two individual shareholders made demand board take legal action mr raymond gilmartin former chairman president chief executive officer individuals allegedly causing damage company respect allegedly improper marketing vioxx response demand letter board directors determined november meeting board would take shareholders request consideration remains consideration table contents addition previously disclosed number putative class actions filed company certain current former officers directors company federal court vioxx erisa lawsuits together vioxx securities lawsuits vioxx derivative lawsuits vioxx shareholder lawsuits behalf certain companys current former employees participants certain companys retirement plans asserting claims employee retirement income security act erisa lawsuits make similar allegations allegations contained vioxx securities lawsuits claim defendants breached duties plan fiduciaries jpml transferred vioxx erisa lawsuits shareholder mdl judge chesler consolidated vioxx erisa lawsuits purposes consolidated amended complaint filed vioxx erisa lawsuits august defendants filed motion dismiss complaint pending international lawsuits previously disclosed addition lawsuits discussed company named defendant litigation relating vioxx various countries collectively vioxx foreign lawsuits europe canada brazil australia turkey israel additional lawsuits based media reports sources company anticipates additional vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits filed andor certain current former officers directors future insurance previously disclosed company product liability insurance claims brought vioxx product liability lawsuits stated upper limits approximately million deductibles coinsurance insurance provides coverage legal defense costs potential damage amounts incurred connection vioxx product liability lawsuits company believes insurance coverage extends additional vioxx product liability lawsuits may filed future company directors officers insurance coverage applicable vioxx securities lawsuits vioxx derivative lawsuits stated upper limits approximately million company fiduciary insurance vioxx erisa lawsuits stated upper limits approximately million additional insurance coverage claims may also available upperlevel excess policies provide coverage variety risks disputes certain insurers availability insurance coverage likely additional disputes time company believes insurance coverage respect vioxx lawsuits adequate cover defense costs losses previously disclosed companys upper level excess insurers provide excess insurance potentially applicable vioxx lawsuits commenced arbitration seeking among things cancel policies void obligations policies raise coverage issues respect vioxx lawsuits second arbitration one companys upper level excess insurers also commenced merck intends contest vigorously insurers claims attempt enforce rights applicable insurance policies amounts actually recovered policies discussed section may less amounts specified preceding paragraph investigations previously disclosed november company advised staff sec commencing informal inquiry concerning vioxx january company announced received notice sec issued formal notice investigation also company received subpoena us department justice doj requesting information related companys research marketing selling activities respect vioxx federal health care investigation criminal statutes also ongoing investigations certain congressional committees previously disclosed companys uk subsidiary notified medicines healthcare table contents products regulatory agency united kingdom mhra investigation mhra compliance company eu adverse experience reporting requirements connection vioxx addition previously disclosed investigations conducted local authorities certain cities europe order determine whether criminal charges brought concerning vioxx company cooperating governmental entities respective investigations vioxx investigations company predict outcome inquiries however could result potential civil andor criminal dispositions previously disclosed company received civil investigative demand cid group attorneys general states district columbia investigating whether company violated state consumer protection laws marketing vioxx company cooperating attorneys general responding cid reserves company currently anticipates number vioxx product liability lawsuits tried company predict timing trials respect vioxx shareholder lawsuits company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits company established reserves potential liability relating vioxx lawsuits vioxx investigations legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december company established reserve million solely future legal defense costs related vioxx litigation company spent million aggregate legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation fourth quarter company recorded charge million increase reserve solely future legal defense costs related vioxx litigation million december reserve based certain assumptions best estimate amount company believes time reasonably estimate spent significant factors considered establishment ongoing review reserve vioxx legal defense costs follows actual costs incurred company time development companys legal defense strategy structure light scope vioxx litigation number cases brought company costs outcomes completed trials anticipated timing progression related costs pretrial activities trials vioxx product liability lawsuits events scheduled trials expected occur throughout inherent inability predict ultimate outcomes trials limit companys ability reasonably estimate legal costs beyond end company continue monitor legal defense costs review adequacy associated reserves unfavorable outcomes vioxx l itigation could material adverse effect companys financial position liquidity results operations commercial litigation beginning company named number antitrust suits certain certified class actions instituted nations retail pharmacies consumers several states company settled federal class action represented single largest group claims settled substantially remaining cases satisfactory terms remaining cases inactive several years company engaged conspiracy admission wrongdoing made included settlement agreements previously disclosed company joined ongoing litigation alleging manipulation table contents pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels jpml ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like company defendants prior pending case may court granted companys motion dismiss consolidated class action dismissed company class action case subsequent companys dismissal plaintiffs filed amended consolidated class action complaint name company defendant company many pharmaceutical manufacturers defendants similar complaints pending federal state court brought individually number counties state new york company defendants awaiting final ruling motion dismiss suffolk county case first new york county cases filed addition december company defendant state cases brought attorneys general kentucky illinois alabama wisconsin mississippi arizona vigorously defended company also received letter inquiry attorney general idaho previously disclosed company named defendant antitrust cases federal court minnesota state court california alleging unlawful conspiracy among different sets pharmaceutical manufacturers protect high prices united states impeding importation united states lowerpriced pharmaceuticals canada court dismissed federal claims minnesota case prejudice plaintiffs filed notice appeal state claims action dismissed without prejudice previously disclosed suit federal court alabama two providers health services needy patients alleges pharmaceutical companies overcharged plaintiffs class similarly situated pharmaceuticals purchased plaintiffs program established section b public health service act company defendants filed motion dismiss complaint numerous grounds recently denied court previously disclosed january doj notified federal court new orleans louisiana going intervene time pending federal false claims act case filed seal december company court issued order unsealing complaint filed physician louisiana ordered complaint served complaint alleged companys discounting pepcid certain louisiana hospitals led increases costs medicaid dismissed amended complaint filed seal case administratively closed court seal lifted state louisiana filed amended complaint incorporating allegations contained sealed amended complaint allegations contained sealed amended complaint unknown april company named qui tam lawsuit nevada false claims act suit nevada attorney general intervened alleges company inappropriately offered nominal pricing marketing pricing inducements certain customers also failed comply obligations medicaid best price scheme related arrangements company vigorously defending lawsuit governmental proceedings previously disclosed company received subpoena doj connection investigation companys marketing selling activities including nominal pricing programs samples company also reported received cid attorney general texas regarding companys marketing selling activities relating texas previously disclosed company received another cid attorney general texas asking additional information regarding companys marketing selling activities related texas including respect certain nominal pricing programs samples april company received subpoena table contents office inspector general district columbia connection investigation companys interactions physicians district columbia maryland virginia november company received letter request doj connection investigation companys pricing pepcid september company received subpoena illinois attorney general subpoena seeks information related repackaging prescription drugs previously disclosed company received letter doj advising existence qui tam complaint alleging company violated certain rules related calculations best price federal pricing benchmark calculations certain may affect companys medicaid rebate obligation company cooperating investigations company predict outcome investigations however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations addition time time federal state foreign regulators authorities may seek information practices pharmaceutical industry companys business practices inquiries investigations discussed section feasible predict outcome inquiries february italian antitrust authorities adopted measure commencing formal investigation merck sharp dohme italia spa msd italy company article italian competition law article ec ascertain whether company msd italy committed abuse dominant position virtue companys refusal grant acs dobfar spa dobfar italian company voluntary license pursuant domestic legislation passed permit dobfar manufacture tienam imipenem cilastatin italy sale outside italy countries patent protection applicable domestic rules expired never existed company supplementary protection certificate spc provides company certain rights respect manufacture sale tienam italy expired january hearing italian antitrust authorities held may june italian antitrust authority ica issued order imposing interim measures requiring company grant license manufacture tienam italy pursuant icas order license granted dobfar limited right manufacture build supply stock tienam allow dobfar export tienam outside italy sell tienam product within italy prior expiry spc november italian administrative court denied companys appeal icas order proceedings ica ongoing vaccine litigation previously disclosed company party claims brought consumer protection act united kingdom allege certain children suffer variety conditions result vaccinated various bivalent vaccines measles rubella andor trivalent vaccines measles mumps rubella including companys mmr ii conditions include autism without inflammatory bowel disease epilepsy encephalitis encephalopathy guillainbarre syndrome transverse myelitis claimants proceeding companys knowledge intending proceed company company vigorously defend lawsuits previously disclosed company also party individual class action product liability lawsuits claims united states involving pediatric vaccines eg hepatitis b vaccine contained thimerosal preservative used vaccines merck distributed thimerosalcontaining pediatric vaccines united states since fall december approximately active thimerosal related lawsuits approximately plaintiffs defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result exposure thimerosal pediatric vaccines two state court cases two federal district court cases scheduled trial cases dismissed one case set trial also dismissed certain dismissals appealed company vigorously defend table contents lawsuits however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations company successful cases type either dismissed stayed ground action prohibited national childhood vaccine injury act vaccine act vaccine act prohibits person filing maintaining civil action state federal court seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims hereinafter vaccine court vaccine act filing civil action vaccine manufacturer petitioner must either pursue petition conclusion vaccine court timely file election proceed civil action lieu accepting vaccine courts adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribed time periods company aware numerous cases pending vaccine court involving allegations thimerosalcontaining vaccines andor mmr ii vaccine cause autism spectrum disorders cases referred preceding paragraph dismissed brought plaintiffs claim made timely withdrawal vaccine court petition company party vaccine court proceedings petitions brought department health human services patent litigation time time generic manufacturers pharmaceutical products file andas fda seeking market generic forms companys products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic form fosamax prilosec nexium propecia trusopt cosopt prior expiration companys astrazenecas case prilosec nexium patents concerning products generic companies andas generally include allegations noninfringement invalidity unenforceability patents generic manufacturers received fda approval market generic form prilosec company filed patent infringement suits federal court companies filing andas generic alendronate fosamax finasteride propecia dorzolamide trusopt dorzolamidetimolol cosopt astrazeneca company filed patent infringement suits federal court companies filing andas generic omeprazole prilosec esomeprazole nexium similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products previously disclosed january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid company exhausted options appeal decision based court appeals decision fosamax lose market exclusivity united states february company expects significant decline us fosamax sales time may federal court canada trial division issued decision refusing bar approval generic alendronate ground mercks patent weekly alendronate likely invalid decision appealed generic alendronate launched canada june july merck sued federal court canada apotex seeking damages lost sales generic weekly alendronate due patent proceeding january high court justice england wales held patents company protecting alendronate daily weekly products invalid united kingdom november court appeals england wales affirmed ruling high court justice england wales table contents european countries permit companies seeking approval generic product reference data innovative product certain circumstances data exclusivity regulations high court justice affirmed decision uk regulatory authority data weekly alendronate may referenced companies seeking approval generic weekly alendronate products company filed leave appeal judgment swedish administration court affirming grant swedish regulatory authority approval generic weekly alendronate products referenced companys data weekly alendronate approval company filed similar cases countries previously announced company july opposition division opposition division european patent office epo rendered oral decision revoke companys patent europe covers onceweekly administration alendronate august written opinion issued confirming oral decision revoking companys patent september company filed appeal decision hearing appeal scheduled march decisions proceedings typically rendered end hearing decision upheld company entitled market exclusivity fosamax major european markets addition mercks basic patent covering use alendronate challenged several european countries company unsuccessful countries company could lose exclusivity rights fosamax countries company defending alendronate weekly product major european markets based patents october action australia challenging validity companys australian patent onceweekly administration alendronate patent found invalid company appealed decision addition previously disclosed japan proceeding filed challenging validity companys japanese patent onceweekly administration alendronate january company sued hitech pharmacal co inc hitech amityville new york patent infringement response hitechs application fda seeking approval generic version mercks ophthalmic drugs trusopt cosopt used treating elevated intraocular pressure people ocular hypertension glaucoma lawsuit merck sued enforce patent covering active ingredient dorzolamide present trusopt cosopt merck elected enforce two us patents listed fda cover combination dorzolamide timolol two active ingredients cosopt lawsuit automatically stay fda approval hitechs andas months adverse court decision whichever may occur earlier patent covering dorzolamide provides exclusivity trusopt cosopt october including six months pediatric exclusivity time company expects sales products decline case omeprazole trial court united states rendered opinion october upholding validity companys astrazenecas patents covering stabilized formulation omeprazole ruling one defendants omeprazole product infringe patents three defendants products found infringe formulation patents december us court appeals federal circuit affirmed decision trial court respect companys patent infringement claims certain generic manufacturers omeprazole products trial scheduled march company astrazeneca received notice october ranbaxy laboratories limited ranbaxy filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium november company astrazeneca sued ranbaxy united states district court new jersey accordingly fda approval ranbaxys anda stayed months april adverse court decision whichever may occur earlier case finasteride anda filed seeking approval generic version propecia alleging invalidity companys patents company filed patent infringement lawsuit district court delaware september trial scheduled june table contents europe company aware various companies seeking registration generic losartan active ingredient cozaar company patent rights losartan via license ei du pont de nemours company du pont company du pont filed patent infringement proceedings various companies portugal litigation july merck served shareholder derivative suit filed new jersey superior court hunterdon county company certain current former officers directors lawsuit seeks recover cancel compensation awarded companys executive officers asserts claims breach fiduciary duty waste unjust enrichment november individual shareholder delivered letter board alleging company sustained damages companys adoption change control separation benefits plan cic plan november shareholder made demand board take legal action boards current former members allegedly causing damage company respect adoption cic plan response demand letter independent members board determined november board meeting board would take shareholders request consideration remains consideration previously disclosed july united states district court district new jersey granted motion company medco health solutions inc medco health certain officers directors dismiss purported class action complaint involving claims related companys revenue recognition practice retail copayments paid individuals medco health provides pharmaceutical benefits well allegations complaint dismissed prejudice august court granted companys motion dismiss prejudice related shareholder derivative action plaintiffs actions appealed decisions december us court appeals third circuit upheld district courts decision dismissing class action complaint separate decision issued day court appeals upheld district courts decision dismissing shareholder derivative suit sent issue whether companys board directors properly refused shareholder demand relating companys treatment retail copayments back district court reconsideration different legal standard previously disclosed prior spinoff medco health company medco health agreed settle class action basis series lawsuits asserting violations erisa gruer cases company medco health certain plaintiffs counsel filed settlement agreement federal district court new york cases commenced number plaintiffs including participants number pharmaceutical benefit plans medco health pharmacy benefit manager well trustees plans consolidated medco health company agreed proposed settlement order avoid significant cost distraction prolonged litigation proposed class settlement agreed plaintiffs five cases filed medco health company proposed settlement company medco health agreed pay total million medco health agreed modify certain business practices continue certain specified business practices period five years financial compensation intended benefit members settlement class includes erisa plans medco health administered pharmacy benefit time since december district court held hearings hear objections fairness proposed settlement approved settlement yet determined number class member plans properly elected participate settlement settlement becomes final appeals resolved certain class member plans indicated participate settlement cases initiated three plans two individuals remain pending southern district new york plaintiffs cases asserted claims based erisa well federal state laws similar claims asserted settling class members gruer cases company medco health named defendants cases table contents three notices appeal filed appellate court heard oral argument may december appellate court issued decision vacating district courts judgment remanding cases district court allow district court resolve certain jurisdictional issues hearing held address issues february spinoff medco health medco health assumed substantially liability exposure matters discussed foregoing two paragraphs cases defended medco health various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed note opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company proceedings separate assessment provided note environmental matters company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs insurers former site owners operators recalcitrant potentially responsible parties previously disclosed december virginia department environmental quality vadeq issued notice violation companys elkton virginia facility air permit limit exceedances reported facility result performance testing process train company settled matter vadeq agreeing make million capital improvements site ii pay vadeq fine iii perform supplemental environmental project december company settled claims brought new jersey department environmental protection alleged damages natural resources four new jersey merck remediation sites settlement company agreed pay million donate acres land adjacent rahway river fund restoration project passaic river watershed groundwater contamination found companys sites item submission matters vote security holders applicable table contents executive officers registrant ages february richard clark age may chief executive officer president june president merck manufacturing division responsible companys manufacturing information services operational excellence organizations worldwide january chairman president chief executive officer medco health solutions inc medco health formerly whollyowned subsidiary company january president medco health david w anstice age august president human healthasia pacific responsible companys prescription drug business asia pacific region japan australia new zealand companys joint venture relationship scheringplough january president human health responsible companys prescription drug business japan latin america canada australia new zealand companys joint venture relationship scheringplough march president americas us human health responsible one two prescription drug divisions comprising us human health well companys prescription drug business canada latin america companys joint venture relationship scheringplough january president human health americas responsible companys human health business united states canada latin america celia colbert age january vice president secretary since september assistant general counsel since november willie deese age may president merck manufacturing division responsible companys global manufacturing procurement operational excellence functions january senior vice president global procurement prior january mr deese senior vice president global procurement logistics glaxosmithkline plc caroline dorsa age august vice president treasurer responsible companys treasury tax functions providing financial support merck manufacturing merck research laboratories divisions well human resources september vice president treasurer responsible companys treasury tax functions providing financial support asia pacific division table contents kenneth c frazier age december senior vice president general counsel responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company richard c henriques jr age august vice president controller responsible corporate controllers group providing financial support human health operations united states canada latin america europe middle east africa japan australianew zealand merck vaccine division mvd november vice president controller since february responsible corporate controllers group providing financial support us human health canada latin america americas mvd peter kim age january president merck research laboratories mrl february executive vice president research development mrl judy c lewent age august executive vice president chief financial officer responsible companys strategic planning financial corporate development functions internal auditing corporate licensing companys joint venture relationships merck capital ventures llc subsidiary company january executive vice president chief financial officer president human health asia responsible financial corporate development functions internal auditing corporate licensing companys prescription drug business asia north asia south companys joint venture relationships merck capital ventures llc february executive vice president chief financial officer since april responsible financial corporate development functions internal auditing corporate licensing companys joint venture relationships merck capital ventures llc adel mahmoud age september chief medical advisor vaccines infectious diseases responsible representing company external medical policy government forums matters infectious diseases vaccines may president merck vaccines margaret g mcglynn age august president merck vaccines global responsibilities vaccines business including companys sanofiaventis joint venture january president us human health responsible one two prescription drug divisions hospital specialty product franchises comprising us human health ushh managed care group ushh august executive vice president customer marketing sales ushh november senior vice president worldwide human health marketing table contents j chris scalet age january senior vice president global process services chief information officer cio responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative march senior vice president information services cio responsible areas information technology services including application development technical support voice data communications computer operations worldwide prior march mr scalet senior vice president information technology cio international paper company global forest products paper packaging company bradley sheares age august president us human health responsible entire prescription drug business comprising us human health ushh january president us human health responsible one two prescription drug divisions primary care product franchises comprising ushh march president us human health responsible one two prescription drug divisions hospital specialty product franchises comprising ushh july vice president hospital marketing sales ushh joan e wainwright age january vice president public affairs per woldolsen age august president human health intercontinental responsible companys prescription drug business europe middle east africa latin america canada worldwide human health marketing january president human healtheurope middle east africa responsible companys prescription drug business europe middle east africa worldwide human health marketing officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities required information market information dividends incorporated reference companys annual report stockholders required information number holders companys common stock incorporated reference companys annual report stockholders issuer purchases equity securities three month period ended december follows issuer purchases equity securities total number millions total shares purchased approx dollar value number average part shares may yet shares price paid publicly announced purchased period purchased per share plans programs plans programs october october november november december december total item selected financial data information required item incorporated reference data last five fiscal years company included results year yearend position selected financial data table companys annual report stockholders item managements discussion analysis financial condition results operations information required item incorporated reference pages companys annual report stockholders item quantitative qualitative disclosures market risk information required item incorporated reference pages beginning caption financial instruments market risk disclosures companys annual report stockholders table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income retained earnings comprehensive income cash flows three years period ended december report dated february pricewaterhousecoopers llp independent registered public accounting firm incorporated reference pages respectively companys annual report stockholders b supplementary data selected quarterly financial data incorporated reference data contained condensed interim financial data table companys annual report stockholders item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended effective management responsible establishing maintaining adequate internal control financial reporting term defined exchange act rule af management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission coso based evaluation management concluded internal control financial reporting effective december based criteria internal control integrated framework issued coso managements assessment effectiveness internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm pricewaterhousecoopers llp issued report managements assessment effectiveness companys internal control financial reporting incorporated reference companys annual report stockholders changes internal control financial reporting period covered report materially affected reasonably likely materially affect companys internal control financial reporting item b information none part iii item directors executive officers registrant required information directors nominees incorporated reference pages companys proxy statement annual meeting stockholders held april information executive officers set forth part document pages table contents required information audit committee financial expert incorporated reference heading financial expert audit committee companys proxy statement annual meeting stockholders held april required information identification audit committee incorporated reference caption board committees companys proxy statement annual meeting stockholders held april required information compliance section securities exchange act incorporated reference caption section beneficial ownership reporting compliance companys proxy statement annual meeting stockholders held april company adopted code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer code conduct available companys website wwwmerckcomaboutcorporategovernance company intends post website amendments waivers code conduct printed copy sent without charge stockholder requests writing chief ethics officer merck co inc one merck drive whitehouse station nj item executive compensation information required item incorporated reference pages caption compensation directors pages beginning caption summary compensation table pages beginning caption annual benefits payable merck co inc retirement plans caption compensation committee interlocks insider participation companys proxy statement annual meeting stockholders held april item security ownership certain beneficial owners management related stockholder matters information respect securities authorized issuance equity compensation plans incorporated reference caption equity compensation plan information companys proxy statement annual meeting stockholders held april information respect security ownership certain beneficial owners management incorporated reference pages caption security ownership certain beneficial owners management companys proxy statement annual meeting stockholders held april item certain relationships related transactions information required item incorporated reference caption relationships outside firms caption indebtedness management companys proxy statement annual meeting stockholders held april item principal accountant fees services information required item incorporated reference pages beginning caption preapproval policy services independent registered public accounting firm companys proxy statement annual meeting stockholders held april table contents part iv item exhibits financial statement schedules documents filed part financial statements following consolidated financial statements report independent registered public accounting firm incorporated herein reference companys annual report stockholders noted document consolidated statement income years ended december consolidated statement retained earnings years ended december consolidated statement comprehensive income years ended december consolidated balance sheet december consolidated statement cash flows years ended december notes consolidated financial statements report pricewaterhousecoopers llp independent registered public accounting firm financial statement schedules schedules omitted either required applicable financial statements affiliates carried equity basis omitted considered individually aggregate affiliates constitute significant subsidiary exhibits exhibit number description master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june restated certificate incorporation merck co inc october incorporated reference form q quarterly report period ended september bylaws merck co inc amended effective may incorporated reference current report form k dated may indenture dated april merck co inc morgan guaranty trust company new york trustee incorporated reference exhibit registration statement form first supplemental indenture merck co inc first trust new york national association trustee incorporated reference exhibit b registration statement form table contents exhibit number description executive incentive plan amended effective february cid incorporated reference annual report fiscal year ended december base salary deferral plan adopted october effective january cid incorporated reference annual report fiscal year ended december merck co inc deferral program amended restated december cid incorporated reference current report form k dated december incentive stock plan amended effective february cid incorporated reference annual report fiscal year ended december incentive stock plan amended restated february cid incorporated reference annual report fiscal year ended december incentive stock plan amended restated february cid incorporated reference annual report fiscal year ended december incentive stock plan amended restated february cid incorporated reference annual report fiscal year ended december merck co inc change control separation benefits plan incorporated reference current report form k dated november nonemployee directors stock option plan amended restated february cid incorporated reference form k annual report fiscal year ended december nonemployee directors stock option plan amended april cid incorporated reference form q quarterly report period ended june nonemployee directors stock option plan amended april cid incorporated reference form q quarterly report period ended june supplemental retirement plan amended effective january cid incorporated reference annual report fiscal year ended december retirement plan directors merck co inc amended restated june cid incorporated reference form q quarterly report period ended june management contract compensatory plan arrangement table contents exhibit number description plan deferred payment directors compensation amended restated may cid incorporated reference current report form k dated may limited liability company agreement merck capital ventures llc dated november cid incorporated reference annual report fiscal year ended december offer letter merck co inc peter kim dated december cid incorporated reference annual report fiscal year ended december amended restated license option agreement dated july astra ab astra merck inc cid incorporated reference form q quarterly report period ended june kbi shares option agreement dated july among astra ab merck co inc merck holdings inc cid incorporated reference form q quarterly report period ended june kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc cid incorporated reference form q quarterly report period ended june kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission cid incorporated reference form q quarterly report period ended june second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc cid incorporated reference form q quarterly report period ended june limited partnership agreement dated july kb usa lp kbi sub inc cid incorporated reference form q quarterly report period ended june distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp cid incorporated reference form q quarterly report period ended june management contract compensatory plan arrangement table contents exhibit number description agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp cid incorporated reference form q quarterly report period ended june computation ratios earnings fixed charges annual report stockholders portions incorporated reference document deemed filed subsidiaries merck co inc consent independent registered public accounting firm cid contained report power attorney certified resolution board directors rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer copies exhibits may obtained stockholders upon written request directed stockholder services department merck co inc po box ws ab whitehouse station new jersey table contents signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized merck co inc dated march richard clark chief executive officer president celia colbert celia colbert attorneyinfact pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signatures title date richard clark chief executive officer march president principal executive officer director judy c lewent executive vice president march chief financial officer principal financial officer richard c henriques jr vice president controller march principal accounting officer lawrence bossidy director march william g bowen director march johnnetta b cole director march william b harrison jr director william n kelley director march rochelle b lazarus director march thomas e shenk director march anne tatlock director samuel thier director march wendell p weeks director march peter c wendell director march celia colbert signing name hereto hereby sign document pursuant powers attorney duly executed persons named filed securities exchange commission exhibit document behalf persons capacities date stated persons including majority directors company celia colbert celia colbert attorneyinfact table contents exhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form nos form nos merck co inc report dated february relating consolidated financial statements managements assessment effectiveness internal control financial reporting effectiveness internal control financial reporting appears annual report stockholders incorporated reference annual report pricewaterhousecoopers llp florham park new jersey march table contents exhibit index exhibit number description master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june restated certificate incorporation merck co inc october incorporated reference form q quarterly report period ended september bylaws merck co inc amended effective may incorporated reference current report form k dated may indenture dated april merck co inc morgan guaranty trust company new york trustee incorporated reference exhibit registration statement form first supplemental indenture merck co inc first trust new york national association trustee incorporated reference exhibit b registration statement form executive incentive plan amended effective february cid incorporated reference annual report fiscal year ended december base salary deferral plan adopted october effective january cid incorporated reference annual report fiscal year ended december merck co inc deferral program amended restated december cid incorporated reference current report form k dated december incentive stock plan amended effective february cid incorporated reference annual report fiscal year ended december incentive stock plan amended restated february cid incorporated reference annual report fiscal year ended december incentive stock plan amended restated february cid incorporated reference annual report fiscal year ended december management contract compensatory plan arrangement table contents exhibit number description incentive stock plan amended restated february cid incorporated reference annual report fiscal year ended december merck co inc change control separation benefits plan incorporated reference current report form k dated november nonemployee directors stock option plan amended restated february cid incorporated reference form k annual report fiscal year ended december nonemployee directors stock option plan amended april cid incorporated reference form q quarterly report period ended june nonemployee directors stock option plan amended april cid incorporated reference form q quarterly report period ended june supplemental retirement plan amended effective january cid incorporated reference annual report fiscal year ended december retirement plan directors merck co inc amended restated june cid incorporated reference form q quarterly report period ended june plan deferred payment directors compensation amended restated may cid incorporated reference current report form k dated may limited liability company agreement merck capital ventures llc dated november cid incorporated reference annual report fiscal year ended december offer letter merck co inc peter kim dated december cid incorporated reference annual report fiscal year ended december amended restated license option agreement dated july astra ab astra merck inc cid incorporated reference form q quarterly report period ended june kbi shares option agreement dated july among astra ab merck co inc merck holdings inc cid incorporated reference form q quarterly report period ended june management contract compensatory plan arrangement table contents exhibit number description kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc cid incorporated reference form q quarterly report period ended june kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission cid incorporated reference form q quarterly report period ended june second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc cid incorporated reference form q quarterly report period ended june limited partnership agreement dated july kb usa lp kbi sub inc cid incorporated reference form q quarterly report period ended june distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp cid incorporated reference form q quarterly report period ended june agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp cid incorporated reference form q quarterly report period ended june computation ratios earnings fixed charges annual report stockholders portions incorporated reference document deemed filed subsidiaries merck co inc consent independent registered public accounting firm cid contained report power attorney certified resolution board directors rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer exhibit merck co inc subsidiaries computation ratios earnings fixed charges millions except ratio data twelve months ended december years ended december income continuing operations taxes add subtract onethird rents interest expense gross interest capitalized net amortization equity income loss affiliates net distributions preferred stock dividends net tax earnings continuing operations onethird rents interest expense gross preferred stock dividends fixed charges continuing operations ratio earnings fixed charges continuing operations purposes computing ratios earnings consist income continuing operations taxes onethird rents deemed company representative interest factor inherent rents interest expense net amounts capitalized equity income loss affiliates net distributions dividends preferred stock subsidiary companies fixed charges consist onethird rents interest expense reported companys consolidated financial statements dividends preferred stock subsidiary companiesexhibit financial section contents financial review financial review description mercks business description mercks business merck global researchdriven pharmaceutical company overview discovers develops manufactures markets broad range competition health care environment innovative products improve human animal health operating results directly joint ventures merck sells products selected joint venture affiliate information primarily drug wholesalers retailers hospitals clinics capital expenditures government agencies managed health care providers analysis liquidity capital resources health maintenance organizations institutions financial instruments market risk disclosures companys professional representatives communicate critical accounting policies matters effectiveness safety value products health care recently issued accounting standards professionals private practice group practices managed cautionary factors may affect future results care organizations cash dividends paid per common share common stock market prices overview condensed interim financial data december merck unveiled plan reclaim consolidated statement income leadership position pharmaceutical industry part consolidated statement retained earnings strategy merck focusing improving research consolidated statement comprehensive income development rd productivity focusing select consolidated balance sheet therapeutic areas implementing new commercial model consolidated statement cash flows deliver greater value customers reducing overall notes consolidated financial statements cost structure companywide managements report mercks new rd model designed increase productivity audit committees report improve probability success prioritizing report independent registered public accounting companys rd resources nine priority disease areas firm alzheimers disease atherosclerosis cardiovascular disease compensation benefits committees report diabetes novel vaccines obesity oncology pain sleep selected financial data disorders therapeutic areas carefully chosen based set criteria including unmet medical needs scientific opportunity commercial opportunity within therapeutic areas merck commit resources achieve research breadth depth develop bestinclass targeted differentiated products valued highly patients payers physicians company also make focused investments pursue specific mechanisms following selected disease areas antibiotics antifungals antivirals hepatitis c virus human immunodeficiency virus asthma chronic obstructive pulmonary disease neurodegeneration ophthalmology osteoporosis schizophrenia stroke addition company capitalize selected opportunities outside areas continuing commercialize attractive clinical development candidates pipeline pursuing appropriate external licensing opportunities mercks report shareholders mercks latestage pipeline showing strong progress million separation costs million three biologics license application bla submissions accelerated depreciation asset impairment costs us food drug administration fda one new manufacturing facilities included action drug application nda already filed fda two ponders end united kingdom okazaki japan kirkland additional fda filings anticipated expected five canada albany georgia danville pennsylvania two programs phase iii first quarter preclinical sites okazaki menuma japan three fda submissions include gardasil company incur significantly larger accelerated depreciation breakthrough vaccine help prevent cervical cancer charges associated actions asset second leading cause cancer deaths women worldwide impairment charge associated abandonment zostavax vaccine reduce incidence shingles certain fixed assets longer used business rotateq pediatric vaccine prevent rotavirus gastroenteritis result restructuring actions company also leading cause diarrhea infants young children plans close basic research center terlings park united leads nearly deaths worldwide year kingdom incurred additional accelerated depreciation costs february merck announced approval fda million respect site rotateq addition february merck announced additional charges approximately million billion fda accepted bla gardasil granted expected recorded based estimated vaccine priority review designation time completion salesclosures facilities february merck announced nda filed previously discussed occur merck expects cost reduction fda januvia proposed trademark program yield cumulative pretax savings compound known mk novel mechanism billion treatment type diabetes accepted standard review american jobs creation act ajca signed law merck also anticipates two additional fda filings october created temporary incentives vorinostat generic name suberoylanilide hydroxamic december us multinationals repatriate acid saha compound histone deacetylase inhibitor accumulated income earned outside united states cancer mk intravenous prodrug aprepitant december connection ajca company treat chemotherapyinduced nausea vomiting repatriated billion result recorded improve commercial selling model merck continue income tax charge million charge streamline restructure marketing sales operations partially offset million benefit associated worldwide improve effectiveness generate greater decision implement certain tax planning strategies efficiencies united states company already previously disclosed september merck reduced number sales representatives promoting announced voluntary worldwide withdrawal vioxx product percent versus historical levels addition arthritis acute pain medication result company merck place emphasis active engagement key recorded charge pretax income million opinion leaders accelerate development diffusion million tax adjustment net income third scientific information devote additional resources utilizing quarter include charges future legal technology demonstrating product value physicians defense costs vioxx withdrawal process completed well payers consumers increasing influence costs associated withdrawal prescription decisions united states approach line original amounts recorded company already resulted considerable productivity improvements pilot programs expected lower companys december company established spending per brand percent reserve million solely future vioxx legal defense maximizing sales performance provide additional support costs company spent million upcoming vaccine launches united states merck aggregate vioxx legal defense costs worldwide fourth redeploying sales representatives currently promote quarter company recorded charge million major inline products support launch new vaccines increase reserve solely future legal defense costs november company announced first phase related vioxx million december global restructuring program designed reduce reserve based certain assumptions best companys cost structure increase efficiency enhance estimate amount company believes time competitiveness initial steps include reasonably estimate spent implementation new supply strategy merck earnings per common share assuming dilution manufacturing division intended create leaner including impact global restructuring program costeffective customerfocused manufacturing model per share net tax charge primarily associated next three years part program merck plans ajca per share additional reserves sell close five manufacturing sites two preclinical sites established solely future legal defense costs vioxx end eliminate approximately positions litigation discussed companywide december approximately positions throughout company eliminated merck incurred million costs associated global restructuring program comprised mercks report shareholders competition health care environment antiretroviral regimens containing either crixivan stocrin markets company conducts business actions merck working highly competitive often highly regulated global efforts independently partners public private toward health care cost containment continue exert pressure sectors alike focus critical barriers access product pricing access medicines developing world need sustainable united states government expanded health care financing increased international assistance additional access enacting medicare prescription drug investments education training health infrastructure improvement modernization act signed capacity developing countries law december prescription drug coverage began increasing amount focus privacy january new benefit supports companys issues countries around world including united states goal improving access medicines expanding insurance eu united states eu governments coverage preserving marketbased incentives pursued legislative regulatory initiatives regarding privacy pharmaceutical innovation time benefit including federal privacy regulations recently enacted state ensure prescription drug costs controlled privacy laws concerning health personal information competitive pressures encouraging appropriate use affected companys operations medicines although one predict outcome addressing costcontainment pressure company legislative regulatory advocacy initiatives company made continuing effort demonstrate medicines wellpositioned respond evolving health care help save costs overall patient health care addition pricing environment market forces flexibility across companys product portfolio certain companys products face patent expiration encouraged growing use medicines mitigated merck consider entering authorized generic agreements effects increasing cost pressures would allow company benefit outside united states difficult environments medicines become available generic form encumbered government costcontainment actions company anticipates worldwide trend toward company worked partnership payers allocating costcontainment continue resulting ongoing pressures scarce resources optimize health care outcomes limiting health care budgets company continues potentially detrimental effects government policies sales successfully launch new products contribute health care growth access innovative medicines vaccines debates monitor reforms new products policies support discovery development innovative products strategies enable maintain strong position benefit patients company also working changing economic environment governments many emerging markets eastern europe latin america asia encourage increase operating results investments health thereby improve citizens access sales medicines countries within european union eu worldwide sales decreased total recognizing economic importance researchbased reflecting decrease related voluntary worldwide pharmaceutical industry value innovative medicines withdrawal vioxx offset revenue growth society working industry representatives products growth reflects favorable effect european commission proposals complete single foreign exchange favorable effect price changes market pharmaceuticals improve competitive climate volume increase sales performance reflects variety means including market deregulation strong growth singulair onceaday oral medicine indicated company committed improving access treatment chronic asthma relief symptoms medicines enhancing quality life people around allergic rhinitis cancidas antifungal infections world african comprehensive hivaids partnerships cozaarhyzaar high blood pressure higher revenues achap botswana partnership government companys relationship astrazeneca lp botswana bill melinda gates foundation azlp primarily driven nexium sales growth offset merck company foundationmerck co inc supporting declining sales zocor high cholesterol botswanas response hivaids comprehensive domestic sales declined reflecting unfavorable effect sustainable approach hiv prevention care treatment voluntary worldwide withdrawal vioxx support may company initiated similar offset revenue growth products partnership peoples republic china focused initially foreign sales declined also reflecting unfavorable effect sichuan province help strengthen chinas response voluntary worldwide withdrawal vioxx hiv epidemic offset revenue growth products foreign catalyze access hiv medicines developing sales represented total sales countries price reduction guidelines company worldwide sales increased total announced merck makes profit sale reflecting favorable effect foreign exchange current hivaids medicines worlds poorest countries favorable effect price changes volume decline hardest hit pandemic offers hivaids sales unfavorably impacted voluntary medicines significantly reduced prices mediumincome worldwide withdrawal vioxx foreign sales represented countries end patients total sales developing countries treated mercks report shareholders sales companys products follows similar growth rates children taking placebo study children taking inhaled steroid slower growth rates millions children either singulair placebo z ocor fda approved two new indications singulair fosamax accepted review supplemental nda singulair cozaarhyzaar use prevention exerciseinduced bronchospasm singulair eib patients years age older december proscar merck received approvable letter fda eib primaxin indication singulair merck currently discussions vasotecvaseretic fda determine additional data revisions cosopttrusopt application necessary obtain approval cancidas indication maxalt august merck announced fda propecia approved singulair symptoms perennial allergic vioxx rhinitis yearround allergies adults children six vaccinesbiologicals months age older january merck announced new indication singulair treat symptoms seasonal allergic rhinitis asthmatic patients launched eu new indication presented net discounts returns launched several countries eu companys products include therapeutic preventive respiratory therapy approved treatment asthma agents generally sold prescription treatment seasonal allergic rhinitis asthmatic patients indication human disorders among zocor mercks largest singulair treatment seasonal allergic rhinitis selling atherosclerosis product fosamax fosamax plus granted united states late mercks osteoporosis products treatment case merck expects seek new indications singulair acute fosamax prevention osteoporosis cozaarhyzaar asthma respiratory syncytial bronchiolitis vasotec companys significant hypertensionheart failure products singulair leukotriene receptor antagonist global sales cozaar companion agent hyzaar respiratory product treatment chronic asthma combination cozaar diuretic hydrochlorothiazide relief symptoms allergic rhinitis proscar urology treatment hypertension strong reaching product treatment symptomatic benign prostate billion increase enlargement primaxin cancidas antibacterialantifungal cozaar hyzaar compete fastestgrowing class products cosopt trusopt largestselling antihypertensive market angiotensin ii antagonists aiia ophthalmological products maxalt acute migraine product cozaarhyzaar continues largestselling branded aiia propecia product treatment male pattern hair loss europe second frequently prescribed aiia vaccinesbiologicals include varivax live virus united states vaccine prevention chickenpox mmr ii pediatric early october fda approved new tablet vaccine measles mumps rubella pneumovax hyzaar mg new dosage offering oncedaily vaccine prevention pneumococcal disease efficacy cozaar mg lowdose diuretic new recombivax hb vaccine prevention hepatitis b formulation addresses need titration flexibility primarily includes sales human intermediate step cozaar mg hyzaar pharmaceuticals pharmaceutical animal health supply mg filings new formulation outside united states sales companys joint ventures revenue occurred throughout including united companys relationship azlp primarily relating sales kingdom germany france italy nexium prilosec revenue azlp billion april fda approved new indication hyzaar billion billion based losartan intervention endpoint reduction respectively life trial reduction risk stroke patients singulair mercks onceaday oral respiratory medicine hypertension left ventricular hypertrophy lvh indicated treatment chronic asthma relief evidence benefit apply black patients symptoms allergic rhinitis continued strong performance global sales fosamax prescribed medicine reflecting continued demand asthma medications worldwide treatment postmenopausal male new indication perennial allergic rhinitis united glucocorticoidinduced osteoporosis billion states total sales singulair billion increase merck enhanced increase osteoporosis franchise addition fosamax plus december merck announced us label change new product provides proven power fosamax singulair incorporating positive results clinical reduce risk hip spine fractures plus study showed children asthma taking singulair assurance offering minimum vitamin intake consistent recommended guidelines became available united states early august mercks report shareholders european commission granted marketing authorization vomiting associated moderately highly emetogenic product known europe fosavance approval cancer chemotherapy maxalt treat migraine pain invanz fosamax plus extend patent fosamax treatment selected moderate severe infection adults fosamax plus important innovation osteoporosis propecia male pattern hair loss also contributing treatment help satisfy unmet medical need mercks total sales revenue resulting estimated women aged almost companys relationship azlp primarily relating sales women age getting adequate intake vitamin nexium vitamin insufficiency associated reduced calcium global sales cancidas oncedaily antifungal medicine absorption bone loss increased risk fracture strong reaching million increase additionally new oneyear extension results us strong results driven new indication fact fosamax actonel comparison trial study showed received fda october empirical therapy fosamax delivered significantly greater increases bone presumed fungal infections febrile neutropenic patients mineral density bmd hip spine proscar mercks urology product treatment risedronate two years increases bmd seen symptomatic benign prostate enlargement go patent fosamax even greater compared risedronate year lose market exclusivity united states june two year one fosamax also delivered superior reductions result company expects significant decline us bone turnover risedronate significantly greater proscar sales time basic patent proscar also effect three months treatment covers propecia however propecia protected additional previously disclosed january us court patents expire october appeals federal circuit washington dc found reported merckscheringplough partnership companys patent claims onceweekly administration global sales zetia vytorin aggregate reached fosamax invalid company exhausted options billion global sales zetia marketed ezetrol outside appeal decision based court appeals united states cholesterolabsorption inhibitor reached decision fosamax lose market exclusivity united billion increase global sales states february company expects significant vytorin marketed inegy outside united states reached decline us fosamax sales time additionally sales billion vytorin first single tablet cholesterol fosamax declined certain countries treatment provide ldl cholesterol lowering dual patent already expired inhibition cholesterol production absorption vytorin zocor mercks statin modifying cholesterol achieved approved united states july demonstrating worldwide sales billion decrease consistent growth sales zocor affected increased competition november merckscheringplough partnership united states generic competition markets announced commencement patient enrollment outside united states currently zocor available largescale clinical outcomes trial improveit improved percent managed care lives percent reduction outcomes vytorin efficacy international trial targeted managed care contracts renewed trial evaluate effectiveness vytorin compared june zocor lose market exclusivity zocor simvastatin alone treating approximately high united states company expects significant decline risk patients coronary artery disease presenting acute us zocor sales time global sales zocor coronary syndromes clinical trial sites opening throughout estimated billion fullyear north america europe products experiencing growth include company records results interest cancidas treat certain lifethreatening fungal infections merckscheringplough partnership equity income primaxin treatment bacterial infections cosopt treat affiliates glaucoma emend prevention acute delayed nausea costs expenses millions change change aterials production marketing administrative research development restructuring costs equity income affiliates income expense net greater mercks report shareholders materials production close two preclinical sites end okazaki materials production costs increased menuma japan connection global restructuring compared decline sales included increase program addition decrease reflects impact unfavorable effect inflation increase million licensing expense initial payments volume increase attributable million recorded certain disclosed research collaborations million primarily related global restructuring program acquired research expense acquisition aton million represents impairment charges associated pharma inc partially offsetting decrease abandonment certain fixed assets longer increase research development activities support used business result restructuring mercks pipeline actions remaining million represents accelerated december merck submitted bla fda depreciation associated mercks plan sell close five gardasil quadrivalent human papillomavirus types owned manufacturing facilities see note variance recombinant vaccine companys vaccine protect costs relative sales decline reflects impact four types human papillomavirus hpv types items noted well unfavorable effect account estimated cervical cancer sales associated voluntary worldwide withdrawal cases types account estimated vioxx genital warts cases cervical cancer results approximately materials production costs increased deaths worldwide year united states compared sales growth rate included increase estimated new cases cervical cancer diagnosed unfavorable effect inflation unfavorable effect approximately deaths exchange increase volume increase estimated million women united states eu costs relative sales growth reflects unfavorable ages expected age range effect associated voluntary worldwide withdrawal initial indication gardasil vioxx impact changes product mix gross margin october merck presented results future ii compared study phase iii efficacy study gardasil women restructuring charge noted aged years data presented infectious impact voluntary worldwide withdrawal vioxx diseases society america idsa annual meeting reported unfavorable effect gross margin gardasil prevented highgrade cervical pre cancers noninvasive cervical cancers cin ais marketing administrative associated hpv types primary analysis marketing administrative expenses decreased compared gardasil placebo women infected included decrease unfavorable effect hpv enrollment remained free inflation unfavorable effect exchange infection completion sevenmonth vaccination decline volume decrease primarily due costs regimen received three doses gardasil women recorded million voluntary worldwide followed average two years enrollment withdrawal vioxx see note million cases cin ais observed vaccine group establishment reserve solely legal defense costs n compared cases placebo group vioxx litigation partially offsetting decrease n cin cervical intraepithelial neoplasia additional reserve million vioxx legal defense costs moderategrade lesion cervix cin represents recorded current year well costs required highgrade lesions cis carcinoma situ immediate prepare launch three new investigational vaccines precursor invasive squamous cell cervical cancer ais maintaining activities support mercks inline products early development adenocarcinoma glandular cancer rolling new product indications critical outcome data cervix globally secondary analysis also presented idsa evaluated marketing administrative expenses increased incidence cin ais starting days included increase unfavorable effect administration first dose women primary inflation unfavorable effect exchange analysis group well women may become increase volume increase reflects impact infected hpv hpv vaccination period additional million reserve recorded solely future women may violated protocol significant ways legal defense costs vioxx litigation million example missing certain protocol visits also estimated costs undertake voluntary worldwide included average women followed withdrawal vioxx approximately two years time enrollment research development group gardasil reduced risk developing highgrade research development expenses decreased cervical precancer noninvasive cervical cancer cin included decrease unfavorable effect ais associated hpv n one inflation decline volume included case observed vaccine group compared accelerated depreciation costs million related placebo group n closure basic research center located terlings park february merck announced fda united kingdom well million associated plans accepted bla gardasil investigational sell cervical cancer vaccine given priority review agency priority designation intended products address unmet mercks report shareholders medical needs prescription drug user fee act lanilide hydroxamic acid new class antitumor agents blas filed fdas goal review act blas inhibits histone deacetylase study eight designated priority review within six months receipt patients advanced refractory cutaneous tcell lymphoma fda informed merck review goal date june ctcl experienced partial responses physician assessment since submission fda december merck percent reduction overall disease burden primary also submitted applications gardasil additional regulatory endpoint study results presented agencies including eu australia mexico brazil annual meeting american society clinical oncology argentina taiwan singapore orlando florida february company announced ctcl type nonhodgkins lymphoma slowgrowing glaxosmithkline gsk entered crosslicense form cancer bodys white blood cells settlement agreement certain patent rights related hpv known tlymphocytes tcells become malignant ctcl vaccines pursuant agreement gsk receive affects patients united states another upfront payment royalties company based upon new cases reported year sales gardasil upon development launch september merck presented two studies phase ii agreement resolves competing intellectual property claims data companys dpp inhibitor januvia proposed related companys gsks vaccine candidates trademark mk sitagliptin potential new approach addition merck entered license agreement treatment type diabetes st annual meeting collaboration csl limited relating technology used european association study diabetes easd gardasil gardasil also subject thirdparty studies showed januvia significantly improved licensing agreements glycemic control patients primarily mildtomoderate september fda approved proquad measles hyperglycemia patients severe hyperglycemia mumps rubella varicella okamerck virus vaccine live compared placebo studies januvia proquad combination vaccine simultaneous vaccination generally welltolerated february merck measles mumps rubella varicella children announced nda januvia accepted standard months years age proquad combines two review fda merck expects fda action nda established merck vaccines mmr ii measles mumps midoctober rubella virus vaccine live varivax varicella virus announced december merck also developing vaccine live okamerck march us centers mka combination januvia metformin disease control cdc announced rubella german treatment type diabetes measles longer public health threat united also announced december merck track states time merck sole manufacturer vaccines first quarter promising drugs phase iii protect rubella well measles mumps development diabetes insomnia high cholesterol heart varicella united states disease hivaids phase iii candidates include august mercks vaccine hepatitis vaqta following approved fda use children months age gaboxadol unique mechanism mercks alliance older previously vaqta approved use people two h lundbeck potential provide benefits beyond years age older existing therapies respect sleep quality nextday february merck announced approval effects fda rotateq pentavalent vaccine protect mka mkb hold significant promise rotavirus gastroenteritis rotateq oral threedose liquid addressing critical need lipidcholesterol management vaccine contains five human serotypes g g g g mka represents novel approach treating hdlc p merck also submitted applications licensure triglycerides combining mercks extended release niacin rotateq australia mexico canada countries asia mk mkb combines mka proven latin america sanofi pasteur msd joint benefits simvastatin potentially reduce risk coronary venture eu heart disease beyond statins provide alone june fda accepted standard review bla mk expected first new class anti zostavax mercks investigational vaccine prevention retrovirals effective inhibiting integrase enzyme herpes zoster commonly known shingles adults necessary survival hiv february merck years age older sanofi pasteur msd submitted announced interim results doseranging phase ii trial application licensure zostavax eu merck mk n showed oral investigational also submitted applications licensure zostavax medication three doses studied mg mg australia canada countries asia latin america mg orally twice daily combination optimized background february fda extended review three months therapy obt greater antiretroviral activity placebo late may obt study results also showed mk may merck announced results phase ii combination obt generally welltolerated open label study vorinostat investigational oral suberoy patients mercks report shareholders advanced hiv infection failing antiretroviral identifying new biomarkers atherosclerotic disease therapy art viruses resistant least one drug progression use development cardiovascular three available classes oral arts compounds mercks pipeline agreement includes limited active arts options treatment results research collaboration three years presented th annual conference retroviruses october agensys inc cancer biotechnology opportunistic infections company merck announced formed global merck continues remain focused augmenting alliance jointly develop commercialize agspsca internal research efforts capitalizing growth opportunities agensys fully human monoclonal antibody mab prostate ranging research collaborations preclinical clinical stem cell antigen psca agreement grants merck world compounds technology transactions drive wide rights agspsca exclusive license psca near longterm growth company completed proprietary target well rights therapeutic transactions across broad range therapeutic diagnostic products developed alliance categories including neuroscience obesity oncology also october merck bristolmyers squibb well earlystage technology transactions merck currently bms jointly announced signed separate license evaluating opportunities actively agreements international partnership microbicides monitoring landscape range targeted acquisitions develop new antiretroviral compounds potential meet companys strategic criteria highlights microbicides protect women hiv agreement marks year include first time pharmaceutical company licensed anti may merck bioxell entered agreement hiv compound development microbicide class develop new treatments sepsis inflammatory drugs early development compounds part disorders new class antiretrovirals known entry inhibitors june vical incorporated exercised three options compounds bind directly hiv others bind ccr amendment existing research collaboration receptor designed prevent hiv efficiently licensing agreement granting merck rights use vicals entering host cells thus preventing infection patented nonviral gene delivery technology cancer vaccine company bms reported october applications fda issued approvable letter pargluva bmss investiga merck vertex pharmaceuticals incorporated announced tional oral medicine treatment type diabetes june initiation additional phase clinical study requested additional safety information address fully vx small molecule inhibitor aurora kinases aurora cardiovascular safety profile pargluva data requirement kinases implicated onset progression human may cause significant delay products launch leukemias result bms merck terminated collaborative agreement sumitomo pharmaceuticals co ltd sumitomo merck pargluva rights pargluva backup signed agreement june collaborate sm compound pargluva returning bms december lurasidone atypical antipsychotic compound currently phase ii development treatment schizophrenia one following chart reflects companys current research chronic disabling severe mental illnesses pipeline february candidates shown phase iii agreement sumitomo granted merck include specific products candidates shown phase ii affiliate exclusive license sm parts include advanced compound specific world except japan china korea taiwan mechanism given therapeutic area backup compounds june merck announced agreement regardless phase development additional indications metabasis therapeutics research develop therapeutic area additional line extensions commercialize novel small molecule therapeutics formulations inline products shown companys potential treat several diseases including type diabetes programs generally designed focus development hyperlipidemia obesity activation enzyme novel medicines address large unmet medical needs liver called ampactivated protein kinase announced december company intends focus july merck geron corporation announced research efforts primarily following nine priority areas agreement develop cancer vaccine telomerase alzheimers disease atherosclerosis cardiovascular disease telomerase enzyme active cancer cells diabetes novel vaccines obesity oncology pain sleep maintains telomere length ends chromosomes disorders activity allows cancer grow metastasize long periods time september foxhollow technologies merck announced formation novel pharmacogenomics collaboration collaboration focus analyzing atherosclerotic plaque removed patient arteries means mercks report shareholders research development expenses increased research pipeline included increase unfavorable effect p hase inflation unfavorable effect exchange lzheimers disease mk mk increase volume reflects companys ongoing arthritis mk commitment basic clinical research well atherosclerosis mk mk impact licensing agreements acquired research mk development discussed cancer mk mk agensys mk research development pharmaceutical industry vx mk inherently longterm process following data show multi cancer vaccine year trend companys research development cardiovascular disease mk spending period compounded annual diabetes mk mk growth rate research development mk research development expenditures endocrine mk millions flu vaccine glaucoma mk insomnia mk obesity nastech pyy osteoporosis mk pain neurogen parkinsons disease mk psychiatric disease mk respiratory disease mk aureus vaccine p hase ii rthritis mk cancer ctcl vorinostat endocrine mk hiv vaccine hpv vaccine hypertension mk obesity mk mk osteoporosis mk pain mk mk mk pediatric vaccine psychiatric disease mk lurasidone stroke ono urinary incontinence mk mk p hase iii restructuring costs ids mk restructuring costs million million atherosclerosis mkb mka respectively included separation cinv mk costs associated mercks plan eliminate approximately diabetes mka positions companywide end fourth insomnia gaboxadol quarter merck incurred million separation costs u nder regulatory review associated global restructuring program h pv related cervical cancer separation costs associated elimination genital warts gardasil approximately positions december shingles zostavax comprised actual headcount reductions elimination diabetes januvia contractors vacant positions well estimates pprovable future terminations roughly positions rthritispain arcoxia probable could reasonably estimated december see note us approvals steoporosis fosamax plus part costreduction initiative announced pediatric vaccine proquad october completed end company us approvals eliminated positions company completed similar r otavirus gastroenteritis rotateq program positions eliminated december result restructuring actions l icensed alliance acquisition pipeline company recorded restructuring costs million ultiple licenses including csl ltd million erck discussions licensing partner regarding plans compoundmercks report shareholders equity income affiliates income expense net equity income affiliates reflects performance decrease income expense net primarily companys joint ventures partnership returns azlp reflects million gain sale increase equity income affiliates primarily companys percent equity stake european joint venture reflects successful performance zetia vytorin johnson johnson well realized gains merckscheringplough partnership higher partnership companys investment portfolio recorded returns azlp relative increase transactions also primary driver increase equity income affiliates reflected successful income expense net performance zetia merckscheringplough partnership well higher partnership returns azlp earnings millions except per share amounts c hange c hange ncome continuing operations sales net income average total assets earnings per common share assuming dilution continuing operations taxes income earnings per common share companys effective income tax rate earnings per common share assuming dilution continuing higher tax rate operations declined compared decline reflects net tax charge primarily related companys reflecting impact net tax charge decision repatriate billion foreign earnings restructuring costs recorded unfavorable impact accordance ajca result company voluntary worldwide withdrawal vioxx recorded income tax charge million taxes income related repatriation charge distribution sales equity income partially offset million benefit associated decision implement certain tax planning strategies net tax charge resulted increase percentage points effective tax rate year change mix domestic foreign income also unfavorable impact income tax rate partially offsetting increase tax rate tax impact restructuring costs lower tax rate resulted change mix domestic foreign income included impact vioxx withdrawal included impact restructuring costs wholesaler distribution program income continuing operations income continuing operations declined compared decline income continuing selected joint venture affiliate information operations percentage sales expand research base realize synergies decrease percentage combining capabilities opportunities assets company sales ratio compared reflects unfavorable impact formed number joint ventures see note voluntary worldwide withdrawal vioxx well financial statements information impact global restructuring charge recorded company scheringplough corporation percentage sales includes scheringplough entered agreements create separate implementation new wholesaler distribution program net equallyowned partnerships develop market united income percentage average total assets states new prescription medicines cholesterol management respiratory therapeutic areas cholesterolmanagement partnership agreements expanded include countries world excluding japan ezetimibe first new class cholesterol lowering agents launched united states zetia marketed ezetrol outside united states reported merckscheringplough partnership global sales zetia totaled billion billion mercks report shareholders million july combination product containing segments sold transactions completed active ingredients zetia zocor approved divestiture merials interest poultry genetics business united states vytorin marketed lnegy outside comparative purposes amounts presented united states vytorin approved countries respectively include revenue outside united states global sales vytorin earned poultry genetics business billion million results merck pasteur merieux connaught sanofi companys interest merckscheringplough pasteur sa established owned joint venture market partnership recorded equity income affiliates merck vaccines europe collaborate development recognized income million million combination vaccines distribution europe september loss million sanofi pasteur msd spmsd mercks vaccine joint venture company entered agreement astra sanofi pasteur entered letter undertaking lou ab astra develop market astra products united european medicines agency due agency concerns states company astra formed equally regarding longterm efficacy hepatitis b component owned joint venture developed marketed hexavac hepatitis b component hexavac astras new prescription medicines united states manufactured merck lou requires relevant part including prilosec first class medications known suspension eu hexavac license suspension proton pump inhibitors slows production acid hexavac distribution recall hexavac product eu cells stomach lining recall hexavac number noneu countries company astra restructured joint surveillance program possible future revaccination venture whereby company acquired astras interest spmsd markets sells hexavac part eu joint venture renamed kbi inc kbi contributed kbis notified merck reserving rights may operating assets new us limited partnership named astra seek damages merck defended indemnified pharmaceuticals lp partnership company held harmless merck event third party claims maintains limited partner interest partnership renamed september european medicines agency astrazeneca lp azlp became exclusive distributor emea initiated formal review longterm efficacy products kbi retained rights hepatitis b vaccine hbvaxpro hepatitis b merck earns ongoing revenue based sales current component hepatitis bhib combination vaccine future kbi products revenue billion procomvax products marketed sold spmsd billion billion european territory sold elsewhere different respectively primarily relating sales nexium prilosec names merck assessment report prepared emea addition merck earns certain partnership returns committee medicinal products human use chmp recorded equity income affiliates returns include recommends limitations use products priority return provided partnership agreement recommendation mercks response considered variable returns based part upon sales certain former chmp meeting february astra usa inc products preferential return representing sales joint venture products follows mercks share undistributed azlp gaap earnings returns aggregated million million million respectively millions results reflect lower preferential return primarily resulting h epatitis vaccines impact generic competition prilosec viral vaccines merck rhnepoulenc sa sanofiaventis vaccines sa combined animal health poultry genetics businesses form merial limited merial fully integrated merck formed joint venture johnson animal health company standalone joint venture johnson develop market broad range nonprescrip equally owned party merial provides comprehensive tion medicines us consumers owned joint range pharmaceuticals vaccines enhance health venture expanded europe canada wellbeing performance wide range animal species march merck sold equity stake sales joint venture products follows european joint venture johnson johnson million recorded million gain income expense millions net merck continue benefit royalties certain f ipronil products products also regained rights potential future avermectin products products switch prescription overthecounter status products europe sales joint venture products follows poultry genetics business consisted three segments domestic turkey layer segments divested millions respectively broiler foreign turkey g astrointestinal products products includes sales european joint venture march mercks report shareholders capital expenditures analysis liquidity capital resources capital expenditures billion billion mercks strong financial profile enables company fully expenditures united states million fund research development focus external alliances billion expenditures support inline products maximize upcoming launches included million production facilities million providing significant cash returns shareholders cash research development facilities million provided operating activities billion continues environmental projects million administrative companys primary source funds finance capital safety general site projects capital expenditures approved expenditures treasury stock purchases dividends paid yet spent december million stockholders december total worldwide capital expenditures estimated billion cash investments billion including billion depreciation billion billion cash cash equivalents shortterm investments billion million respectively billion longterm investments applied locations united states total depreciation october ajca signed law ajca includes accelerated depreciation million created temporary incentives decembers associated global restructuring plan million us multinationals repatriate accumulated income earned associated closure terlings park basic research outside united states december center see note company incur significantly larger connection ajca company repatriated accumulated depreciation charges result billion result company recorded restructuring actions income tax charge million taxes income related repatriation million paid capital expenditures million paid first quarter millions december approximately billion ajca repatriation invested fully collateralized overnight repurchase agreements included short term investments consolidated balance sheet first quarter company began reinvesting repurchase agreement balances short longterm investments selected data millions w orking capital total debt total liabilities equity cash provided operations total debt enable execution ajca repatriation company changed mix investments longterm shortterm resulting significant increase working capital december working capital levels adequate meet operating requirements company ratios total debt total liabilities equity cash provided operations total debt reflect strength companys operating cash flows ability company cover contractual obligations companys contractual obligations december follows payments due period millions total thereafter p urchase obligations loans payable current portion longterm debt longterm debt operating leases mercks report shareholders purchase obligations consist primarily goods services research development extent dollar value enforceable legally binding include obligations cash flows diminished result strengthening dollar minimum inventory contracts research development companys ability fund research dollarbased advertising research contracts include milestone strategic initiatives consistent level may impaired payments contingent upon future events loans payable company established revenue hedging balance sheet current portion longterm debt includes million notes risk management programs protect volatility future final maturity annual basis foreign currency cash flows changes fair value caused either repurchased holders option volatility foreign exchange rates remarketing agent remarketed redeemed objective revenue hedging program reduce company loans payable current portion longterm debt potential longerterm unfavorable changes foreign also reflect million longdated notes subject exchange decrease us dollar value future cash flows repayment option holders annual basis derived foreign currency denominated sales primarily loans payable also includes billion commercial paper euro japanese yen achieve objective company issued foreign subsidiary billion commercial partially hedge anticipated thirdparty sales paper borrowing facility established october provide expected occur planning cycle typically funding portion companys ajca repatriation three years future company layer hedges required funding obligations relating companys time increasing portion sales hedged gets pension postretirement benefit plans expected closer expected date transaction material probable hedged transaction occur portion sales december company increased capacity hedged based assessments costbenefit profiles shelf registration statement filed securities consider natural offsetting exposures revenue exchange exchange commission sec issue debt securities rate volatilities correlations cost hedging additional billion february company issued instruments hedged anticipated sales specified billion tenyear notes shelf component portfolio similarly denominated foreign remaining capacity companys shelf registration currencybased sales transactions responds statement approximately billion hedged risk manner merck manages february company established billion anticipated transaction exposure principally purchased local year revolving credit facility provide backup liquidity currency put options provide company right commercial paper borrowing facility general corporate obligation sell foreign currencies future purposes company drawn funding predetermined price us dollar strengthens relative facility currency hedged anticipated sales total changes companys longterm credit ratings assigned moodys options cash flows fully offset decline expected future standard poors aa aa respectively us dollar cash flows hedged foreign currency sales ratings continue allow access capital markets conversely us dollar weakens options value flexibility obtaining funds competitive terms company reduces zero company benefits increase continues maintain conservative financial profile total cash value anticipated foreign currency cash flows investments billion exceeds sum loans weaker us dollar would result net benefit market payable longterm debt billion company also value companys hedges would declined longterm credit ratings remain among top million million respectively uniform rated nonfinancial corporations despite strong financial weakening us dollar december profile certain contingent events realized market value determined using foreign discussed note could material adverse impact exchange option pricing model holding factors except companys liquidity capital resources company exchange rates constant merck principally uses participate offbalance sheet arrangements purchased local currency put options uniform weakening involving unconsolidated subsidiaries provide financing us dollar yield largest overall potential loss potentially expose company unrecorded financial market value options sensitivity measurement obligations assumes change one foreign currency relative july board directors approved purchases us dollar would affect foreign currencies relative time billion merck shares total treasury us dollar although predictive nature company stock purchased program billion believes threshold reflects reasonably possible near december billion remains term changes mercks major foreign currency exposures stock repurchase authorization approved merck board relative us dollar cash flows contracts directors reported operating activities consolidated statement cash flows financial instruments market risk disclosures primary objective balance sheet risk management foreign currency risk management program protect us dollar value foreign currency us dollar functional currency companys denominated net monetary assets effects volatility foreign subsidiaries significant portion companys foreign exchange might occur prior conversion revenues denominated foreign currencies merck relies us dollars merck principally utilizes forward exchange sustained cash flows generated foreign sources contracts enable company buy support longterm commitment us dollarbased mercks report shareholders sell foreign currencies future fixed exchange rates companys investment portfolio includes cash economically offset consequences changes foreign equivalents shortterm investments december exchange amount us dollar cash flows derived included repurchase agreements market values net assets merck routinely enters contracts fully significantly impacted changes interest offset effects exchange exposures denominated rates market value companys medium longterm developed country currencies primarily euro japanese fixedrate investments modestly impacted changes us yen exposures developing country currencies interest rates changes medium longterm us interest company enter forward contracts limited rates significant impact market value basis deemed economical based companys fixedrate borrowings generally longer costbenefit analysis considers magnitude maturities sensitivity analysis measure potential changes exposure volatility exchange rate cost market value companys investments debt hedging instrument company also minimize effect related swap contracts change interest rates indicated exchange monetary assets liabilities managing one percentage point increase interest rates operating activities net asset positions local level december would positively impacted company periodically uses forward contracts hedge net aggregate market value instruments changes fair value certain foreign currency denominated million million respectively one percentage availableforsale securities attributable fluctuations foreign point decrease december would currency exchange rates sensitivity analysis changes negatively impacted net aggregate market value value us dollar foreign currency denominated million million respectively increased derivatives investments monetary assets liabilities sensitivity attributable change mix investments indicated us dollar uniformly weakened longterm fixed rate shortterm variable rate currency exposures company december december fair value companys debt income continuing operations taxes would determined using pricing models reflecting one percentage point declined million merck net short shifts appropriate yield curves fair value position relative major foreign currencies companys investments determined using combination consideration forward contracts uniform weakening pricing duration models us dollar yield largest overall potential net loss earnings due exchange december critical accounting policies matters company net long position relative major foreign consolidated financial statements include certain amounts currencies consideration forward contracts therefore based managements best estimates judgments uniform strengthening us dollar would estimates used determining items provisions reduced income continuing operations taxes sales discounts returns depreciable amortizable lives million measurement assumes change one recoverability inventories produced preparation product foreign currency relative us dollar would affect launches amounts recorded contingencies environmental foreign currencies relative us dollar although liabilities reserves pension postretirement predictive nature company believes threshold benefit plan assumptions taxes income reflects reasonably possible nearterm changes mercks uncertainty inherent estimates actual results may differ major foreign currency exposures relative us dollar estimates application following accounting cash flows contracts reported operating policies result accounting estimates potential activities consolidated statement cash flows significant impact financial statements interest rate risk management revenue recognition addition revenue hedging balance sheet risk revenues sales products recognized title management programs company may use interest rate risk loss passes customer revenues domestic swap contracts certain investing borrowing transactions pharmaceutical sales recognized time shipment manage net exposure interest rate changes many foreign subsidiaries well vaccine sales reduce overall cost borrowing company use revenues recognized time delivery recognition leveraged swaps general leverage revenue also requires reasonable assurance collection investment activities would put principal capital risk sales proceeds completion performance obligations december company party three pay domestically sales discounts issued customers direct floating receivefixed interest rate swap contracts designated discounts pointofsale indirectly fair value hedges fixedrate notes maturing intermediary wholesale purchaser known chargebacks respectively notional amounts swaps indirectly form rebates additionally sales generally match amount hedged fixedrate notes made limited right return certain conditions million million million respectively revenues recorded net provisions sales discounts swaps effectively convert fixedrate obligations floating returns established time sale rate instruments cash flows contracts reported operating activities consolidated statement cash flows mercks report shareholders subsequent expiration date generally six months provision aggregate indirect customer discounts twelve months product expiration covers chargebacks rebates chargebacks discounts estimate provision returns based upon historical occur contracted customer purchases directly experience actual returns additionally company intermediary wholesale purchaser contracted considers factors levels inventory distribution customer generally purchases product contracted price channel product dating expiration period whether products plus markup wholesaler wholesaler turn discontinued entrance market additional charges company back difference price generic competition changes formularies launch initially paid wholesaler contract price paid thecounter products name product returns wholesaler customer provision chargebacks provision well actual returns approximately based expected sellthrough levels companys net sales wholesale customers contracted customers well distribution program us wholesalers estimated wholesaler inventory levels rebates amounts implemented company incents wholesalers align owed based upon definitive contractual agreements legal purchases underlying demand maintain inventories requirements private sector public sector medicaid within specified levels terms program allow benefit providers final dispensing product wholesalers earn fees upon providing visibility pharmacy benefit plan participant provision based inventory levels well achieving certain performance expected payments driven patient usage parameters inventory management customer service contract performance benefit provider customers levels reducing shortage claims reducing product returns medicare prescription drug improvement information provided wholesaler distribution modernization act commonly referred medicare program includes items sales trends inventory part became effective january company hand onorder quantity product returns anticipate medicare part material impact wholesalers generally provide mentioned results operations data company regulatory requirement company assumes firstin firstout movement report lot level information manufacturers level inventory within supply chain purposes estimating information needed determine remaining shelf life aggregate indirect customer discount accrual addition original sale date inventory given current wholesaler company uses historical customer segment mix adjusted inventory levels generally less month known events order estimate expected provision company believes collection order lot information across amounts accrued aggregate indirect customer discounts wholesale customers would limited use estimating evaluated quarterly basis comparison sales discounts returns information provided wholesalers customers amounts accrued adjustments recorded trends inventories produced preparation significant events indicate change estimated product launches provision appropriate company capitalizes inventories produced preparation company continually monitors provision product launches sufficient support initial market demand aggregate indirect customer discounts material typically capitalization inventory begin adjustments estimates associated aggregate indirect related product candidates phase iii clinical trials customer discount provision considered high probability regulatory approval summarized information changes aggregate december inventories produced preparation indirect customer discount accrual follows product launches consisted three vaccine products phase iii clinical trials new formulation existing vaccine product new compound type diabetes b alance january company continues monitor status respective current provision product within regulatory approval process however adjustments relating prior years company generally disclose specific timing payments regulatory approval company aware specific b alance december risks contingencies normal regulatory approval process specific issues identified accruals chargebacks reflected direct reduction research process relating safety efficacy manufacturing accounts receivable accruals rebates accrued marketing labeling related inventory would generally expenses accrued balances relative provisions capitalized significant issues respect included accounts receivable accrued current products expiry dates inventory liabilities million billion respectively impacted stage completion company manages december million million levels inventory stage optimize shelf life respectively december inventory relation anticipated market demand order company maintains returns policy allows avoid product expiry issues shelf lives substantially customers return product within specified period prior products range minimum years anticipated future sales mercks report shareholders products support realization inventory value follows actual costs incurred company inventory shelf life sufficient meet initial product launch time development companys legal defense requirements strategy structure light scope vioxx addition company produced inventory preparation litigation number cases brought launch arcoxia united states arcoxia company costs outcomes completed trials launched countries europe latin america asia anticipated timing progression related costs pretrial africa additionally company continues work activities trials vioxx product liability lawsuits regulatory agencies countries registration events scheduled trials expected occur materials launch arcoxia countries october throughout inherent inability company received approvable letter fda predict ultimate outcomes trials limit companys companys nda arcoxia fda informed ability reasonably estimate legal costs beyond end company letter approval nda company continue monitor legal defense issued additional safety efficacy data arcoxia costs review adequacy associated reserves required outside united states merck continues work company currently anticipates number vioxx local regulatory agencies review adjust prescribing product liability lawsuits tried company information contained arcoxias label countries predict timing trials respect vioxx minimum shelf life arcoxia approximately shareholder lawsuits company believes years anticipated worldwide market demand countries meritorious defenses vioxx lawsuits vigorously arcoxia approved supports value defend view inherent difficulty predict inventory capitalized buildup inventory arcoxia ing outcome litigation particularly many inventories produced preparation product launches claimants claimants seek indeterminate damages material effect companys liquidity company unable predict outcome matters time reasonably estimate possible loss contingencies environmental liabilities range loss respect vioxx lawsuits company company involved various claims legal established reserves potential liability proceedings nature considered normal business relating vioxx litigation including product liability intellectual property commercial company party number proceedings brought litigation well additional matters antitrust actions comprehensive environmental response see note financial statements information compensation liability act commonly known company records accruals contingencies superfund legitimate claim contribution asserted probable liability incurred amount liability initially accrued based upon estimated reasonably estimated accruals adjusted transaction costs manage site accruals adjusted periodically assessments change additional information feasibility studies related cost assessments remedial becomes available product liability claims portion techniques completed extent overall accrual actuarially determined considers potentially responsible parties prps may jointly factors past experience number claims reported severally liable expected contribute determined estimates claims incurred yet reported individually company also remediating environmental significant contingent losses accrued probable contamination resulting past industrial activity certain reasonably estimable sites takes active role identifying providing legal defense costs expected incurred connection costs worldwide survey initially performed loss contingency accrued probable assess sites potential contamination resulting past reasonably estimable december company industrial activities assessment indicated physical established reserve million solely future investigation warranted investigation performed legal defense costs related vioxx lawsuits vioxx providing better evaluation need remedial action investigations company spent million need identified remedial action aggregate legal defense costs worldwide related initiated estimates extent contamination site vioxx product liability lawsuits ii vioxx shareholder initially made preinvestigation stage liabilities lawsuits iii vioxx foreign lawsuits iv vioxx potential cost remediation accrued time investigations collectively vioxx litigation fourth definitive information became available quarter company recorded charge million course investigations andor remedial efforts site increase reserve solely future legal defense costs estimates refined accruals adjusted accordingly related vioxx million december estimates related accruals continue refined reserve based certain assumptions best annually estimate amount company believes time company believes compliance material reasonably estimate spent respects applicable environmental laws regulations significant factors considered establishment expenditures remediation environmental liabilities ongoing review reserve vioxx legal defense costs million estimated million years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled mercks report shareholders million million december portfolio approximates reflects equity december respectively liabilities allocation diversification benefits among asset undiscounted consider potential recoveries insurers classes portfolio invests parties paid periods actuarial assumptions based upon managements best remediation applicable sites expected occur estimates judgment reasonably possible change plus primarily next years although possible minus basis points discount rate assumption predict certainty outcome matters assumptions held constant would estimated ultimate costs remediation management believe million favorable unfavorable impact net pension reasonably possible expenditures may incurred postretirement benefit cost reasonably possible change excess liabilities accrued exceed million plus minus basis points expected rate return aggregate management also believe assumption assumptions held constant would expenditures result material adverse effect estimated million favorable unfavorable impact net companys financial position results operations liquidity pension postretirement benefit cost company capital resources year expect minimum pension funding requirement internal revenue code preceding pensions postretirement benefit plans hypothetical changes discount rate expected rate return assumptions would impact companys funding net pension postretirement benefit cost totaled requirements million million pension postretirement benefit plan information financial unrecognized net loss amounts reflect experience reporting purposes calculated using actuarial assumptions differentials primarily relating differences expected including discount rate plan benefit obligations actual returns plan assets well effects expected rate return plan assets changes actuarial assumptions expected returns based calculated marketrelated value assets company reassesses benefit plan assumptions methodology asset gainslosses resulting actual returns regular basis pension postretirement differ companys expected returns recognized benefit plans discount rate evaluated annually modified reflect prevailing market rate december marketrelated value assets ratably fiveyear portfolio highquality fixedincome debt instruments period total unrecognized net loss amounts excess would provide future cash flows needed pay benefits certain thresholds amortized net pension postretirement benefit cost average remaining service included benefit obligation come due life employees amortization total unrecognized net losses december company changed discount rate companys us plans december us pension plan discount rate companys us postretirement benefit plan remained expected increase net pension postretirement benefit cost approximately million annually expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits taxes income included benefit obligation paid developing companys effective tax rate based pretax income expected rate return company considers longterm statutory tax rates tax planning opportunities available compound annualized returns historical market data well various jurisdictions company operates actual returns companys plan assets applies estimated effective tax rate year applied adjustments reflect recent capital market experience companys quarterly operating results event using reference information company develops significant unusual onetime item recognized expected forwardlooking return expectations asset category recognized companys quarterly operating results weighted average expected longterm rate return tax attributable item would separately calculated targeted portfolio allocated across investment categories recorded time unusual onetime item expected portfolio performance reflects contribution company considers resolution prior year tax matters active management appropriate result analysis items significant judgment required determining companys expected rate return companys effective tax rate evaluating tax remained unchanged us pension positions company establishes reserves despite postretirement benefit plans belief tax return positions fully supportable certain target investment portfolio companys us positions likely challenged may pension postretirement benefit plans allocated succeed see note financial statements us equities international equities information company adjusts reserves light fixedincome investments cash changing facts circumstances closing tax investments portfolios equity weighting audit consistent longterm nature plans benefit tax regulations require items included tax return obligation expected annual standard deviation returns different times items reflected financial target statements result effective tax rate reflected financial statements different reported mercks report shareholders tax return differences permanent transition election related accounting tax effects expenses deductible tax return sharebased payment awards provides optional timing differences depreciation expense timing short cut method calculating historical pool windfall differences create deferred tax assets liabilities deferred benefits upon adoption fas r company adopt tax assets generally represent items used tax fas r fsp effective january deduction credit tax return future years company continue use blackscholes valuation company already recorded tax benefit financial method apply modified prospective method statements company establishes valuation allowances result adoption statement mercks compensation deferred tax assets amount expected future expense sharebased payments expected taxable income likely support use deduction approximately million credit deferred tax liabilities generally represent tax expense november fasb issued fsp fsp recognized financial statements payment meaning otherthantemporary impairment deferred expense company already application certain investments fsp addresses taken deduction tax return yet recognized determination investment considered impaired expense financial statements whether impairment temporary previously disclosed october ajca measurement impairment loss well accounting signed law ajca creates temporary incentive considerations subsequent recognition otherthan us multinationals repatriate accumulated income earned temporary impairment requires certain disclosures outside united states december unrealized losses recognized otherthan connection ajca company repatriated temporary impairments fsp effective beginning billion see note result repatriation january effect statement companys company recorded income tax charge million financial position results operations expected taxes income related repatriation material charge partially offset million benefit associated december sec issued interpretation decision implement certain tax planning strategies commission guidance regarding accounting sales company changed intention indefinitely reinvest vaccines bioterror countermeasures federal accumulated earnings earned subsequent december government placement pediatric vaccine stockpile december foreign earnings billion strategic national stockpile effective beginning retained indefinitely subsidiary companies january interpretation sec reinvestment provision made income taxes object revenue recognition sale vaccines would payable upon distribution earnings bioterror countermeasures federal government practicable determine amount related placement stockpiles related vaccines unrecognized deferred income tax liability children program strategic national stockpile effect adoption interpretation companys financial recently issued accounting standards position results operations expected material november fasb issued statement inventory costsan amendment arb chapter fas cautionary factors may affect future results effective beginning january fas annual report written reports oral statements requires abnormal amounts idle facility expense freight made time time company may contain socalled handling costs wasted material recognized current forwardlooking statements based period charges statement also requires allocation managements current expectations subject risks fixed production overhead based normal capacity uncertainties may cause results differ materially production facilities effect statement set forth statements one identify companys financial position results operations forwardlooking statements use words expected material expects plans estimates forecasts projects december fasb issued statement r words similar meaning one also identify sharebased payment fas r originally fact relate strictly historical current intended become effective beginning july facts statements likely address companys april securities exchange commission growth strategy financial results product development product sec issued new rule delayed companys effective approvals product potential development programs one date fas r beginning january fas r must carefully consider statement requires sharebased payments employees understand many factors could cause actual results differ expensed requisite service period based grant materially companys forwardlooking statements date fair value awards requires unvested factors include inaccurate assumptions broad portion outstanding awards upon adoption recognized variety risks uncertainties including using fair value attribution methodologies known forwardlooking statement previously determined statement accounting guaranteed actual future results may vary materially stockbased compensation november fasb issued fasb staff position fsp r mercks report shareholders company assume obligation update cash dividends paid per common share forwardlooking statement one carefully evaluate statements light factors including risk factors described year th q rd q nd q st q companys filings securities exchange commission especially forms k q k item companys annual report year ended december filed march common stock market prices company discusses detail various important factors could cause actual results differ expected historic th q rd q nd q st q results company notes factors investors h igh permitted private securities litigation reform act low prior filing year ended december reference made item companys annual report year ended h igh december one understand low possible predict identify factors consequently principal market trading common stock reader consider list complete new york stock exchange nyse symbol mrk statement potential risks uncertainties common stock market price information based historical nyse market prices condensed interim financial data millions except per share amounts th q rd q nd q st q ales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income continuing operations taxes net income basic earnings per common share earnings per common share assuming dilution ales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income continuing operations taxes net income basic earnings per common share earnings per common share assuming dilution prior period amounts reclassified reflect separate line item presentation restructuring costs amounts include impact restructuring actions see note amounts include impact reserve vioxx legal defense costs see note amounts include impact voluntary worldwide withdrawal vioxx see note amounts include impact net tax charge primarily associated ajca repatriation see note mercks report shareholders consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts ales c osts expenses materials production marketing administrative research development restructuring costs equity income affiliates income expense net ncome continuing operations taxes taxes income ncome continuing operations income discontinued operations net taxes n et income b asic earnings per common share continuing operations discontinued operations net income e arnings per common share assuming dilution continuing operations discontinued operations net income amount add result rounding consolidated statement retained earnings merck co inc subsidiaries years ended december millions b alance january n et income common stock dividends declared spinoff medco health b alance december consolidated statement comprehensive income merck co inc subsidiaries years ended december millions n et income ther comprehensive income loss net unrealized gain loss derivatives net tax net income realization net unrealized gain loss investments net tax net income realization minimum pension liability net tax cumulative translation adjustment relating equity investees net tax c omprehensive income accompanying notes integral part consolidated financial statements mercks report shareholders consolidated balance sheet merck co inc subsidiaries december millions ssets current assets cash cash equivalents shortterm investments accounts receivable inventories excludes inventories classified assetssee note prepaid expenses taxes otal current assets nvestments p roperty plant equipment cost land buildings machinery equipment office furnishings construction progress less allowance depreciation g oodwill ther intangibles net ther assets liabilities stockholders equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable otal current liabilities l ongterm debt eferred income taxes noncurrent liabilities inority interests tockholders equity common stock one cent par value authorized shares issued shares shares paidin capital retained earnings accumulated comprehensive income loss less treasury stock cost shares shares otal stockholders equity accompanying notes integral part consolidated financial statement mercks report shareholders consolidated statement cash flows merck co inc subsidiaries years ended december millions c ash flows operating activities continuing operations net income less income discontinued operations net taxes ncome continuing operations adjustments reconcile income continuing operations net cash provided operating activities continuing operations depreciation amortization deferred income taxes equity income affiliates dividends distributions equity affiliates net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities n et cash provided operating activities continuing operations c ash flows investing activities continuing operations capital expenditures purchase securities subsidiaries investments proceeds sale securities subsidiaries investments acquisitions banyu shares n et cash provided used investing activities continuing operations c ash flows financing activities continuing operations net change shortterm borrowings proceeds issuance debt payments debt redemption preferred units subsidiary purchase treasury stock dividends paid stockholders proceeds exercise stock options n et cash used financing activities continuing operations e ffect exchange rate changes cash cash equivalents iscontinued operations revised net cash provided medco health operating activities net cash provided medco health investing activities dividend received medco health net intercompany settlements cash transferred n et cash provided discontinued operations n et increase decrease cash cash equivalents cash cash equivalents beginning year c ash cash equivalents end year accompanying notes integral part consolidated financial statement mercks report shareholders notes consolidated financial statements merck co inc subsidiaries millions except per share amounts fair value company considers available evidence nature operations evaluating potential impairment investments including merck global researchdriven pharmaceutical company duration extent fair value less cost discovers develops manufactures markets broad companys ability intent hold investment range innovative products improve human animal health directly joint ventures companys revenue recognition revenues sales products products include therapeutic preventive agents generally recognized title risk loss passes customer sold prescription treatment human disorders revenues domestic pharmaceutical sales recognized time shipment many foreign subsidiaries well vaccine sales revenues recognized time summary accounting policies delivery recognition revenue also requires reasonable principles consolidation consolidated financial assurance collection sales proceeds completion statements include accounts company performance obligations domestically sales discounts subsidiaries controlling interest maintained issued customers direct discounts pointofsale controlling interest determined majority ownership indirectly intermediary wholesale purchaser known interest absence substantive thirdparty participating chargebacks indirectly form rebates rights case variable interest entities majority additionally sales generally made limited right exposure expected losses residual returns return certain conditions revenues recorded net consolidated subsidiaries merck ownership less provisions sales discounts returns outside stockholders interests shown established time sale accruals chargebacks minority interests investments affiliates reflected direct reduction accounts receivable company significant influence controlling accruals rebates accrued expenses accrued interest interests entities owned equally balances relative provisions included accounts company third party shared control receivable accrued current liabilities carried equity basis million billion respectively december foreign currency translation us dollar million million respectively functional currency companys foreign subsidiaries december cash cash equivalents cash equivalents depreciation depreciation provided estimated comprised certain highly liquid investments original useful lives assets principally using straightline maturities less three months method tax purposes accelerated methods used estimated useful lives primarily range years inventories substantially domestic pharmaceutical buildings years machinery equipment inventories valued lower lastin firstout lifo office furnishings cost market book tax purposes foreign pharmaceutical inventories valued lower firstin goodwill intangibles goodwill represents firstout fifo cost market inventories consist currently excess acquisition costs fair value net assets marketed products certain products awaiting regulatory businesses purchased goodwill assigned reporting units approval evaluating recoverability inventories within companys segments evaluated impairment produced preparation product launches company least annual basis using fair value based test considers probability revenue obtained acquired intangibles recorded cost future sale related inventory together status amortized straightline basis estimated useful product within regulatory approval process lives see note events circumstances warrant review company assess recoverability future investments investments classified availableforsale operations intangibles using undiscounted cash flows reported fair value unrealized gains losses derived lowest appropriate asset groupings generally extent hedged reported net tax accumulated subsidiary level impairments recognized operating comprehensive income investments debt securities results extent carrying value exceeds fair value classified heldtomaturity consistent managements determined based net present value intent reported cost impairment losses charged estimated future cash flows income expense net otherthantemporary declines mercks report shareholders research development research development grantdate fair value awards requires expensed incurred upfront milestone payments made unvested portion outstanding awards upon adoption third parties connection research development recognized using fair value attribution collaborations prior regulatory approval expensed methodologies previously determined statement incurred payments made third parties subsequent accounting stockbased compensation regulatory approval capitalized amortized november fasb issued fasb staff position shorter remaining license product patent life fsp r transition election related accounting tax effects sharebased payment awards stockbased compensation employee stockbased provides optional short cut method calculating compensation recognized using intrinsic value method historical pool windfall benefits upon adoption fas r generally employee stock options granted purchase company adopt fas r fsp effective shares company stock fair market value time january company continue use black grant accordingly compensation expense recognized scholes valuation method apply modified companys stockbased compensation plans prospective method performancebased awards restricted stock units accordance current accounting requirements options granted employees certain equity method company recognizes pro forma compensation expense investees employees including retirementeligible employees effect net income earnings per common share vesting period employee stock options upon company applied fair value method recognizing adoption fas r compensation expense employee stockbased compensation follows recognized immediately awards granted retirement eligible employees period grant date years ended december date retirement eligibility achieved approach known n et income reported nonsubstantive vesting period approach compensation expense net company applying nonsubstantive vesting tax period approach stock options granted retirementeligible reported employees effect pro forma earnings per share fair value method assuming dilution periods presented provided p ro forma net income table would significant e arnings per common share prior pro forma compensation expense options continuing operations graded vesting terms calculated using black assuming dilutionas reported scholes model based singleoption valuation approach assuming dilutionpro forma using straightline method amortization earnings per common share company revised assumptions utilized black basic reported scholes model determining pro forma compensation basicpro forma expense based historical data expense assuming dilutionas reported determined using separate expected term assumptions assuming dilutionpro forma vesting tranche result pro forma compensation expense stock options granted january average fair value employee nonemployee prior january calculated using director options granted accelerated amortization method prescribed fasb respectively fair value interpretation accounting stock appreciation rights estimated using blackscholes optionpricing model based variable stock option award plans upon weighted average market price grant date adoption fas r effective january following company recognize compensation expense using weighted average assumptions straightline method connection medco health solutions inc years ended december medco health spinoff options granted medco health ividend yield employees prior february options granted riskfree interest rate february became fully vested accordance volatility original terms grants result pro forma expected life years compensation expense reflects accelerated vesting options addition certain stock options granted december financial accounting standards medco health employees converted board fasb issued statement r sharebased medco health options terms amounts maintained payment fas r originally intended option holders positions therefore pro forma become effective beginning july april compensation expense options reflected securities exchange commission sec issued new rule date spinoff delayed companys effective date fas r beginning january fas r requires share based payments employees expensed requisite service period based mercks report shareholders pretax costs restructuring program legal defense costs legal defense costs expected million expected million incurred connection loss contingency accrued billion end initial probable reasonably estimable phase restructing program expected use estimates consolidated financial statements substantially complete cumulative pretax costs prepared conformity accounting principles generally program expected range billion billion accepted united states gaap accordingly approximately cumulative pretax costs non include certain amounts based managements best cash relating primarily accelerated depreciation estimates judgments estimates used determining facilities scheduled closure items provisions sales discounts returns million costs incurred depreciable amortizable lives recoverability inventories comprised million separation costs recorded produced preparation product launches amounts restructuring costs million accelerated recorded contingencies environmental liabilities depreciation asset impairment costs reserves pension postretirement benefit plan million recorded materials production assumptions taxes income uncertainty million recorded research development inherent estimates actual results may differ company also plans close basic research center estimates terlings park united kingdom incurred additional accelerated depreciation costs million recorded reclassifications certain reclassifications made research development reduced prior year amounts conform current year assets research center net realizable presentation values subsequent december research development performed site separation costs associated elimination voluntary product withdrawal approximately positions december september company announced comprised actual headcount reductions voluntary worldwide withdrawal vioxx arthritis acute elimination contractors vacant positions well pain medication companys decision effective estimates future terminations roughly positions immediately based new threeyear data probable could reasonably estimated prospective randomized placebocontrolled clinical trial december included million approve adenomatous polyp prevention vioxx separation costs million related curtailment connection withdrawal company settlement termination charges companys pension recorded unfavorable adjustment net income postretirement benefit plans see note million per share adjustment pretax million approximately million income million amount million associated abandonment certain fixed assets related estimated customer returns product previously longer used business result sold recorded reduction sales million restructuring actions must therefore written related writeoffs inventory held company remaining million reflects accelerated depreciation costs recorded materials production expense primarily related five merck owned manufacturing million related estimated costs undertake facilities worldwide two preclinical sites sold withdrawal product recorded marketing closed end manufacturing facilities administrative expense tax benefit adjustment included action ponders end united kingdom million reflects geographical mix vioxx okazaki japan kirkland canada albany georgia returns cost withdrawal adjustment danville pennsylvania two preclinical sites okazaki include charges future legal defense costs see note menuma japan actions effort reduce december million remaining costs consolidate companys manufacturing accrued balance reported accrued current research facilities december buyers liabilities million reported reduction identified sites however closures accounts receivable vioxx withdrawal process anticipated completed end subject completed costs associated compliance legal obligations sites withdrawal line original amounts recorded continue operate respective closure dates company since future cash flows sufficient recover respective book values merck required accelerate restructuring depreciation site assets rather writing immediately site assets include manufacturing november company announced first phase research facilities equipment global restructuring program designed reduce part costreduction initiative announced companys cost structure increase efficiency enhance october completed end company competitiveness initial steps include eliminated positions company completed similar implementation new supply strategy merck program positions eliminated manufacturing division intended create leaner costeffective customerfocused manufacturing model next three years part program merck plans sell close five manufacturing sites two preclinical sites end eliminate approximately positions companywidemercks report shareholders december result restructuring actions continued could receive additional payments well company recorded restructuring costs million royalties based upon achieving program objectives million amounts july merck entered agreement geron respectively million million related corporation geron develop cancer vaccine employee severance benefits million telomerase telomerase enzyme active cancer million related curtailment settlement termination cells maintains telomere length ends charges companys pension postretirement chromosomes activity allows cancer grow benefit plans see note million related metastasize long periods time geron received modification terms certain employees stock option upfront payment based upon certain developments grants regulatory events could receive additional payments well company records restructuring activities accordance royalties fas employers accounting postemployment sumitomo pharmaceuticals co ltd sumitomo benefitsan amendment fasb statement merck signed agreement june collaborate fas employers accounting settlements sm lurasidone atypical antipsychotic compound curtailments defined benefit pension plans termination currently phase ii development treatment benefits fas accounting impairment schizophrenia one chronic disabling disposal longlived assets fas accounting severe mental illnesses agreement sumitomo costs associated exit disposal activities granted merck affiliate exclusive license summarized information relative employee sm parts world except japan china severance benefits accrual excluding pension korea taiwan postretirement benefit activity see note follows april merck bristolmyers squibb company bms entered worldwide collaborative agreement globally develop market pargluva bmss investigational b alance january oral medicine treatment type diabetes expense previously reported company bms payments october fda issued approvable letter b alance december pargluva requested additional safety information address fully cardiovascular safety profile pargluva data requirement may cause significant delay research collaborations acquisitionsdivestitures products launch result bms merck license agreements terminated collaborative agreement pargluva merck continues strategy establishing strong external rights pargluva backup compound pargluva alliances complement substantial internal research returning bms december capabilities including research collaborations licensing pre march company acquired aton pharma inc clinical clinical compounds technology transfers aton privately held biotechnology company focusing drive nearand longterm growth merck development novel treatments cancer serious signed agreements diseases atons clinical pipeline histone deacetylase october agensys inc agensys cancer inhibitors represents class antitumor agents potential biotechnology company merck announced formation efficacy based novel mechanism action atons lead global alliance jointly develop commercialize ags product candidate suberoylanilide hydroxamic acid known psca agensys fully human monoclonal antibody mab vorinostat extensively studied treatment prostate stem cell antigen psca agreement grants cutaneous tcell lymphoma consideration acquisition merck worldwide rights agspsca exclusive license consisted upfront payment may include contingent psca proprietary agensys target well rights payments based upon regulatory filing approval sale therapeutic diagnostic products developed products connection transaction company alliance upon signing agreement agensys received recorded charge million acquired research upfront payment could receive million associated products development milestone payments upon successful development acquisition date technological feasibility launch could increase million multiple established alternative future use existed charge oncology indications successfully developed approved recorded research development expense addition royalties worldwide sales remaining net assets acquired transaction september foxhollow technologies inc material aton development stage company foxhollow merck announced formation novel commenced planned principal operations pharmacogenomics collaboration collaboration focus transaction accounted acquisition assets analyzing atherosclerotic plaque removed patient rather business combination therefore goodwill arteries means identifying new biomarkers recorded atons results operations atherosclerotic disease progression use development included companys since acquisition date cardiovascular compounds mercks pipeline february merck h lundbeck lundbeck agreement includes research collaboration three entered agreement exclusive us development years foxhollow received upfront payment commercialization gaboxadol compound collaboration treatment sleep disorders terms agreement lundbeck received initial payment million dur mercks report shareholders ing term agreement could receive following summary assets liabilities million additional milestone payments future discontinued operations spun company recorded upfront payment research development expense merck fund majority august remaining development activities june merck ssets lundbeck extended agreement exclusive c ash cash equivalents development commercialization gaboxadol japan current assets company wholly owned subsidiary property plant equipment net msd japan co ltd launched tender offers acquire goodwill remaining common shares banyu intangibles net pharmaceutical co ltd banyu already assets aggregate purchase price approximately billion substantially shares acquired l iabilities march merck completed acquisition banyu full c urrent liabilities ownership banyu strengthens mercks position japan longterm debt worlds second largest pharmaceutical market deferred income taxes companys acquisitions banyu shares accounted purchase method pro forma information provided impact transactions n et assets transferred material effect companys consolidated results operations aggregate purchase price financial instruments allocated based upon fair values portion assets foreign currency risk management liabilities acquired allocation aggregate us dollar functional currency purchase price resulted reversal billion companys foreign subsidiaries significant portion minority interest liability recognition million companys revenues denominated foreign currencies intangibles million goodwill million merck relies sustained cash flows generated foreign deferred income tax liabilities million net sources support longterm commitment us dollar assets principally property plant equipment based research development extent dollar intangibles included million inline product rights value cash flows diminished result strengthening year weighted average useful life dollar companys ability fund research dollar million representing year life tradename based strategic initiatives consistent level may connection transactions company also incurred impaired company established revenue hedging charge million acquired research recorded balance sheet risk management programs protect research development expense associated products volatility future foreign currency cash flows changes development acquisition date technological fair value caused volatility foreign exchange rates feasibility established alternative future objective revenue hedging program reduce use existed potential longerterm unfavorable changes foreign august merck completed spinoff exchange decrease us dollar value future cash medco health income medco health presented flows derived foreign currency denominated sales separately discontinued operations prior spinoff primarily euro japanese yen achieve merck received billion dividend medco health objective company partially hedge anticipated third merck paid million settlement net party sales expected occur planning cycle intercompany payable medco health addition date typically three years future spinoff million cash cash equivalents company layer hedges time increasing portion included net assets medco health sales hedged gets closer expected date spun statement cash flows restated transaction probable hedged transaction separately disclose operating investing portions occur portion sales hedged based cash flows attributable discontinued operations assessments costbenefit profiles consider natural amounts previously reported combined basis offsetting exposures revenue exchange rate volatilities summarized financial information discontinued correlations cost hedging instruments operations follows hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales year ended december transactions responds hedged risk otal net revenues manner merck manages anticipated transaction income taxes exposure principally purchased local currency put options taxes income provide company right obligation income net taxes sell foreign currencies future predetermined price us dollar strengthens relative currency includes operations august hedged anticipated sales total changes mercks report shareholders options cash flows fully offset decline expected fair values forward exchange contracts reported future us dollar cash flows hedged foreign currency following four balance sheet line items accounts receiv sales conversely us dollar weakens options able current portion gain position assets non value reduces zero company benefits current portion gain position accrued current increase value anticipated foreign currency cash liabilities current portion loss position deferred income flows taxes noncurrent liabilities noncurrent portion loss designated hedge relationship based total position changes options cash flows accordingly entire fair value change options deferred accumulated interest rate risk management comprehensive income aoci reclassified sales company may use interest rate swap contracts certain hedged anticipated revenue recognized investing borrowing transactions manage net expo hedge relationship perfectly effective therefore hedge sure interest rate changes reduce overall cost ineffectiveness recorded fair values currency options borrowing company use leveraged swaps reported accounts receivable assets general leverage investment activities primary objective balance sheet risk would put principal capital risk management program protect us dollar value december company party three foreign currency denominated net monetary assets payfloating receivefixed interest rate swap contracts desig effects volatility foreign exchange might occur prior nated fair value hedges fixedrate notes maturing conversion us dollars merck principally utilizes respectively notional amounts forward exchange contracts enable company buy swaps match amount hedged fixedrate sell foreign currencies future fixed exchange rates notes million million million economically offset consequences changes respectively swaps effectively convert fixedrate foreign exchange amount us dollar cash flows obligations floatingrate instruments fair value changes derived net assets merck routinely enters notes fully offset interest expense fair value contracts fully offset effects exchange exposures changes swap contracts fair values denominated developed country currencies primarily contracts reported accounts receivable assets euro japanese yen exposures developing country accrued current liabilities deferred income taxes currencies company enter forward contracts noncurrent liabilities limited basis deemed economical based costbenefit analysis considers fair value financial instruments magnitude exposure volatility exchange rate summarized carrying values fair values cost hedging instrument company also companys financial instruments december minimize effect exchange monetary assets fair values estimated based market prices liabilities managing operating activities net asset available dealer quotes positions local level foreign currency denominated monetary assets liabilities remeasured spot rates effect balance carrying fair carrying fair sheet date effects changes spot rates reported value value value value income expense net forward contracts ssets designated hedges marked market c ash cash income expense net accordingly fair value changes equivalents forward contracts help mitigate changes value shortterm remeasured assets liabilities attributable changes investments foreign currency exchange rates except extent longterm spotforward differences differences significant investments due shortterm nature contracts typically purchased currency average maturities inception less one year options company periodically uses forward contracts hedge forward exchange changes fair value certain foreign currency contracts denominated availableforsale securities attributable interest rate swaps fluctuations foreign currency exchange rates changes l iabilities fair value hedged securities due fluctuations l oans payable spot rates offset income expense net fair current portion value changes forward contracts attributable spot rate longterm debt fluctuations hedge ineffectiveness material longterm debt changes contracts fair value due written currency spotforward differences excluded designated options hedge relationship recognized income expense forward exchange net amounts significant years ended contracts december none currency swap outstanding december mercks report shareholders connection american jobs creation act concentrations credit risk ajca company repatriated billion see part ongoing control procedures company moni note december billion ajca tors concentrations credit risk associated corporate repatriation invested fully collateralized overnight issuers securities financial institutions repurchase agreements included shortterm conducts business credit risk minimal credit exposure investments consolidated balance sheet limits established avoid concentration single summary december carrying values fair issuer institution four us customers represented values companys investments gross unrealized aggregate approximately onethird companys accounts gains losses companys availableforsale receivable december company monitors investments recorded net tax aoci follows creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral carrying fair gross unrealized security support credit sales value value gains losses vailableforsale inventories repurchase inventories december consisted agreements corporate notes bonds f inished goods commercial paper raw materials work process municipal securities supplies us government agency securities otal approximates current cost debt securities reduction lifo cost equity securities otal availableforsale r ecognized heldtomaturity inventories securities assets inventories valued lifo method comprised approximately inventories december carrying fair gross unrealized respectively amounts recognized value value gains losses assets comprised entirely raw materials work vailableforsale process inventories include inventories produced corporate notes preparation product launches principally vaccines bonds inventories products principally vaccines us government arcoxia expected sold within one year agency securities intangibles commercial paper intangibles december consisted municipal securities foreign government bonds p atents product rights debt securities equity securities otal acquired cost otal availableforsale heldtomaturity p atents product rights securities availableforsale debt securities maturing within one year otal accumulated amortization totaled billion december remaining aggregate amortization expense substantially debt securities million mature within five years recorded materials production expense million million million estimated aggregate amortization expense next five years follows million million million million million mercks report shareholders partnership returns recorded equity income affiliates returns include priority return provided joint ventures equity method affiliates partnership agreement variable returns based part company scheringplough corporation upon sales certain former astra usa inc products scheringplough entered agreements create separate preferential return representing mercks share undistributed equallyowned partnerships develop market azlp gaap earnings returns aggregated united states new prescription medicines cholesterol million million million management respiratory therapeutic areas respectively results reflect lower cholesterolmanagement partnership agreements preferential return primarily resulting impact expanded include countries world excluding generic competition prilosec astrazeneca merger japan ezetimibe first new class triggers partial redemption mercks limited partnership cholesterollowering agents launched united states interest upon redemption azlp distribute zetia marketed ezetrol outside united states kbi amount based primarily multiple mercks reported merckscheringplough partnership global average annual variable returns derived sales sales zetia totaled billion billion former astra usa inc products three years prior million july combination redemption limited partner share agreed value product containing active ingredients zetia conjunction restructuring payment zocor approved united states vytorin million deferred astra purchased option marketed inegy outside united states vytorin asset option buy mercks interest kbi products approved countries outside united states excluding gastrointestinal medicines nexium prilosec global sales vytorin billion asset option exercisable exercise price million results companys equal net present value march interest merckscheringplough partnership recorded projected future pretax revenue received equity income affiliates income company kbi products appraised value merck million million loss also right require astra purchase interest million appraised value addition company merck entered agreement astra ab granted astra option buy mercks common stock interest astra develop market astras products royalty kbi exercisable two years astras purchase mercks bearing license companys total sales astra interest kbi products exercise option products reached level triggered first step astra also provided year combined establishment joint venture business carried astra annual sales two products fall minimum amount merck inc ami merck astra owned provided case long either merck option share joint venture formed developed astrazenecas option exercised marketed astras new prescription medicines exercise price based net present value united states including prilosec first class estimated future net sales nexium prilosec medications known proton pump inhibitors slows determined time exercise production acid cells stomach lining astrazeneca merger constituted trigger event merck astra completed restructuring kbi restructuring agreements result ownership operations joint venture whereby merger exchange mercks relinquishment rights company acquired astras interest ami renamed kbi inc future astra products existing pending us patents kbi contributed kbis operating assets new us time merger astra paid million limited partnership astra pharmaceuticals lp advance payment subject trueup calculation partnership exchange limited partner interest may require repayment portion astra contributed net assets wholly owned subsidiary amount trueup amount directly dependent fair astra usa inc partnership exchange market value astra product rights retained general partner interest partnership renamed company accordingly recognition contingent income astrazeneca lp azlp upon astras merger deferred realizable amount zeneca group plc astrazeneca merger became determinable anticipated prior exclusive distributor products kbi retained provisions kbi restructuring agreements rights trigger event occurred sum limited maintaining limited partner interest azlp partner share agreed value appraised value merck consent protective rights intended preserve trueup amount guaranteed minimum billion business economic interests including restrictions distribution limited partner share agreed value power general partner make certain distributions payment trueup amount occur dispositions furthermore limited events default astrazenecas purchase mercks interest kbi products additional rights granted company including contingent upon exercise either mercks option powers direct actions remove replace astrazenecas option therefore payment partnerships chief executive officer chief financial officer appraised value may may occur merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium prilosec addition merck earns certain mercks report shareholders merck rhnepoulenc sa sanofi million million respectively longdated notes aventis sa combined animal health poultry subject repayment option holders genetics businesses form merial limited merial fully annual basis million notes annual interest rate integrated animal health company standalone joint resets final maturity annual basis venture equally owned party merial provides notes either repurchased holders option comprehensive range pharmaceuticals vaccines remarketing agent remarketed redeemed enhance health wellbeing performance wide company loans payable december also range animal species merial sales billion included million fixedrate notes due billion billion billion fixed rate notes due respectively merck pasteur mrieux connaught weighted average interest rate borrowings sanofi pasteur sa established equallyowned joint december respectively venture market vaccines europe collaborate longterm debt december consisted development combination vaccines distribution europe joint venture vaccine sales million million million astra note due merck formed joint venture johnson notes due johnson develop market broad range nonprescrip notes due tion medicines us consumers owned venture debentures due expanded europe canada debentures due march merck sold equity stake european notes due joint venture johnson johnson million variablerate borrowing due recorded million gain income expense net debentures due see note merck continue benefit royalties notes due certain products also regained rights potential future products switch prescription overthe counter status europe sales product marketed joint venture including sales european joint venture company party interest rate swap contracts march million effectively convert fixedrate million million notes floatingrate instruments see note investments affiliates accounted using equity presented table december method including joint ventures totaled billion consisted primarily million borrowings december billion december variable rates averaging respectively amounts reported assets dividends borrowings million subject repayment option distributions received affiliates billion holders beginning million subject million million repayment option holders beginning summarized information affiliates follows years also included foreign borrowings varying rates years ended december aggregate maturities longterm debt ales next five years follows million materials production costs million billion million expense net million income taxes rental expense companys operating leases net ecember sublease income million minimum c urrent assets aggregate rental commitments noncancellable leases noncurrent assets follows million million current liabilities million million million noncurrent liabilities thereafter million company significant capital leases loans payable longterm debt contingencies environmental liabilities commitments company involved various claims legal loans payable december included proceedings nature considered normal business billion million respectively commercial including product liability intellectual property commercial paper borrowings commercial paper borrowings december litigation well additional matters antitrust actions include billion issued foreign subsidiary company records accruals contingencies billion commercial paper borrowing facility probable liability incurred amount established october provide funding portion reasonably estimated accruals adjusted periodically companys repatriation connection ajca see assessments change additional information note loans payable december also included mercks report shareholders becomes available product liability claims portion judge fallon indicated intends try series overall accrual actuarially determined considers cases period november factors past experience number claims reported following categories heart attack short term use ii heart estimates claims incurred yet reported individually attack long term use iii stroke iv cardiovascular significant contingent losses accrued probable injury involving prescription written april reasonably estimable legal defense costs expected labeling vioxx revised include results vigor incurred connection loss contingency accrued trial probable reasonably estimable november december case brought evelyn companys decision obtain insurance coverage irvin plunkett behalf late husband richard irvin jr dependent market conditions including cost died apparent heart attack tried houston availability existing time decisions made texas plaintiff alleged mr irvin took vioxx approximately result number factors product liability insurance one month thus action fell within category heart become less available cost increased attack short term use deliberating two onehalf significantly company evaluated risks days court found jury deadlocked declared determined cost obtaining product liability insurance mistrial federal court rules require unanimous verdict outweighs likely benefits coverage available retrial case commenced february new insurance certain product liabilities orleans louisiana february jury returned verdict effective august including liability products first favor merck counts sold date company continue evaluate next scheduled mdl trial diaz vs merck case insurance needs costs availability benefits plaintiffs claim heart attack long term use product liability insurance future scheduled may addition diaz case garza case discussed vioxx product liability lawsuits vioxx litigation currently scheduled trial product liability lawsuits previously disclosed august trial state previously disclosed federal state product liability court texas jury ernst vs merck reached verdict lawsuits involving individual claims well putative class favor plaintiff purported award total actions filed company respect million compensatory punitive damages vioxx december company texas law maximum amount could awarded served aware named defendant plaintiff capped approximately million company approximately lawsuits include approximately intends appeal verdict completion posttrial plaintiff groups alleging personal injuries resulting proceedings trial court company believes use vioxx lawsuits approximately strong points raise appeal hopeful appeals lawsuits representing approximately plaintiff groups process correct verdict since company believes slated federal mdl discussed potential unfavorable outcome probable approximately lawsuits representing approximately established reserve respect verdict plaintiff groups included coordinated proceeding november case frederick mary new jersey superior court judge carol e higbee jackson humeston vs merck co inc superior court new certain lawsuits include allegations regarding jersey law division atlantic county jury returned verdict gastrointestinal bleeding cardiovascular events thrombotic favor merck counts case second vioxx events kidney damage company also named personal injury case go trial mr humeston year old defendant approximately putative class actions united states postal employee idaho alleged alleging personal injuries seeking medical monitoring suffered heart attack september result taking result putative class members use vioxx ii vioxx sought compensatory punitive damages jury disgorgement certain profits common law unjust found vote merck fail provide enrichment theories andor iii various remedies state adequate warning prescribing physicians association consumer fraud fair business practice statutes including vioxx increased risk serious cardiovascular recovering cost vioxx purchased individuals events prior mr humestons heart attack jury also thirdparty payors union health plans actions unanimously found merck violate new jersey discussed paragraph collectively referred consumer fraud act marketing drug prescribing vioxx product liability lawsuits actions filed physicians state courts california texas new jersey trial garza vs heart clinic evans posada merck philadelphia pennsylvania respectively co inc began january th judicial transferred single judge state coordinated district court starr county texas company believes proceedings addition february judicial evidence case show vioxx cause heart panel multidistrict litigation jpml transferred attack leonel garza sr mr garza died heart attack vioxx product liability lawsuits pending federal courts april following years cardiovascular disease nationwide one multidistrict litigation mdl prior heart attack approximately one coordinated pretrial proceedings mdl transferred united states district court eastern district louisiana district judge eldon e fallon mercks report shareholders consolidated amended class action complaint superseding month death company maintains prior complaints various cases complaint plaintiffs mr garza given oneweek supply vioxx mg request certification class purchasers company stock samples pain may october complaint merck entered tolling agreement tolling alleges defendants made false misleading agreement mdl plaintiffs steering committee statements regarding vioxx violation sections b establishes procedure halt running statute securities exchange act seeks limitations tolling certain categories claims allegedly unspecified compensatory damages costs suit arising use vioxx nonnew jersey citizens including attorneys fees complaint also asserts claim tolling agreement applies individuals filed section securities exchange act lawsuits may may eventually file lawsuits certain defendants relating sales merck stock claimants seek toll claims alleging injuries addition complaint includes allegations sections resulting thrombotic cardiovascular event results securities act certain defendants myocardial infarction ischemic stroke tolling made incomplete misleading statements registration agreement provides counsel additional time evaluate statement certain prospectuses filed connection potential claims tolling agreement requires tolled merck stock investment plan dividend reinvestment plan claims filed federal court december defendants filed motion dismiss complaint approximately claimants entered tolling pending agreements previously disclosed august complaint lawsuits filed oregon state court state oregon previously disclosed july new jersey state oregon state treasurer behalf oregon public employee trial court certified nationwide class thirdparty payors retirement fund company certain current unions health insurance plans paid whole former officers directors complaint brought part vioxx used plan members insureds oregon securities law alleges plaintiff suffered named plaintiff case seeks recovery certain damages connection purchases merck common vioxx purchase costs plus penalties based allegations stock artificially inflated prices due companys alleged purported class members paid vioxx violations law related disclosures vioxx would known products alleged risks company removed lawsuit us district court merck believes class improperly certified trial district oregon however plaintiff moved remand case courts ruling procedural address merits state court motion granted plaintiffs allegations company intends defend previously disclosed number shareholder derivative vigorously new jersey state superior court appellate actions filed federal court new jersey division accepted mercks appeal class certification superior court naming company nominal defendant order expedited basis certain members board past present together previously reported company also named certain executive officers defendants complaints arise defendant separate lawsuits brought attorneys substantially factual allegations made general louisiana mississippi texas attorney vioxx securities lawsuits derivative suits general alaska also recently filed lawsuit purportedly brought assert rights company assert actions allege company misrepresented safety claims board members officers breach vioxx seek recovery cost vioxx purchased fiduciary duty waste corporate assets unjust enrichment reimbursed state agencies ii reimbursement abuse control gross mismanagement actions sums paid state agencies medical services discussed paragraph collectively referred treatment persons injured vioxx iii damages vioxx derivative lawsuits jpml transferred vioxx various common law theories andor iv remedies derivative lawsuits pending federal court shareholder various state statutory theories including state mdl judge chesler consolidated vioxx derivative consumer fraud andor fair business practices medicaid lawsuits purposes june federal fraud statutes including civil penalties derivative plaintiffs filed verified consolidated shareholders derivative complaint superseding prior complaints various shareholder lawsuits cases defendants filed motion dismiss complaint previously disclosed addition vioxx product pending addition vioxx derivative lawsuits liability lawsuits company along various current pending new jersey superior court consolidated former officers directors company defendants transferred judge higbee atlantic county april number putative class actions individual lawsuits state plaintiffs filed superseding verified consolidated filed removed federal court shareholders amended shareholder derivative complaint january federal securities laws vioxx securities lawsuits aii two shareholder derivative cases dismissed transferred jpml along related without prejudice cases dismissed court lawsuits discussed united states district court granted defendants motion stay cases courts order district new jersey district judge stanley r permits plaintiffs refile complaints consolidated chesler inclusion nationwide mdl coordinated federal shareholder derivative case resolved pretrial proceedings shareholder mdl judge chesler consolidated vioxx securities lawsuits purposes june plaintiffs vioxx securities lawsuits filed fourth mercks report shareholders previously disclosed october two insurers availability insurance individual shareholders made demand board coverage likely additional disputes take legal action mr raymond gilmartin former time company believes insurance coverage chairman president chief executive officer respect vioxx lawsuits adequate cover individuals allegedly causing damage company defense costs losses respect allegedly improper marketing vioxx previously disclosed companys upperlevel excess response demand letter board directors insurers provide excess insurance potentially applicable determined november meeting vioxx lawsuits commenced arbitration board would take shareholders request seeking among things cancel policies void consideration remains consideration obligations policies raise addition previously disclosed number coverage issues respect vioxx lawsuits second putative class actions filed arbitration one companys upperlevel excess company certain current former officers insurers also commenced merck intends contest directors company federal court vioxx vigorously insurers claims attempt enforce erisa lawsuits together vioxx securities rights applicable insurance policies amounts actually lawsuits vioxx derivative lawsuits vioxx recovered policies discussed section may shareholder lawsuits behalf certain less amounts specified preceding paragraph companys current former employees participants certain companys retirement plans investigations asserting claims employee retirement income previously disclosed november company security act erisa lawsuits make similar advised staff sec commencing allegations allegations contained vioxx informal inquiry concerning vioxx january securities lawsuits claim defendants company announced received notice sec issued breached duties plan fiduciaries formal notice investigation also company received jpml transferred vioxx erisa lawsuits subpoena us department justice doj shareholder mdl judge chesler consolidated requesting information related companys research vioxx erisa lawsuits purposes consolidated marketing selling activities respect vioxx federal amended complaint filed vioxx erisa lawsuits health care investigation criminal statutes also august defendants filed motion ongoing investigations certain congressional committees dismiss complaint pending previously disclosed companys uk subsidiary notified medicines healthcare products regulatory international lawsuits agency united kingdom mhra investigation previously disclosed addition lawsuits mhra compliance company european discussed company named union eu adverse experience reporting requirements defendant litigation relating vioxx various countries connection vioxx addition previously disclosed collectively vioxx foreign lawsuits europe investigations conducted local authorities certain canada brazil australia turkey israel cities europe order determine whether criminal charges brought concerning vioxx company additional lawsuits cooperating governmental entities respective based media reports sources company investigations vioxx investigations company anticipates additional vioxx product liability lawsuits predict outcome inquiries however could result vioxx shareholder lawsuits vioxx foreign lawsuits potential civil andor criminal dispositions collectively vioxx lawsuits filed previously disclosed company received civil andor certain current former officers investigative demand group attorneys general directors future states district columbia investigating whether company violated state consumer protection laws insurance marketing vioxx company cooperating attorneys previously disclosed company product liability general responding civil investigative demand insurance claims brought vioxx product liability lawsuits stated upper limits approximately reserves million deductibles coinsurance company currently anticipates number vioxx insurance provides coverage legal defense costs product liability lawsuits tried company potential damage amounts predict timing trials respect vioxx incurred connection vioxx product liability shareholder lawsuits company believes lawsuits company believes insurance meritorious defenses vioxx lawsuits vigorously coverage extends additional vioxx product liability defend view inherent difficulty predicting lawsuits may filed future company outcome litigation particularly many directors officers insurance coverage applicable claimants claimants seek indeterminate damages vioxx securities lawsuits vioxx derivative lawsuits stated upper limits approximately million company fiduciary insurance vioxx erisa lawsuits stated upper limits approximately million additional insurance coverage claims may also available upperlevel excess policies provide coverage avariety risks disputes certain mercks report shareholders company unable predict outcome also expanded number manufacturers include matters time reasonably estimate like company defendants prior possible loss range loss respect vioxx pending case may court granted companys lawsuits company established reserves motion dismiss consolidated class action dismissed potential liability relating vioxx lawsuits vioxx company class action case subsequent investigations collectively vioxx litigation companys dismissal plaintiffs filed amended legal defense costs expected incurred connection consolidated class action complaint name loss contingency accrued probable company defendant company many reasonably estimable december company pharmaceutical manufacturers defendants similar established reserve million solely future complaints pending federal state court brought individually legal defense costs related vioxx litigation number counties state new york company company spent million aggregate defendants awaiting final ruling legal defense costs worldwide related vioxx product motion dismiss suffolk county case first liability lawsuits ii vioxx shareholder lawsuits iii new york county cases filed addition vioxx foreign lawsuits iv vioxx investigations december company defendant state collectively vioxx litigation fourth quarter cases brought attorneys general kentucky illinois company recorded charge million increase alabama wisconsin mississippi arizona reserve solely future legal defense costs related vigorously defended company also received vioxx litigation million december letter inquiry attorney general idaho reserve based certain assumptions best previously disclosed company named estimate amount company believes defendant antitrust cases federal court minnesota time reasonably estimate spent state court california alleging unlawful conspiracy significant factors considered establishment among different sets pharmaceutical manufacturers protect ongoing review reserve vioxx legal defense high prices united states impeding importation costs follows actual costs incurred united states lowerpriced pharmaceuticals canada company time development companys court dismissed federal claims minnesota case legal defense strategy structure light scope prejudice plaintiffs filed notice appeal vioxx litigation number cases brought state claims action dismissed without prejudice company costs outcomes completed trials previously disclosed suit federal court alabama anticipated timing progression related costs pretrial two providers health services needy patients alleges activities trials vioxx product liability lawsuits pharmaceutical companies overcharged plaintiffs class events scheduled trials expected occur similarly situated pharmaceuticals purchased throughout inherent inability plaintiffs program established section b predict ultimate outcomes trials limit public health service act company companys ability reasonably estimate legal costs defendants filed motion dismiss complaint numerous beyond end company continue monitor grounds recently denied court legal defense costs review adequacy previously disclosed january doj notified associated reserves unfavorable outcomes vioxx federal court new orleans louisiana going litigation could material adverse effect intervene time pending federal false claims act case companys financial position liquidity results filed seal december operations company court issued order unsealing complaint filed physician louisiana ordered commercial litigation complaint served complaint alleged beginning company named number companys discounting pepcid certain louisiana hospitals antitrust suits certain certified class actions led increases costs medicaid dismissed instituted nations retail pharmacies amended complaint filed seal case consumers several states company settled federal administratively closed court seal lifted class action represented single largest group state louisiana filed amended complaint claims settled substantially remaining cases incorporating allegations contained sealed amended satisfactory terms remaining cases complaint allegations contained sealed amended inactive several years company engaged complaint unknown conspiracy admission wrongdoing made april company named qui tam lawsuit included settlement agreements nevada false claims act suit previously disclosed company joined nevada attorney general intervened alleges ongoing litigation alleging manipulation pharmaceutical company inappropriately offered nominal pricing manufacturers average wholesale prices awp marketing pricing inducements certain customers also sometimes used calculations determine public failed comply obligations medicaid best price private sector reimbursement levels jpml scheme related arrangements company ordered transfer consolidation pending federal vigorously defending lawsuit awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions mercks report shareholders tienam product within italy prior expiry spc governmental proceedings november italian administrative court denied previously disclosed company received companys appeal icas order proceedings subpoena doj connection investigation ica ongoing companys marketing selling activities including nominal pricing programs samples company vaccine litigation also reported received civil investigative demand previously disclosed company party claims brought cid attorney general texas regarding consumer protection act united companys marketing selling activities relating texas kingdom allege certain children suffer variety previously disclosed company received another cid conditions result vaccinated various bivalent attorney general texas asking additional vaccines measles rubella andor trivalent vaccines information regarding companys marketing selling measles mumps rubella including companys mmr ii activities related texas including respect certain conditions include autism without inflammatory bowel nominal pricing programs samples april disease epilepsy encephalitis encephalopathy guiltainbarr company received subpoena office inspector syndrome transverse myelitis claimants general district columbia connection proceeding companys knowledge intending investigation companys interactions physicians proceed company company vigorously district columbia maryland virginia defend lawsuits november company received letter request previously disclosed company also party doj connection investigation companys individual class action product liability lawsuits claims pricing pepcid september company received united states involving pediatric vaccines eg hepatitis b subpoena illinois attorney general subpoena vaccine contained thimerosal preservative used seeks information related repackaging prescription drugs vaccines merck distributed thimerosalcontaining previously disclosed company received letter pediatric vaccines united states since fall doj advising existence qui tam december approximately active complaint alleging company violated certain rules thimerosal related lawsuits approximately plaintiffs related calculations best price federal pricing defendants include vaccine manufacturers benchmark calculations certain may affect produced pediatric vaccines containing thimerosal well companys medicaid rebate obligation manufacturers thimerosal actions plaintiffs allege company cooperating among things suffered neurological injuries investigations company predict outcome result exposure thimerosal pediatric vaccines two investigations however possible unfavorable state court cases two federal district court cases outcomes could material adverse effect scheduled trial cases companys financial position liquidity results dismissed one case set trial also dismissed operations addition time time federal state certain dismissals appealed company foreign regulators authorities may seek information vigorously defend lawsuits however possible practices pharmaceutical industry companys unfavorable outcomes could material adverse effect business practices inquiries investigations companys financial position liquidity results discussed section feasible predict operations outcome inquiries company successful cases february italian antitrust authorities type either dismissed stayed ground action adopted measure commencing formal investigation prohibited national childhood vaccine injury act merck sharp dohme italia spa msd italy vaccine act vaccine act prohibits person filing company article italian competition law maintaining civil action state federal court seeking article ec ascertain whether company msd italy damages vaccine manufacturer vaccinerelated committed abuse dominant position virtue injuries unless petition first filed united states court companys refusal grant acs dobfar spa dobfar federal claims hereinafter vaccine court italian company voluntary license pursuant domestic vaccine act filing civil action vaccine legislation passed permit dobfar manufacture manufacturer petitioner must either pursue tienam imipenem cilastatin italy sale outside italy petition conclusion vaccine court timely file countries patent protection applicable election proceed civil action lieu accepting domestic rules expired never existed company vaccine courts adjudication petition b timely exercise supplementary protection certificate spc right withdraw petition prior vaccine court adjudication provides company certain rights respect accordance certain statutorily prescribed time periods manufacture sale tienam italy expires company aware numerous cases pending january hearing italian antitrust authorities vaccine court involving allegations thimerosalcontaining held may june italian vaccines andor mmr ii vaccine cause autism spectrum antitrust authority ica issued order imposing interim disorders cases referred preceding paragraph measures requiring company grant license dismissed brought plaintiffs manufacture tienam italy pursuant icas order license granted dobfar limited right manufacture build supply stock tienam allow dobfar export tienam outside italy sell mercks report shareholders claim made timely withdrawal vaccine regulatory authority data weekly alendronate may court petition company party vaccine referenced companies seeking approval generic weekly court proceedings petitions brought alendronate products company filed leave appeal department health human services judgment swedish administration court affirming grant swedish regulatory authority approval generic weekly patent litigation alendronate products referenced companys data time time generic manufacturers pharmaceutical weekly alendronate approval company filed products file abbreviated new drug applications andas similar cases countries fda seeking market generic forms previously announced company july companys products prior expiration relevant patents opposition division european patent office rendered owned company generic pharmaceutical oral decision revoke companys patent europe manufacturers submitted andas fda seeking covers onceweekly administration alendronate market united states generic form fosamax august written opinion issued confirming prilosec propecia trusopt cosopt prior expiration oral decision revoking companys patent september companys astrazenecas case prilosec company filed appeal decision decision nexium patents concerning products generic appeal expected company defending companies andas generally include allegations non alendronate weekly product major european markets infringement invalidity unenforceability patents based patents generic manufacturers received fda approval market october action australia challenging generic form prilosec company filed patent validity companys australian patent onceweekly infringement suits federal court companies filing administration alendronate patent found invalid andas generic alendronate fosamax finasteride company appealed decision proscarpropecia dorzolamide trusopt addition previously disclosed japan proceeding dorzolamidetimolol cosopt astrazeneca filed challenging validity companys company filed patent infringement suits federal court japanese patent onceweekly administration companies filing andas generic omeprazole alendronate esomeprazole similar patent challenges exist certain january company sued hitech pharmacal foreign jurisdictions company intends vigorously co inc hitech amityville new york patent defend patents believes valid infringement response hitechs application fda infringement generic companies attempting market seeking approval generic version mercks ophthalmic products prior expiration dates patents drugs trusopt cosopt used treating elevated litigation assurance outcomes intraocular pressure people ocular hypertension adverse could result significantly shortened periods glaucoma lawsuit merck sued enforce patent exclusivity products covering active ingredient dorzolamide present previously disclosed january us trusopt cosopt merck elected enforce two court appeals federal circuit washington dc us patents listed fda cover combination found companys patent claims onceweekly dorzolamide timolol two active ingredients cosopt administration fosamax invalid company lawsuit automatically stay fda approval hitechs exhausted options appeal decision based andas months adverse court decision court appeals decision fosamax lose market whichever may occur earlier patent covering dorzolamide exclusivity united states february provides exclusivity trusopt cosopt october company expects significant decline us fosamax sales including six months pediatric exclusivity time time company expects sales products decline may federal court canada trial division case omeprazole trial court united states issued decision refusing bar approval generic alen rendered opinion october upholding validity dronate ground mercks patent weekly alen companys astrazenecas patents covering stabilized dronate likely invalid decision appealed formulation omeprazole ruling one defendants generic alendronate launched canada omeprazole product infringe patents june july merck sued federal court three defendants products found infringe formulation canada apotex seeking damages lost sales patents december us court appeals generic weekly alendronate due patent proceeding federal circuit affirmed decision trial court january high court justice england respect companys patent infringement claims wales held patents company protecting certain generic manufacturers omeprazole products trial alendronate daily weekly products invalid scheduled march united kingdom november court appeals company astrazeneca received notice england wales affirmed ruling high court october ranbaxy laboratories limited ranbaxy justice england wales filed anda esomeprazole magnesium anda contains european countries permit companies seeking approval paragraph iv challenges patents nexium generic product reference data innovative product november company astrazeneca sued certain circumstances data exclusivity regulations ranbaxy united states district court new jersey high court justice affirmed decision uk accordingly fda mercks report shareholders certain plaintiffs counsel filed settlement agreement approval ranbaxys anda stayed months federal district court new york cases commenced april adverse court decision whichever number plaintiffs including participants number may occur earlier pharmaceutical benefit plans medco health case finasteride anda filed seeking pharmacy benefit manager well trustees plans approval generic version propecia alleging consolidated medco health company agreed invalidity companys patents company filed proposed settlement order avoid significant cost patent infringement lawsuit district court delaware distraction prolonged litigation proposed class september trial scheduled june settlement agreed plaintiffs five cases europe company aware various companies filed medco health company seeking registration generic losartan active ingredient proposed settlement company medco health cozaar company patent rights losartan via agreed pay total million medco health license ei dupont de nemours company dupont agreed modify certain business practices continue certain company dupont filed patent infringement specified business practices period five years proceedings various companies portugal financial compensation intended benefit members settlement class includes erisa plans medco litigation health administered pharmacy benefit time since july merck served shareholder december district court held hearings hear derivative suit filed new jersey superior court objections fairness proposed settlement hunterdon county company certain current approved settlement yet determined former officers directors lawsuit seeks recover number class member plans properly elected cancel compensation awarded companys executive participate settlement settlement becomes final officers asserts claims breach fiduciary appeals resolved certain class member duty waste unjust enrichment plans indicated participate november individual shareholder delivered settlement cases initiated three plans two letter board alleging company sustained individuals remain pending southern district new york damages companys adoption change plaintiffs cases asserted claims based erisa control separation benefits plan cic plan well federal state laws november shareholder made demand similar claims asserted settling class board take legal action boards current former members gruer cases company medco health members allegedly causing damage company named defendants cases respect adoption cic plan response three notices appeal filed appellate court demand letter independent members board heard oral argument may december determined november board meeting appellate court issued decision vacating district courts board would take shareholders request judgment remanding cases district court allow consideration remains consideration district court resolve certain jurisdictional issues previously disclosed july united states district court scheduled hearing february district court district new jersey granted motion address issues company medco health solutions inc medco spinoff medco health medco health assumed health certain officers directors dismiss substantially liability exposure matters discussed purported class action complaint involving claims related foregoing two paragraphs cases companys revenue recognition practice retail defended medco health copayments paid individuals medco health various legal proceedings principally product provides pharmaceutical benefits well allegations liability intellectual property suits involving company complaint dismissed prejudice august pending feasible predict outcome court granted companys motion proceedings proceedings discussed note dismiss prejudice related shareholder derivative action opinion company proceedings either plaintiffs actions appealed decisions adequately covered insurance covered december us court appeals third ultimately result liability would material adverse circuit upheld district courts decision dismissing class effect financial position liquidity results operations action complaint separate decision issued day company proceedings separate court appeals upheld district courts assessment provided note decision dismissing shareholder derivative suit sent issue whether companys board directors environmental matters properly refused shareholder demand relating company party number proceedings brought companys treatment retail copayments back district comprehensive environmental response court reconsideration different legal standard compensation liability act commonly known superfund previously disclosed prior spinoff medco legitimate claim contribution asserted liability health company medco health agreed settle initially accrued based upon estimated transaction costs class action basis series lawsuits asserting violations erisa gruer cases company medco health mercks report shareholders manage site accruals adjusted feasibility studies december respectively liabilities related cost assessments remedial techniques undiscounted consider potential recoveries insurers completed extent potentially parties paid periods responsible parties prps may jointly severally remediation applicable sites expected occur liable expected contribute determined primarily next years although possible company also remediating environmental predict certainty outcome matters contamination resulting past industrial activity certain ultimate costs remediation management believe sites takes active role identifying providing reasonably possible expenditures may incurred costs worldwide survey initially performed excess liabilities accrued exceed million assess sites potential contamination resulting past aggregate management also believe industrial activities assessment indicated physical expenditures result material adverse effect investigation warranted investigation companys financial position results operations liquidity performed providing better evaluation need capital resources year remedial action need identified remedial action initiated estimates extent preferred stock subsidiary companies contamination site initially made pre december company redeemed variablerate investigation stage liabilities potential cost preferred units subsidiary billion par value plus remediation accrued time definitive accrued dividends preferred securities held information became available course subsidiary level previously included minority investigations andor remedial efforts site estimates interests consolidated financial statements refined accruals adjusted accordingly connection restructuring ami see note estimates related accruals continue refined annually company assumed billion par value preferred stock previously disclosed december virginia obligation dividend rate per annum carried department environmental quality vadeq issued kbi included minority interests small portion notice violation companys elkton virginia facility preferred stock carried kbi convertible kbi common air permit limit exceedances reported facility result shares none preferred securities convertible performance testing process train companys common shares therefore included company settled matter vadeq agreeing common shares issuable purposes computing earnings make million capital improvements site ii pay per common share assuming dilution see note vadeq fine iii perform supplemental environmental project stockholders equity december company settled claims paidin capital increased million brought new jersey department environmental decreased million increased protection alleged damages natural resources four million changes primarily reflect impact new jersey merck remediation sites settlement shares issued upon exercise stock options related income company agreed pay million donate acres land tax benefits well issuance restricted shares adjacent rahway river fund restoration summary treasury stock transactions shares millions project passaic river watershed groundwater follows contamination found companys sites managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million shares cost shares cost shares cost b alance jan purchases issuances b alance dec issued primarily stock option plans mercks report shareholders december million shares number outstanding options increased million preferred stock without par value authorized none average exercise price decreased approximately issued addition certain stock options granted medco health employees converted medco health options terms amounts maintained option stockbased compensation plans holders positions company stockbased compensation plans summarized information relative companys stock employees nonemployee directors employees option plans options thousands follows certain companys equity method investees may granted options purchase shares company common number average stock fair market value time grant options price plans approved companys shareholders option utstanding december grants beginning generally vest ratably three granted years grants prior generally vest five years exercised options expire ten years date grant subject forfeited converted terms applicable awards medco health spinoff adjustment company made certain changes stock utstanding december based compensation plans began granting performance granted share units psus restricted stock units rsus exercised addition stock options certain management level forfeited employees financial value individual stockbased utstanding december incentive grants approach designed granted equivalent prior approach mix stockbased exercised compensation awards changed psu rsu payouts forfeited shares company stock end three year period subject terms applicable awards utstanding december additionally psu payouts contingent companys weighted average exercise price performance preset objective set objectives includes million options converted medco health options company granted million psus number options average price options weightedaverage grant date fair values exercisable december respectively company granted million rsus million options million options weightedaverage grant date fair million options respectively values respectively december million shares forfeitures vestings significant either period million shares respectively available future grants connection medco health spinoff terms companys stockbased compensation plans number exercise prices outstanding options summarized information stock options outstanding proportionately adjusted maintain option holders exercisable december options thousands positions spinoff result follows adjustment exercise outstanding exercisable price number average average number average range options life price options price u nder weighted average contractual life remaining years weighted average exercise price retirees similar benefits dependents pension postretirement benefit plans postretirement benefit plans company uses december company defined benefit pension plans covering measurement date substantially pension plans eligible employees united states certain postretirement benefit plans international subsidiaries pension benefits united connection companys restructuring actions see states based formula considers final average pay note merck recorded termination charges years credited service addition company million million million provides medical dental life insurance benefits principally respectively pension plans million million eligible us mercks report shareholders million respectively postretirement cost health care life insurance benefits active benefit plans related expanded eligibility certain employees million million employees exiting company million also connection restructuring activities summarized information changes plan assets company recorded curtailment losses million benefit obligation follows settlement losses million pension plans well curtailment losses million million postretirement benefit plans postretirement pension benefits benefits respectively company changed participant contributions f air value plan assets service recognized eligibility postretirement january benefit plans amendments generated curtailment gains actual return plan million million assets addition company recorded settlement gain company contributions million settlement loss million benefits paid plan certain domestic pension plans resulting assets employees electing receive pension benefits lump sum payments f air value plan assets company recognized federal subsidy december medicare prescription drug improvement modernization act act reduced benefit b enefit obligation obligation certain postretirement benefit plans january million company recognizing subsidy subsidy act accordance current accounting requirements service cost continue evaluate act regulations follow interest cost determine optimal approach incorporating impact actuarial losses gains act benefits paid net cost companys pension plans consisted plan amendments following components curtailments termination benefits years ended december ervice cost b enefit obligation interest cost december expected return plan assets net amortization fair value us pension plan assets included termination benefits preceding table billion billion curtailments pension benefit obligation us plans included table settlements billion billion n et pension cost reconciliation plans funded status net asset liability recognized december follows net pension cost attributable us plans included table million million postretirement million pension benefits benefits net cost postretirement benefits pensions consisted following components p lan assets less benefit obligation years ended december unrecognized net loss ervice cost unrecognized plan interest cost changes expected return plan assets n et asset liability net amortization r ecognized curtailments assets termination benefits accrued n et postretirement benefit cost current liabilities deferred income taxes noncurrent liabilities accumulated comprehensive loss mercks report shareholders weighted average asset allocations investment december accumulated benefit portfolio pension postretirement benefit plans obligation billion billion respectively december follows pension plans billion billion respectively us pension plans company minimum pension liability million million december postretirement respectively representing extent pension benefits benefits accumulated benefit obligation exceeded plan assets certain u equities companys pension plans pension plans benefit obligations excess plan international equities assets december fair value plan fixedincome investments assets million billion respectively real estate benefit obligation billion billion respectively investments plans accumulated benefit obligations excess cash cash equivalents plan assets december fair value plan assets million million respectively accumulated benefit obligation million target investment portfolios companys pension million respectively plans determined country based nature unrecognized net loss amounts reflect experience differentials liabilities considering demographic composition primarily relating differences expected actual plan participants average age years service active returns plan assets well effects changes versus retiree status accordance local regulations actuarial assumptions unrecognized net loss amounts excess weighted average target allocation us certain thresholds amortized net pension equities international equities fixedincome postretirement benefit cost average remaining service investments real estate investments life employees amortization unrecognized net losses cash cash equivalents investments include companys us plans december expected insurance contracts certain international pension plans increase net pension postretirement benefit cost target investment portfolio companys approximately million annually postretirement benefit plans allocated us company reassesses benefit plan assumptions equities international equities regular basis weighted average assumptions used fixedincome investments cash determining pension plan information follows investments portfolios asset allocation consistent longterm nature plans benefit obligation well december diversified among asset classes portfolio n et cost invests iscount rate contributions pension plans postretirement expected rate return plan assets benefit plans expected million million respectively salary growth rate expected benefit payments follows b enefit obligation iscount rate salary growth rate pension postretirement benefits benefits assumptions used determining us pension plan postretirement benefit plan information follows december n et cost iscount rate expected rate return plan assets salary growth rate expected benefit payments based b enefit obligation assumptions used measure benefit obligations include estimated future employee service expected receipts iscount rate subsidy act reflected salary growth rate expected postretirement benefit payments included used postretirement benefit plans preceding table follows million million million million million mercks report shareholders expected rate return pension net primarily reflects million gain postretirement benefit plans represents average rate sale companys percent equity stake return earned plan assets period benefits european joint venture johnson johnson well included benefit obligation paid realized gains companys investment portfolio net determined country basis developing expected rate primarily reflects million gain sale return within country longterm historical returns aggrastat product rights united states realized gains data considered well actual returns plan assets companys investment portfolios relating favorable capital markets experience using reference interest rate environment information longterm return expectations asset interest paid million million category weighted average expected return million countrys target portfolio developed according allocation among investment categories expected taxes income portfolio performance reflects contribution active management appropriate companys reconciliation companys effective tax rate expected rate return remain unchanged us statutory rate follows us pension postretirement benefit plans tax rate health care cost trend rate assumptions post amount retirement benefit plans follows us statutory rate applied income continuing december operations taxes h ealth care cost trend rate assumed next differential arising year foreign earnings rate cost trend rate assumed tax exemption puerto decline rico operations year rate reached ultimate trend state taxes rate ajca one percentage point change health care cost trend rate would following effects includes tax effect minority interests contingency one percentage point increase decrease reserves research credits export incentives miscellaneous e ffect total service interest cost items components domestic companies contributed approximately effect benefit obligation consolidated income continuing operations taxes taxes income continuing operations consisted income expense net years ended december c urrent provision years ended december nterest income federal foreign interest expense state exchange gains minority interests net eferred provision federal foreign minority interests include third parties share exchange state gains losses arising translation financial statements us dollars reduced minority interest attributable redemption subsidiary variable rate preferred units see note mercks report shareholders deferred income taxes december consisted taxes would payable upon distributions earnings practicable determine amount related unrecognized deferred income lax liability addition assets liabilities assets liabilities company subsidiaries operating puerto rico ther intangibles singapore tax incentive grants expire inventory related respectively accelerated companys federal income tax returns audited depreciation previously disclosed internal revenue advance payment service irs substantially completed examination equity investments companys tax returns years pensions opeb april connection examination irs issued compensation related preliminary notice deficiency respect partnership vioxx legal defense transaction entered december cost reserve company received final notice deficiency respect net operating losses transaction regard tax return specifically irs disallowed certain royalty expenses claimed ubtotal deductions tax return preliminary notice valuation allowance proposed disallowing similar type expenses tax otal deferred taxes returns company anticipates receiving similar preliminary n et deferred tax notice deficiency irs ultimately prevails liabilities positions companys income tax due would r ecognized increase approximately million plus interest approximately million penalties approximately prepaid expenses million years tax would increase taxes approximately million plus interest approximately assets million irs likely make similar claims years income taxes subsequent respect transaction potential payable disallowance later years computed similar basis deferred income disallowances would approximately taxes million plus interest approximately million irs noncurrent proposed penalties company respect periods liabilities subject preliminary notice adjustment company net operating loss nol carryforwards company anticipates irs would seek impose penalties number jurisdictions significant periods united kingdom nol carryforwards million october irs issued summonses several expiration date valuation allowance current former executives company connection established certain canadian nol carryforwards matter irs began interviewing individuals resulting legal entity reorganization december income taxes paid company vigorously disagrees proposed billion billion billion respectively stock adjustments intends aggressively contest matter option exercises significant impact taxes applicable irs judicial procedures appropriate paid stock option exercises reduced income taxes although final resolution proposed adjustments paid million million uncertain involves unsettled areas law based respectively currently available information company provided previously disclosed october ajca best estimate probable tax liability matter signed law ajca creates temporary incentives resolution issue may result tax liabilities us multinationals repatriate accumulated income earned significantly higher lower reserves established outside united states december matter management currently believes resolution accordance ajca company repatriated material effect companys financial position billion company recorded income liquidity however unfavorable resolution could tax charge million taxes income material effect companys results operations cash related repatriation million paid flows quarter adjustment recorded tax million paid first quarter due paid charge partially offset million january irs issued summons requesting benefit associated decision implement certain tax certain information connection minority interest equity planning strategies financing transaction entered merck intends company changed intention indefinitely cooperate terms summons reinvest accumulated earnings earned subsequent december december foreign earnings billion retained indefinitely subsidiary companies reinvestment provision made income mercks report shareholders components accumulated comprehensive earnings per share income loss follows weighted average common shares used computations basic earnings per common share december earnings per common share assuming dilution shares n et unrealized gain loss derivatives millions follows net unrealized gain investments minimum pension liability years ended december cumulative translation adjustment relating verage common shares equity investees outstanding common shares issuable verage common shares december million net unrealized gain outstanding assuming dilution derivatives associated options maturing next issuable primarily stockbased compensation plans months hedge anticipated foreign currency denominated sales period million million million common shares issuable companys segment reporting stockbased compensation plans excluded companys operations principally managed computation earnings per common share assuming dilution products basis merck pharmaceutical segment includes effect would antidilutive products marketed either directly joint ventures products consist therapeutic preventive agents sold comprehensive income prescription treatment human disorders merck sells components comprehensive income loss human health products primarily drug wholesalers follows retailers hospitals government agencies managed health care providers health maintenance organizations institutions pretax tax tax ear ended december includes nonreportable human animal health segments revenues profits segments n et unrealized gain derivatives follows net loss realization erivatives merck n et unrealized gain pharm aceutical total investments ear ended december net loss realization nvestments egment revenues segment profits inimum pension liability included segment profits c umulative translation adjustment equity income affiliates relating equity investees depreciation amortization ear ended december ear ended december n et unrealized loss derivatives egment revenues net loss realization segment profits erivatives ncluded segment profits n et unrealized gain equity income affiliates investments depreciation amortization net income realization ear ended december nvestments egment revenues inimum pension liability segment profits c umulative translation adjustment included segment profits relating equity investees equity income affiliates depreciation amortization ear ended december n et unrealized loss derivatives net loss realization erivatives n et unrealized gain investments net income realization nvestments inimum pension liability net applicable minority interestmercks report shareholders segment profits comprised segment revenues less consolidated revenues geographic area derived certain elements materials production costs follows operating expenses including components equity income loss affiliates depreciation amortization years ended december expenses internal management reporting presented u nited states chief operating decision maker company allocate europe middle east africa vast majority indirect production costs research japan development expenses general administrative expenses well cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed reconciliation total segment profits consolidated assets utilized divisions therefore income continuing operations taxes follows included segment profits reconciliation total segment revenues consolidated years ended december sales follows egment profits profits years ended december adjustments egment revenues unallocated revenues interest income interest expense equity income loss revenues primarily comprised miscellaneous affiliates corporate revenues sales related divested products depreciation businesses supply sales amortization sales companys products follows research development expenses net years ended december z ocor fosamax profits primarily comprised miscellaneous cozaarhyzaar corporate profits well operating profits related divested singulair products businesses supply sales adjustments proscar represent elimination effect double counting certain primaxin items income expense equity income loss affiliates vasotecvaseretic includes taxes paid joint venture level portion cosopttrusopt equity income reported segment profits cancidas expenses net include expenses corporate maxalt manufacturing cost centers miscellaneous income propecia expense net vioxx property plant equipment net geographic area vaccinesbiologicals located follows december u nited states presented net discounts returns europe middle east africa primarily includes sales human japan pharmaceuticals pharmaceutical animal health supply sales companys joint ventures revenue companys relationship azlp primarily relating sales nexium prilosec revenue azlp billion company disaggregate assets products billion billion services basis internal management reporting respectively therefore information presented mercks report shareholders managements report managements responsibility financial statements included companys filing addition responsibility integrity objectivity companys may company submitted new york stock financial statements rests management financial exchange nysf certificate ceo certifying statements report managements stewardship company aware violation company nyse corporate assets statements prepared conformity governance listing standards generally accepted accounting principles accordingly managements report lnternal control financial include amounts based managements best reporting estimates judgments nonfinancial information included annual report also prepared management management responsible establishing maintaining consistent financial statements adequate internal control financial reporting term assure financial information reliable assets defined exchange act rule af management conducted safeguarded management maintains effective system evaluation effectiveness internal control financial internal controls procedures important elements reporting based framework internal controlintegrated include careful selection training development framework issued committee sponsoring operating financial managers organization organizations treadway commission coso based provides appropriate division responsibility evaluation management concluded internal control communications aimed assuring company policies financial reporting effective december based procedures understood throughout organization staff criteria internal controlintegrated framework issued internal auditors regularly monitors adequacy coso managements assessment effectiveness application internal controls worldwide basis internal control financial reporting december ensure personnel continue understand audited pricewaterhousecoopers llp system internal controls procedures policies independent registered public accounting firm concerning good prudent business practices pricewaterhousecoopers llp issued report company periodically conducts managements managements assessment effectiveness stewardship program key management financial companys internal control financial reporting personnel program reinforces importance included herein understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding richard clark judy c lewent commitment high ethical standards conduct chief executive officer executive vice president business president chief financial officer financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission audit committees report audit committee comprised independent directors met independent auditors judgments regarding quality independent registered public accounting firm acceptability companys accounting principles clarity independent auditors management internal auditors disclosures degree aggressiveness assure carrying respective conservatism accounting principles underlying responsibilities audit committee discussed estimates audit committee reviewed discussed received letter independent auditors confirming audited financial statements management independence independent auditors internal recommended board directors financial auditors full access committee including regular statements included companys filing meetings without management present securities exchange commission audit committee met independent auditors discuss fees scope results audit work peter cwendell rochelle b lazarus including adequacy internal controls quality chairperson thomas e shenk financial reporting committee also discussed wendell p weeks mercks report shareholders report independent registered public accounting firm companys management responsible maintaining effective stockholders internal control financial reporting assessment board directors merck co inc effectiveness internal control financial reporting responsibility express opinions managements completed integrated audits merck co incs assessment effectiveness companys internal consolidated financial statements control financial reporting based audit conducted internal control financial reporting december audit internal control financial reporting accordance audit consolidated financial standards public company accounting oversight statements accordance standards public board united states standards require plan company accounting oversight board united states perform audit obtain reasonable assurance whether opinions based audits presented effective internal control financial reporting maintained consolidated financial statements material respects audit internal control financial opinion accompanying consolidated balance sheets reporting includes obtaining understanding internal control related consolidated statements income retained financial reporting evaluating managements assessment earnings comprehensive income cash flows present testing evaluating design operating effectiveness fairly material respects financial position merck internal control performing procedures co inc subsidiaries december consider necessary circumstances believe december results operations audit provides reasonable basis opinions cash flows three years period ended companys internal control financial reporting december conformity accounting principles process designed provide reasonable assurance regarding generally accepted united states america reliability financial reporting preparation financial financial statements responsibility companys statements external purposes accordance generally management responsibility express opinion accepted accounting principles companys internal control financial statements based audits conducted financial reporting includes policies procedures audits statements accordance pertain maintenance records reasonable standards public company accounting oversight board detail accurately fairly reflect transactions united states standards require plan dispositions assets company ii provide reasonable perform audit obtain reasonable assurance assurance transactions recorded necessary permit whether financial statements free material preparation financial statements accordance generally misstatement audit financial statements includes accepted accounting principles receipts examining test basis evidence supporting amounts expenditures company made accordance disclosures financial statements assessing authorizations management directors company accounting principles used significant estimates made iii provide reasonable assurance regarding prevention management evaluating overall financial statement timely detection unauthorized acquisition use disposition presentation believe audits provide reasonable companys assets could material effect basis opinion financial statements inherent limitations internal control internal control financial reporting financial reporting may prevent detect misstatements also also opinion managements assessment included projections evaluation effectiveness future periods accompanying managements report internal control subject risk controls may become inadequate financial reporting company maintained changes conditions degree effective internal control financial reporting compliance policies procedures may deteriorate december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso fairly stated material respects based florham park new jersey pricewaterhousecoopers llp criteria furthermore opinion company february maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso compensation benefits committees report compensation benefits committee comprised consistent longterm focus inherent companys independent directors approves compensation objectives rdbased pharmaceutical business policy policies employees sets compensation committee make high proportion executive officer companys executive officers committee seeks ensure compensation dependent longterm performance rewards closely linked company division team enhancing stockholder value individual performances committee also seeks ensure compensation benefits set levels enable lawrence bossidy william g bowen merck attract retain highly qualified employees chairperson johnnetta b cole committee views stock ownership vehicle align william n kelley interests employees companysstockholders mercks report shareholders selected financial data merck co inc subsidiaries millions except per share amounts r esults year sales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income continuing operations taxes taxes income income continuing operations income discontinued operations net taxes net income basic earnings per common share continuing operations discontinued operations net income earnings per common share assuming dilution continuing operations discontinued operations net income cash dividends declared cash dividends paid per common share capital expenditures depreciation earend position working capital property plant equipment net total assets longterm debt stockholders equity f inancial ratios income continuing operations sales net income average total assets earend statistics average common shares outstanding millions average common shares outstanding assuming dilution millions number stockholders record number employees prior year amounts reclassified reflect separate line item presentation restructuring costs amounts include impact net tax charge primarily associated ajca repatriation restructuring actions additional vioxx legal defense costs amounts include impact withdrawal vioxx vioxx legal defense costs amounts include impact implementation new distribution program us wholesalers amount add result rounding decrease primarily reflects impact spinoff medco healthmercks report shareholders exhibit merck co inc subsidiaries following list subsidiaries company business name stated country state name incorporation amrad pharmaceuticals pty ltd australia aton pharma inc delaware banyu pharmaceutical company ltd japan blue jay investments cv netherlands brc ltd bermuda charles e frosst uk limited great britain chibret denmark chibret pharmazeutische gmbh germany chinamsd hivaids public private partnership inc china chippewa holdings llc delaware cloverleaf international holdings sa luxembourg cm delaware llc delaware comsort inc delaware coophavet sas france coordinated patient care scandinavia norway crosswinds bv netherlands dieckmann arzneimittel gmbh germany european insurance risk excess limited ireland farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal financiere msd sas france fontelaborprodutos farmaceuticos lda portugal fregenal holdings sa panama frosst iberica sa spain frosst laboratories inc delaware frosst portuguesa produtos farmaceuticos lda portugal hangzhou msd pharmaceutical company limited china hawk falcon llc delaware infodoc norway international indemnity ltd bermuda istituto di richerche di biologia molecolare spa italy istituto gentili spainc italydelaware johnson johnson merck consumer pharmaceuticals company new jersey kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware kiinteisto oy viistotie finland laboratoires merck sharp dohmechibret snc france laboratorios abello sa spain laboratorios biopat sa spaincountry state name incorporation laboratorios chibret sa spain laboratorios frosst sa spain laboratorios medichip sl spain laboratorios neurogard sa spain laboratorios quimicofarmaceuticos chibret lda portugal maple leaf holdings srl barbados mcm vaccine co pennsylvania medco de mexico managed care de rl de cv mexico medco holdings de rl de cv mexico medco servicios de mexico de rl de cv mexico merck company incorporated delaware merck borinquen holdings inc delaware merck capital resources inc delaware merck capital ventures llc delaware merck cardiovascular health company nevada merck enterprises canada ltd canada merck finance co inc delaware merck foreign sales corporation ltd bermuda merck frosst canada ltd canada merck frosst company canada merck frosst finco lp canada merck hamilton inc california merck holdings ii corp delaware merck holdings inc delaware merck institute vaccinology delaware merck investment co inc delaware merck liability management company delaware merck lmc cash management bermuda ltd bermuda merck lmc cash management inc delaware merck oncology holdings inc delaware merck resource management inc delaware merck respiratory health company nevada merck sh inc delaware merck sharp dohme argentina inc delaware merck sharp dohme asia limited hong kong merck sharp dohme australia pty limited australia merck sharp dohme china limited hong kong merck sharp dohme enterprises bv netherlands merck sharp dohme europe inc delaware merck sharp dohme holdings bv netherlands merck sharp dohme holdings limited great britain merck sharp dohme ia corp delaware merck sharp dohme international limited bermuda merck sharp dohme investments bv netherlands merck sharp dohme ireland ltd bermuda merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy merck sharp dohme lebanon sal lebanon merck sharp dohme middle east limited cyprus merck sharp dohme new zealand limited new zealandcountry state name incorporation merck sharp dohme panama sa panama merck sharp dohme philippines inc philippines merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda merck sharp dohme sweden ab sweden merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme bv netherlands merck sharp dohme chibret ag switzerland merck sharp dohme comercializadora de rl de cv mexico merck sharp dohme doo croatia merck sharp dohme de espana sa spain merck sharp dohme de mexico sa de cv mexico merck sharp dohme de venezuela srl venezuela merck sharp dohme farmaceutica ltda brazil merck sharp dohme finance europe limited great britain merck sharp dohme gmbh austria merck sharp dohme holdings de mexico sa de cv mexico merck sharp dohme idea inc switzerland merck sharp dohme industria quimica e veterinaria limitada brazil merck sharp dohme inovativna zdravila doo slovenia merck sharp dohme international services bv netherlands merck sharp dohme ireland human health ltd ireland merck sharp dohme sland hf iceland merck sharp dohme llc russian federation merck sharp dohme limited great britain merck sharp dohme luxembourg holdings sarl luxembourg merck sharp dohme manufacturing ireland merck sharp dohme ou estonia merck sharp dohme pakistan limited pakistan merck sharp dohme peru srl peru merck sharp dohme quimica de puerto rico inc delaware merck sharp dohme research ltd bermuda merck sharp dohme de rl de cv mexico merck sharp dohme sa morocco merck sharp dohme sas france merck sharp dohme sia latvia merck sharp dohme tunisie sarl tunisia merck sharp dohme limitada portugal merck sharp dohme ilaclari limited sirketi turkey merck technology us company inc nevada merck ventures inc delaware merial ia llp puerto rico merial thailand ltd thailand merial animal health co ltd china merial animal health ltd great britain merial argentina sa argentina merial asia pte ltd singapore merial australia pty ltd australia merial bv netherlands merial belgium belgiumcountry state name incorporation merial colombia sa colombia merial distribution sas france merial gmbh germany merial hong kong limited hong kong merial inc delaware merial international trading shanghai co ltd china merial italia spa italy merial japan limited japan merial korea ltd korea merial laboratorios sa spain merial limitedllc great britaindelaware merial nanjing animal health co ltd china merial new zealand limited new zealand merial norden denmark merial philippines inc philippines merial portuguesa saude animal lda portugal merial sa uruguay merial sas france merial saude animal ltda brazil merial taiwan co ltd taiwan merial venezuela ca venezuela ml holdings canada inc canada msd nippon holdings bv netherlands msd norge norway msd proprietary limited south africa msd thailand ltd thailand msd australia pty ltd australia msd australia superannuation pty ltd australia msd brazil investments bv netherlands msd chibropharm gmbh germany msd finance bv netherlands msd finance mexico llc delaware msd international holdings inc delaware msd ireland holdings sa luxembourg msd ireland investments ltd bermuda msd korea ltd korea msd lakemedel scandinavia aktiebolog sweden msd latin america services ltd bermuda msd latin america services de rl de cv mexico msd limited great britain msd magyarorszg kft hungary msd mexico investments bv netherlands msd overseas manufacturing co bermuda msd overseas manufacturing co ireland ireland msd pharmaceuticals private limited india msd polska spzoo poland msd sharp dohme gmbh germany msd somerset ltd bermuda msd stamford singapore pte ltd singapore msd technology singapore pte ltd singaporecountry state name incorporation msd technology lp delaware msd unterstutzungskasse gmbh germany msd ventures singapore pte ltd singapore msd warwick manufacturing ltd bermuda msdessex gmbh switzerland msdj holdings canada inc canada msdsp ltd great britain msp distribution services c llc nevada msp distribution services r llc nevada msp marketing services c llc nevada msp marketing services r llc nevada msp singapore company llc delaware msp technology us company llc delaware neopharmed spa italy pt merck sharp dohme indonesia indonesia pasteur vaccins sa france readington investments inc new jersey rosetta inpharmatics llc delaware ruskin limited bermuda sanofi pasteur msd denmark sanofi pasteur msd ag switzerland sanofi pasteur msd gestion sa france sanofi pasteur msd gmbh austria sanofi pasteur msd gmbh germany sanofi pasteur msd ltd great britain sanofi pasteur msd ltd ireland sanofi pasteur msd nvsa belgium sanofi pasteur msd sa spain sanofi pasteur msd spa italy sanofi pasteur msd snc france seneca llc delaware sharp dohme sa spain stellarx inc nevada suomen msd oy finland telerx marketing inc pennsylvania msd foundation limited great britain thomas morson son limited great britain tradewinds manufacturing srl barbados transrow manufacturing ltd bermuda uab merck sharp dohme lithuania variopharm arzneimittel gmbh germany less exhibit power attorney undersigned hereby appoint celia colbert kenneth c frazier severally hisher true lawful attorney attorneys execute behalf undersigned whether behalf company officer director thereof attesting seal company otherwise annual report merck co inc fiscal year ended december securities exchange act including amendments thereto